Clinical and internal medicine Books

Book SynopsisAn Aid to the MRCP PACES Volume 3: Station 5 is a brand new, fully updated edition of the best-selling PACES revision guide to address the newest Station, covering Integrated Clinical Assessment, with content guided by the experiences of PACES candidates.Table of ContentsPreface ix Introduction xiii Section G: Examination Routines 1 1 Pulse 7 2 Heart 8 3 Chest 13 4 Abdomen 17 5 Visual fields 22 6 Cranial nerves 23 7 Arms 26 8 Legs 30 9 Legs and arms 34 10 Gait 35 11 Ask some questions 36 12 Fundi 39 13 Eyes 43 14 Face 45 15 Hands 47 16 Skin 51 17 Rash 53 18 Neck 54 19 Thyroid status 56 20 Knee 58 21 Hip 60 22 What is the diagnosis? 61 Section H: Integrated Clinical Assessment 65 Station 5 Scenarios by specialty 75 Dermatology 1 Non-resolving leg ulcer: pyoderma gangrenosum 77 2 Generalized rash: psoriasis 81 3 Dermatomyositis and falls 85 Rheumatology 4 Systemic sclerosis and Raynaud’s syndrome 90 5 Rheumatoid arthritis and effects on activities of daily living (ADL) 94 6 Psoriatic arthropathy 98 7 Ankylosing spondylitis: short notes 101 8 Gout: short notes 102 9 Steroid toxicity: short notes 103 Endocrine 10 Thyroid eye disease 105 11 Acromegaly 109 12 Diabetes mellitus and Charcot joint 112 13 Diabetes mellitus: foot ulcer and diabetes control 116 14 Goitre and weight loss 119 Eyes 15 Retinitis pigmentosa 125 16 Optic atrophy 128 17 Visual blurring in a patient with diabetes mellitus 132 Gastroenterology 18 Iron deficiency anaemia 137 19 Haematemesis 141 20 Elevated liver function tests: non-alcoholic fatty liver disease (NAFLD) 146 21 Elevated liver function tests and hepatitis B serology 151 22 Crohn’s disease/inflammatory bowel disease 155 23 Dysphagia and weight loss 158 24 Diarrhoea: recent antibiotics 162 25 Weight loss 166 26 Gastrointestinal bleed: significant bleed 169 Haematology 27 Anaemia 173 28 Easy bruising/idiopathic thrombocytopenic purpura 176 29 Epistaxis/elevated international normalized ratio (INR) 180 30 Neutropenic sepsis 184 Cardiology 31 Young syncope 188 32 Angina/chest pain 193 33 Palpitations ?atrial fibrillation 197 34 Breathlessness/congestive cardiac failure 201 35 Syncope/aortic stenosis 205 36 Syncope (orthostatic) 208 Respiratory 37 Chronic obstructive pulmonary disease (COPD) 211 38 Asthma 214 39 Pleural effusion 217 40 Short of breath ?pulmonary embolism 221 41 Rheumatoid arthritis/breathlessness 226 42 Haemoptysis 229 Neurology 43 Headache: progressive/memory issues 233 44 Headache: migraine 236 45 Subarachnoid haemorrhage 240 46 Transient ischaemic attack: loss of vision 243 47 Left-sided weakness in a young woman 247 48 Parkinson’s disease/falls in an elderly woman 250 49 Cranial nerve VI palsy: sudden onset 254 50 Blackout: first fit 258 51 Essential tremor 263 52 Temporal arteritis 267 53 Carpal tunnel syndrome 270 54 Multiple sclerosis/diplopia 274 55 Peripheral neuropathy 279 Miscellaneous cases 56 Urinary tract infection: male/sexual history 283 57 Swollen calf in a young woman 287 58 Deep venous thrombosis (DVT) secondary to neoplasia: elderly patient 291 59 Deterioration in renal function 295 60 Fever in the returning traveller 299 Section I: Short Case Records 305 Station 5 Skin 309 1 Systemic sclerosis/CREST syndrome 311 2 Neurofibromatosis (von Recklinghausen’s disease) 312 3 Osler–Weber–Rendu syndrome 314 4 Psoriasis 316 5 Rash of uncertain cause 318 6 Dermatomyositis 319 7 Xanthomata 321 8 Vitiligo 324 9 Adenoma sebaceum in tuberous sclerosis complex 328 10 Pseudoxanthoma elasticum 330 11 Lichen planus 333 12 Yellow nail syndrome 335 13 Gouty tophi 336 14 Alopecia areata 337 15 Eczema 339 16 Pretibial myxoedema 342 17 Clubbing 343 18 Necrobiosis lipoidica diabeticorum 345 19 Lupus pernio 347 20 Tinea 350 21 Koilonychia 352 22 Raynaud’s phenomenon 353 23 Erythema nodosum 355 24 Sturge–Weber syndrome 358 25 Purpura 360 26 Peutz–Jeghers syndrome 363 27 Vasculitis 364 28 Ehlers–Danlos syndrome 366 29 Livedo reticularis 368 30 Pemphigus/pemphigoid 370 31 Radiation burn on the chest 373 32 Herpes zoster 374 33 Henoch–Schönlein purpura 376 34 Mycosis fungoides 378 35 Morphoea 380 36 Kaposi’s sarcoma (AIDS) 382 37 Porphyria 385 38 Lupus vulgaris 387 39 Dermatitis herpetiformis 389 40 Urticaria pigmentosa (mastocytosis) 391 41 Palmoplantar keratoderma (tylosis) 393 42 Secondary syphilis 395 43 Ectodermal dysplasia 397 44 Partial lipodystrophy 399 45 Fabry’s disease 401 46 Reiter’s syndrome/reactive arthritis/keratodermablennorrhagica 403 47 Malignant melanoma 405 48 Acanthosis nigricans 407 49 Keratoacanthoma 410 50 Pyoderma gangrenosum 411 51 Psychogenic/factitious 413 Station 5 Locomotor 415 1 Rheumatoid arthritis 416 2 Psoriatic arthropathy 422 3 Systemic sclerosis/CREST syndrome 425 4 Diabetic foot/Charcot’s joint 428 5 Tophaceous gout 431 6 Ankylosing spondylitis 433 7 Paget’s disease 435 8 Osteoarthritis 437 9 Marfan’s syndrome 439 10 Vasculitis 441 11 Proximal myopathy 442 12 One leg shorter and smaller than the other 443 13 Radial nerve palsy 444 14 Arthropathy associated with infl ammatory bowel disease 445 15 Polymyositis 447 16 Systemic lupus erythematosus 448 17 Old rickets 450 18 Juvenile idiopathic arthritis 452 19 Swollen knee 454 Station 5 Endocrine 457 1 Exophthalmos 458 2 Acromegaly 461 3 Graves’ disease 464 4 Goitre 467 5 Hypothyroidism 470 6 Cushing’s syndrome 473 7 Addison’s disease 478 8 Hypopituitarism 481 9 Pretibial myxoedema 483 10 Gynaecomastia 485 11 Turner’s syndrome 488 12 Klinefelter’s syndrome/hypogonadism 490 13 Bitemporal hemianopia 494 14 Diabetic foot/Charcot’s joint 495 15 Necrobiosis lipoidica diabeticorum 496 16 Short stature 497 17 Pseudohypoparathyroidism 499 18 Pendred’s syndrome 502 Station 5 Eyes 505 1 Diabetic retinopathy 506 2 Retinitis pigmentosa 511 3 Optic atrophy 512 4 Ocular palsy 514 5 Visual field defect 515 6 Retinal vein occlusion 516 7 Old choroiditis 518 8 Papilloedema 520 9 Cataracts 522 10 Myasthenia gravis 524 11 Albinism 525 12 Exophthalmos 526 13 Myelinated nerve fibres 527 14 Hypertensive retinopathy 528 15 Glaucoma/peripheral fi eld loss 530 16 Retinal artery occlusion 532 17 Asteroid hyalosis 533 18 Drusen 534 19 Laurence–Moon–Bardet–Biedl syndrome 535 20 Cytomegalovirus choroidoretinitis (AIDS) 537 21 Normal fundus 540 Station 5 Other 541 1 Bilateral parotid enlargement/Mikulicz’s syndrome 542 2 Deep venous thrombosis (DVT)/Baker’s cyst/cellulitis 543 3 Peripheral vascular disease 546 4 Osteogenesis imperfecta 548 5 Down’s syndrome 549 6 Pernicious anaemia 550 7 Klippel–Feil syndrome 552 8 Leg oedema 554 Appendices 557 1 Checklists 559 2 Examination frequency of MRCP PACES short cases 563 3 Texidor’s twinge and related matters 567 4 Abbreviations 569 Index 572

Read more less

Book Synopsis* Integrated textbook combining three subjects, haematology, clinical biochemistry and immunology to provide a one-stop text on blood science, in line with the new IBMS and NHS training structure * Suitable for blood science courses opening in many universities at senior Undergraduate level (units) and Masters level.Table of ContentsPreface, xiii Acknowledgements, xv List of Abbreviations, xvii About the Companion Website, xxi 1 Introduction to Blood Science, 1 1.1 What is blood science?, 1 1.2 Biochemistry, 6 1.3 Blood transfusion, 8 1.4 Genetics, 10 1.5 Haematology, 14 1.6 Immunology, 17 1.7 The role of blood science in modern healthcare, 19 1.8 What this book will achieve, 22 Summary, 23 References, 23 Further reading, 23 Web sites, 23 2 Analytical Techniques in Blood Science, 25 2.1 Venepuncture, 25 2.2 Anticoagulants, 26 2.3 Sample identification and tracking, 27 2.4 Technical and analytical confidence, 27 2.5 Major techniques, 32 2.6 Molecular genetics, 43 2.7 Point of care testing, 47 2.8 Health and safety in the laboratory, 48 Summary, 49 Further reading, 50 Web sites, 50 3 The Physiology of the Red Blood Cell, 51 3.1 Introduction, 51 3.2 The development of blood cells, 52 3.3 Erythropoiesis, 56 3.4 The red cell membrane, 58 3.5 The cytoplasm of the red cell, 60 3.6 Oxygen transport, 66 3.7 Recycling the red cell, 68 3.8 Red cell indices in the full blood count, 69 3.9 Morphology of the red cell, 72 Summary, 74 Further reading, 74 4 The Pathology of the Red Blood Cell, 75 4.1 Introduction: diseases of red cells, 75 4.2 Anaemia resulting from attack on, or stress to, the bone marrow, 78 4.3 Anaemia due to deficiency, 80 4.4 Intrinsic defects in the red cell, 85 4.5 External factors acting on healthy cells, 100 4.6 Erythrocytosis and polycythaemia, 103 4.7 Molecular genetics and red cell disease, 105 4.8 Inclusion bodies, 105 4.9 Case studies, 105 Summary, 107 References, 107 Further reading, 107 5 White Blood Cells in Health and Disease, 109 5.1 Introduction, 109 5.2 Leukopoiesis, 111 5.3 Neutrophils, 115 5.4 Lymphocytes, 116 5.5 Monocytes, 117 5.6 Eosinophils, 118 5.7 Basophils, 119 5.8 Leukocytes in action, 120 5.9 White cells in clinical medicine, 127 5.10 Case studies, 132 Summary, 132 Further reading, 133 6 White Blood Cell Malignancy 135 6.1 The genetic basis of leukocyte malignancy, 135 6.2 Tissue techniques in haemato-oncology, 139 6.3 Leukaemia, 141 6.4 Lymphoma, 149 6.5 Myeloma and related conditions, 152 6.6 Myelofibrosis and myelodysplasia, 157 6.7 Case studies, 157 Summary, 158 Further reading, 159 Guidelines, 159 7 The Physiology and Pathology of Haemostasis, 161 7.1 The blood vessel wall, 162 7.2 Platelets, 163 7.3 The coagulation pathway, 165 7.4 Haemostasis as the balance between thrombus formation and removal, 168 7.5 The haemostasis laboratory, 171 7.6 The pathology of thrombosis, 173 Summary, 175 Further reading, 175 8 The Diagnosis and Management of Disorders of Haemostasis, 177 8.1 Thrombosis 1: overactive platelets and thrombocytosis, 177 8.2 Thrombosis 2: overactive coagulation, 181 8.3 Haemorrhage 1: platelet underactivity and thrombocytopenia, 193 8.4 Haemorrhage 2: coagulation underactivity, 199 8.5 Disseminated intravascular coagulation, 203 8.6 Molecular genetics in haemostasis, 204 8.7 Case studies, 205 Summary, 206 References, 206 Further reading, 207 Guidelines, 207 Web sites, 207 9 Immunopathology, 209 9.1 Introduction, 209 9.2 Basics of the immune system, 210 9.3 Humoral immunity, 212 9.4 Immunopathology 1: immunodeficiency, 215 9.5 Immunopathology 2: hypersensitivity, 221 9.6 Immunopathology 3: autoimmune disease, 226 9.7 Immunotherapy, 232 9.8 The immunology laboratory, 234 9.9 Case studies, 238 Summary, 239 References, 240 Further reading, 240 Guidelines, 240 Web sites, 240 10 Immunogenetics and Histocompatibility, 241 10.1 The genetics of antigen recognition, 241 10.2 Human leukocyte antigens, 245 10.3 Transplantation, 251 10.4 Autoimmunity and human leukocyte antigens, 257 Summary, 260 Further reading, 260 Guidelines, 260 Web sites, 260 11 Blood Transfusion, 261 11.1 Blood collection and processing, 262 11.2 Blood groups, 265 11.3 Laboratory practice of blood transfusion, 273 11.4 Clinical practice of blood transfusion, 279 11.5 Hazards of blood transfusion, 281 Summary, 284 References, 284 Further reading, 284 Guidelines, 284 Web sites, 285 12 Waste Products, Electrolytes and Renal Disease, 287 12.1 Renal anatomy and physiology, 287 12.2 Homeostasis, 288 12.3 Excretion, 295 12.4 Renal endocrinology, 297 12.5 Renal disease, 298 12.6 Case studies, 301 Summary, 303 Further reading, 303 Guidelines, 303 Web sites, 303 13 Hydrogen Ions, pH, and Acid–Base Disorders, 305 13.1 Ions and molecules, 305 13.2 Blood gases, 308 13.3 Acidosis (pH <7.3), 312 13.4 Alkalosis (pH >7.5), 313 13.5 Mixed acid–base conditions, 314 13.6 Clinical interpretation, 314 13.7 Case studies, 315 Summary, 316 Further reading, 317 Web site, 317 14 Glucose, Lipids and Atherosclerosis, 319 14.1 Glucose, 319 14.2 Dyslipidaemia, 333 14.3 Atherosclerosis, 343 14.4 Case studies, 347 Summary, 348 Further reading, 348 Guidelines, 349 Web sites, 349 15 Calcium, Phosphate, Magnesium and Bone Disease, 351 15.1 Calcium, 352 15.2 Phosphates, 355 15.3 Magnesium, 355 15.4 The laboratory, 355 15.5 Disorders of calcium homeostasis, 357 15.6 Disorders of phosphate homeostasis, 360 15.7 Disorders of magnesium homeostasis, 362 15.8 Bone physiology, 363 15.9 Bone disease, 364 15.10 Case studies, 368 Summary, 369 Further reading, 370 Guidelines, 370 Web sites, 370 16 Nutrients and Gastrointestinal Disorders, 371 16.1 Nutrients, 371 16.2 The intestines, 375 16.3 Case studies, 381 Summary, 382 Further reading, 382 Guidelines, 382 17 Liver Function Tests and Plasma Proteins, 383 17.1 Anatomy and physiology of the liver, 384 17.2 Liver function tests, 389 17.3 Diseases of the liver, 390 17.4 Plasma proteins, 396 17.5 Case studies, 405 Summary, 406 Further reading, 406 Web sites, 406 18 Hormones and Endocrine Disorders, 407 18.1 Endocrine physiology, 407 18.2 The pathology of the endocrine system, 417 18.3 Case studies, 434 Summary, 435 Further reading, 435 Web sites, 436 19 Cancer and Tumour Markers, 437 19.1 General concepts in cancer biology, 437 19.2 Blood science and cancer, 440 19.3 Molecular genetics, 444 19.4 Case studies, 445 Summary, 446 Further reading, 446 Guidelines, 447 Web sites, 447 20 Inherited Metabolic Disorders, 449 20.1 The genetics of inheritance, 449 20.2 Molecular inherited metabolic disorders, 451 20.3 Organelle inherited metabolic disorders, 455 20.4 Antenatal diagnosis and neonatal screening, 455 20.5 Case studies, 456 Summary, 457 Further reading, 457 21 Drugs and Poisons, 459 21.1 Toxicology, 459 21.2 Toxicology of specific compounds, 461 21.3 Therapeutic drug monitoring, 465 21.4 Case studies, 468 Summary, 469 References, 469 Further reading, 469 22 Case Reports in Blood Science, 471 Abbreviations, 471 Case report 1, 472 Anaemia, hypercalcaemia, proteinuria, myeloma Case report 2, 473 Diabetes, glycated haemoglobin, chronic renal failure Case report 3, 474 Acute kidney injury, leucocytosis, neutrophilia, viruses Case report 4, 475 Part 1: Obesity, colorectal cancer, CEA, hypothyroidism. Part 2: Alcoholism, raised GGT and triacylglycerols Case report 5, 477 Part 1: No abnormalities. Part 2: Asthma, raised IgE. Part 3: Falling haemoglobin, rising ESR, lung cancer Case report 6, 479 Hypothyroidism, marginally reduced haemoglobin Case report 7, 480 Raised CRP, ESR, rheumatoid factor and anti-nuclear antibodies; borderline anti-dsDNA antibodies, low C3, low eGFR and so mild renal failure, systemic lupus erythematosus Case report 8, 481 Normal blood results in renal transplantation Case report 9, 482 Falling albumin, eGFR, haemoglobin, red cell count and platelets, rising ESR, white cell count and neutrophila, CRP, urea and creatinine, septicaemia Case report 10, 484 Microcytic anaemia, thrombocytopenia, lymphocytosis, abnormal LFTs, falling albumin, raised CRP, myositis with raised CK, viruses Case report 11, 486 Acidosis, hyperglycaemia, diabetic ketoacidosis, acute renal injury, raised urea and creatinine Case report 12, 487 Low haemoglobin, thrombocytopenia, raised CRP and d-dimers, abnormal LFTs, malaria, pregnancy Case report 13, 488 Raised aldosterone, hypernatraemia, hypokalaemia, Conn’s syndrome Case report 14, 489 Paediatric diabetic ketoacidosis, hyperglycaemia, low bicarbonate, raised phosphates, ALP and proteins References, 490 Appendix: Reference Ranges, 491 Further Reading, 493 Glossary, 495 Index, 519

Read more less

Book SynopsisThe definitive companion for medical science study and revision Medical Sciences at a Glance consolidates the scientific knowledge a student needs to know to provide a solid framework of key facts to build on.Table of ContentsPreface 7 Contributors 8 Abbreviations 9 How To Use Your Textbook 12 About the Companion Website 15 Part 1 Cellular Structure and Function 1 Cells 16 Sebastiaan Winkler 2 Organisation of Cell Membranes 18 Sebastiaan Winkler 3 Cell Organelles 20 Sebastiaan Winkler 4 Protein Biochemistry 22 Fergus Doherty 5 Lipid Biochemistry 24 Jane Arnold 6 Carbohydrate Biochemistry 26 Fergus Doherty 7 Basic Mechanisms of Drug Action 28 Michael D Randall Part 2 Cellular Metabolism 8 General Principles of Cellular Metabolism 30 Fergus Doherty 9 Enzymes 32 Michael D Randall 10 Central Metabolic Pathways 34 Fergus Doherty 11 Fat Metabolism 36 Fergus Doherty 12 Glucose Metabolism 38 Fergus Doherty 13 Amino Acid Metabolism 40 Jane Arnold Part 3 Molecular and Medical Genetics 14 Principles of Molecular Genetics 42 Stuart Brown 15 DNA and RNA 44 Stuart Brown 16 Gene Expression 46 Stuart Brown 17 Medical Genetics 48 Stuart Brown Part 4 Nerve and Muscle 18 Cell Excitability 50 Michael D Randall 19 Nervous Conduction 52 Michael D Randall 20 Synaptic Transmission 54 Michael D Randall 21 Autonomic Nervous System 56 Michael D Randall 22 Neuromuscular Transmission 58 Michael D Randall Part 5 Respiratory System 23 Structure of the Respiratory System 60 Siobhan Loughna and Deborah Merrick 24 Respiratory Physiology 62 Steven Burr 25 Gas Transport 64 Steven Burr 26 Control of Breathing 66 Steven Burr 27 Acid-Base Physiology 68 Steven Burr 28 Respiratory Pathophysiology 70 Steven Burr Part 6 Cardiovascular System 29 Structure of the Cardiovascular System 72 Siobhan Loughna and Deborah Merrick 30 Cardiac Physiology 74 Michael D Randall 31 Cardiovascular Physiology 76 Michael D Randall 32 Blood Pressure 78 Michael D Randall 33 Blood: 1 80 Michael D Randall 34 Blood: 2 82 Michael D Randall 35 Cardiovascular Pathophysiology 84 Michael D Randall Part 7 Renal System 36 Structure of the Renal System 86 Deborah Merrick 37 Renal Physiology: Filtration and Tubular Function 88 Sue Chan 38 Renal Physiology: Loop of Henle 90 Sue Chan 39 Regulation of Body Fluids 92 Sue Chan 40 Bladder Function and Dysfunction 94 Michael D Randall Part 8 Digestive System 41 Structure of the Gastrointestinal System 96 Deborah Merrick 42 Upper Gastrointestinal Physiology 98 Michael D Randall 43 Lower Gastrointestinal Physiology 100 Michael D Randall 44 The Liver 102 Michael D Randall Part 9 Endocrine System 45 Hypothalamus and Pituitary 104 Sue Chan 46 Endocrine Pancreas 106 Sue Chan 47 Thyroid Gland 108 Sue Chan 48 Adrenal Glands and Steroid Hormones 110 Sue Chan Part 10 Reproductive Function 49 The Genital System 112 Deborah Merrick 50 Reproductive Physiology 114 Michael D Randall 51 Human Embryology 116 Deborah Merrick Part 11 Central Nervous System 52 Structure of the Central Nervous System 118 Deborah Merrick 53 The Sensory System 120 Deborah Merrick 54 The Motor System 122 Deborah Merrick 55 Hypothalamus and Thalamus 124 Deborah Merrick 56 Central Nervous System Function 126 Michael D Randall 57 CNS Disorders and Treatments 128 Michael D Randall Part 12 Infections and Immunity 58 Pathogens 130 James Lazenby And Chien-Yi Chang 59 Recognition of Pathogens 134 Lucy Fairclough and Ian Todd 60 Defence Against Pathogens 136 Lucy Fairclough and Ian Todd 61 Integration of the Immune Response 138 Lucy Fairclough and Ian Todd 62 Immunopathology 140 Ian Todd and Lucy Fairclough 63 Immunodeficiency Disorders 142 Ian Todd and Lucy Fairclough Part 13 Cancer 64 Cancer 145 Stuart Brown 65 Chemotherapy 148 Michael D Randall Appendix 1 Cross References to Medicine at a Glance (Davey) 150 Index 154

Read more less

Book SynopsisInterest in the field of medical toxicology has grown rapidly, but the medical literature lacks an authoritative toxicology reference work dedicated to natural substances and drugs of abuse. This two-volume set combines Medical Toxicology of Natural Substances and Medical Toxicology of Drugs Abuse to deliver an in-depth, sub-specialty, readily accessible reference on these topics. Professionals in diverse fields, who typically do not need most of the information in a general medical toxicology book, can quickly apply the contents of these volumes to searchable databases and other electronic venues.

Read more less

Book SynopsisABC of Multimorbidity is the first title to provide primary care practitioners with a practical approach to the complex issues of treating and managing patients with more than one morbidity. Ageing populations and earlier diagnosis of chronic conditions mean more people are living longer with multimorbidity.Trade Review“This ABC series book is a practical resource that is very useful to all physicians, regardless of their specialty and level of practice. Readers will find in this book information that will contribute to improving the quality of multimorbid patient’s management.” (European Urology Today,1 October 2014)Table of ContentsContributors vii Preface ix Foreword xi 1 Introducing Multimorbidity 1Martin Fortin StewartW. Mercer and Chris Salisbury 2 How Common Is Multimorbidity? 5Marjan van den Akker and Christiane Muth 3 How Does Multimorbidity Affect Patients? 8Elizabeth A. Bayliss 4 Effects of Multimorbidity on Healthcare Resource Use 12Efrat Shadmi Karen Kinder and Jonathan P.Weiner 5 Multimorbidity and the Primary Care Clinic 17Stewart W. Mercer and Chris Salisbury 6 Multimorbidity and Patient-Centred Care 22Moira Stewart and Martin Fortin 7 Multimorbidity and the Healthcare Electronic Medical Record 26Amanda L. Terry and Sonny Cejic 8 Treatment Burden and Multimorbidity 30Katie I. Gallacher Victor M. Montori Carl R. May and Frances S. Mair 9 Multimorbidity and Mental Health 34Peter Bower Peter Coventry Linda Gask and Jane Gunn 10 The Impact of Multimorbidity on Quality and Safety of Health Care 38Jose M. Valderas Ignacio Ricci-Cabello and Concepción Violán 11 Implications of Multimorbidity for Health Policy 41Chris Salisbury and Martin Roland 12 Optimizing Outcomes in Multimorbidity 46Stewart W. Mercer Martin Fortin and Chris Salisbury Index 49

Read more less

Book SynopsisMolecular Aspects of Aging: Understanding Lung Aging covers recent research in the mechanisms that contribute to cellular senescence.Table of ContentsContributors xi Preface xiii 1 The Demography of Aging 1 David E. Bloom and Sinead Shannon 1.1 Introduction 1 1.2 Demographic trends 1 1.2.1 Fertility rates 2 1.2.2 Mortality rates and life expectancy 2 1.2.3 Proportion of older people 3 1.3 Impact of aging 4 1.3.1 Noncommunicable disease trends 4 1.3.2 Risk factors 5 1.3.3 Impact of NCDs on health and disability 6 1.3.4 Increase in multimorbidities 7 1.3.5 Impact on expenditure 7 1.4 Policy responses 8 1.4.1 Preventing and managing NCDs 8 1.4.2 Promoting exercise 9 1.4.3 Monitoring health-risk behaviors (and chronic health conditions) 9 1.5 Conclusion 9 References 10 2 The Omics of Aging: Insights from Genomes upon Stress 13 Ismene Karakasilioti, Anna Ioannidou, and George A. Garinis 2.1 Introduction 13 2.2 Safeguarding the nuclear genome 14 2.3 NER progerias and their connection to lifespan regulatory mechanisms 15 2.4 Triggering a survival response in the absence of a DNA repair defect 16 2.5 The omics connection between progeria and longevity 19 2.6 Triggering of systemic versus cell-autonomous features of the survival response 20 2.7 The omics connection between NER progeria, transcription, and longevity 21 2.8 Future perspectives 22 References 22 3 Protein Quality Control Coming of Age 27 Silke Meiners 3.1 Introduction 27 3.2 The aging molecular chaperone network 29 3.3 Protein degradation pathways in aging 30 3.3.1 Lysosomal autophagy pathway 30 3.3.2 Ubiquitin–proteasome system 32 3.4 Compartment-specific protein quality control 34 3.4.1 The aging ER stress response 34 3.5 Conclusion 35 References 35 4 Telomerase Function in Aging 41 Rodrigo T. Calado 4.1 Telomeres 41 4.2 Telomerase 43 4.3 Telomeres and human disease 45 4.3.1 Telomere dysfunction in the lungs 46 4.4 Telomeres biology, aging, and longevity 47 4.5 Conclusion 48 References 48 5 The Cellular Senescence Program 53 Pooja Shivshankar and Claude Jourdan Le Saux 5.1 Cellular senescence and evidence of senescence in a cell 53 5.1.1 Characteristics of senescent cells and the inflammatory microenvironment 53 5.1.2 Detection of senescent cells in vitro and in vivo 54 5.2 Conditions associated with cellular senescence 55 5.2.1 Oxidative stress 55 5.2.2 DNA damage 55 5.2.3 Cell cycle arrest and senescence 56 5.3 Mechanisms/pathways of senescence induction 56 5.3.1 The p53/p21 pathway 56 5.3.2 The p16/pRB pathway 57 5.3.3 Convergence/coactivation of p53/p21 and p16/pRB pathways 57 5.3.4 Induction of senescence via molecular signaling 57 5.4 Cellular senescence in aging and age-related diseases of the lungs 58 5.4.1 Normal aging 59 5.4.2 Pneumonia 59 5.4.3 Chronic obstructive pulmonary disease 60 5.4.4 Idiopathic pulmonary fibrosis 60 5.5 Conclusion 61 References 61 6 Signaling Networks Controlling Cellular Senescence 67 Leena P. Desai, Yan Y. Sanders, and Victor J. Thannickal 6.1 Introduction 67 6.2 Classification of cellular senescence 69 6.2.1 Intrinsic pathway 69 6.2.2 Extrinsic pathway 69 6.2.3 Reversibility of cellular senescence 70 6.3 Cross talk of signaling pathways 70 6.3.1 Protein kinases 70 6.3.2 Metabolic pathways 71 6.3.3 Mitochondria and reactive oxygen species 71 6.3.4 Integrin and focal adhesion signaling 72 6.3.5 Transforming growth factor-β1 73 6.3.6 Epigenetic mechanisms 73 6.4 Conclusion 76 References 77 7 Immune Senescence 85 Kevin P. High 7.1 Introduction 85 7.2 Barrier defenses and innate immunity in older adults 86 7.2.1 Barrier defenses 86 7.2.2 Innate immunity 86 7.3 Adaptive immune responses 88 7.3.1 B cell number and function 88 7.3.2 T cell number, subtypes, and function 89 7.3.3 T cell activation, differentiation, exhaustion, and senescence 90 7.4 Consequences of immune senescence 91 7.4.1 Impaired vaccine responses, increased risk of infection, and age-related illness 91 7.4.2 Immune senescence: A cause of aging itself 93 7.5 Conclusion 94 References 95 8 Developmental and Physiological Aging of the Lung 99 Kent E. Pinkerton, Lei Wang, Suzette M. Smiley-Jewell, Jingyi Xu, and Francis H.Y. Green 8.1 Introduction 99 8.2 The aging lung 99 8.2.1 Alterations in lung function and anatomy 99 8.2.2 Oxidative stress and lung antioxidant defenses 101 8.2.3 Immune system changes with aging 101 8.2.4 Body mass 102 8.2.5 Airway receptor and endocrine changes with aging 103 8.3 An animal model of the aging lung: The rat 104 8.3.1 The tracheobronchial tree and epithelium of the aging rat 104 8.3.2 Parenchymal lung structure in the aging rat 105 8.3.3 Alveolar tissue compartments 106 8.4 Conclusion 110 Acknowledgments 110 References 111 9 Mouse Models to Explore the Aging Lung 117 Mingyi Wang and Deepak A. Deshpande 9.1 Pulmonary changes during aging 117 9.1.1 Advantages of mouse models for studying physiological lung changes 118 9.2 Key findings from mouse models of aging 119 9.2.1 Longevity and lung function in mice 120 9.2.2 Different strains of mice have different alterations in lung mechanics 120 9.2.3 Transgenic mouse model to study aging in the lungs 121 9.3 Age is a risk factor for obstructive pulmonary diseases 123 9.4 Challenges ahead 124 9.5 Conclusion 125 Acknowledgments 126 References 126 10 Evidence for Premature Lung Aging of the Injured Neonatal Lung as Exemplified by Bronchopulmonary Dysplasia 131 Anne Hilgendorff 10.1 Introducing bronchopulmonary dysplasia 131 10.2 Altered pulmonary function in infants with BPD 132 10.3 Response to injury 133 10.3.1 Oxidative stress response 134 10.3.2 Extracellular matrix remodeling 136 10.3.3 Inflammation 136 10.3.4 Morphogenetic response 137 10.4 Prenatal and genetic predisposition 137 10.5 Conclusion 138 References 138 11 Remodeling of the Extracellular Matrix in the Aging Lung 145 Jesse Roman 11.1 Introduction 145 11.2 The aging lung 145 11.3 Activation of tissue remodeling in the senescent lung 146 11.4 The aging lung fibroblast 148 11.5 Potential role of oxidant stress in triggering remodeling in the aging lung 149 11.6 Implications for remodeling of the lung extracellular matrix in the aged lung 150 11.7 Conclusions 152 Acknowledgments 154 References 154 12 Aging Mesenchymal Stem Cells in Lung Disease 159 Maria G. Kapetanaki, Ana L. Mora, and Mauricio Rojas 12.1 Aging and lung diseases 159 12.2 Mesenchymal stem cells (MSCs) 160 12.2.1 Description of MSCs 160 12.2.2 Characterization of MSCs 160 12.2.3 Functional properties of MSCs 161 12.3 Impact of aging on mesenchymal stem cells 162 12.3.1 In vitro aging of MSCs 162 12.3.2 Age-related changes in B-MSCs 163 12.3.3 Aging of B-MSCs versus aging of the organism 163 12.4 B-MSCs in disease 164 12.5 B-MSCs in therapy 166 12.5.1 Ex vivo expansion 166 12.5.2 Conditions affecting the expansion 167 12.5.3 Autologous versus allogeneic B-MSCs 167 12.5.4 Combination of cell preparations 167 12.5.5 Delivery and targeting 167 12.6 Conclusion 167 Acknowledgments 168 References 168 13 COPD as a Disease of Premature Aging 173 Laurent Boyer, Jorge Boczkowski, and Serge Adnot 13.1 Introduction 173 13.2 Senescent cells contribute to the pathogenesis of COPD 174 13.2.1 Accumulation of senescent cells in COPD lungs 174 13.2.2 Inflammation and lung-cell senescence in COPD 175 13.2.3 Emphysema and lung-cell senescence in COPD 176 13.2.4 Pulmonary hypertension and cell senescence in COPD 177 13.3 Lung dysfunction and the general process of premature aging in COPD 179 13.3.1 Clinical manifestations of premature aging in COPD patients 179 13.3.2 Role for lung alterations in systemic premature aging during COPD 180 13.4 Conclusion 181 References 181 14 Lung Infections and Aging 185 Jacqueline M. Kruser and Keith C. Meyer 14.1 Introduction 185 14.2 Aging and immunosenescence 185 14.2.1 Innate immunity 187 14.2.2 Adaptive immunity 188 14.2.3 Autoimmunity 189 14.2.4 Lung-specific changes in immunity with aging 190 14.3 Inflamm-aging and susceptibility to infection 190 14.4 Respiratory infection and regulation of host responses 192 14.5 Preventing respiratory infection 194 14.6 Summary and conclusions 195 References 195 Index 201

Read more less

Book SynopsisKnowledge Translation in Health Care is a practical introduction to knowledge translation for everyone working and learning within health policy and funding agencies, and as researchers, clinicians and trainees. Using everyday examples, it explains how to use research findings to improve health care in real life.Trade Review"The content will be of value to lecturers and trainers and those intent on orchestrating change to improve health care in daily practice and committed to using evidence base to drive change." (British Global & Travel Health Journal, 1 January 2013) Table of ContentsSection 1: Introduction 1.1 Introduction: Knowledge translation-What it is and what it isn’t Sharon E. Straus, Jacqueline Tetroe, and Ian D. Graham 1.2 Integrated Knowledge Translation Sarah Bowen and Ian D. Graham Section 2: Knowledge Creation 2.0 Introduction-The K in KT: Knowledge Creation Sharon E. Straus 2.1 Knowledge Synthesis Andrea C. Tricco, Jennifer Tetzlaff, and David Moher 2.2 Knowledge Translation Tools Melissa C. Brouwers, Annette M. O’Connor, and Dawn Stacey 2.3 Searching for Research Findings and KT Literature K. Ann McKibbon and Cynthia Lokker 2.4 Knowledge Dissemination: End of Grant Knowledge Transfer Ian D. Graham, Jacqueline M. Tetroe, and Michelle Gagnon Section 3: The Action Cycle 3.0 Introduction Sharon E. Straus 3.1 Identifying the knowledge to action gaps Alison L Kitson and Sharon E. Straus 3.2 Adapting knowledge to a local context Margaret B. Harrison, Ian D. Graham, Beatrice Fervers, and Joan van den Hoek Subsection 3.3: Barriers 3.3.a Barriers and facilitators – strategies for identification and measurement France Légaré and Peng Zhang 3.3.b Selecting and tailoring Knowledge Translation interventions; Mapping KT interventions to barriers and facilitators Heather Colquhoun, Jeremy Grimshaw, and Michel Wensing Subsection 3.4: Selecting KT Interventions 3.4.a Developing and selecting Knowledge Translation interventions Michel Wensing, Marije Bosch, and Richard Grol 3.4.b Formal educational interventions Dave Davis, Nancy Davis, and Nathan Johnson 3.4.c Linkage and Exchange Interventions Ann C. Macaulay and Jonathan Salsberg 3.4.d Audit and feedback interventions Robbie Foy and Martin Eccles 3.4.e Informatics interventions Samir Gupta and K. Ann McKibbon 3.4.f Patient-direct and Patient-mediated KT Interventions Dawn Stacey and Sophie Hill 3.4.g Organisational interventions Ewan B. Ferlie 3.4.h Shared decision making France Légaré and Peng Zhang 3.4.i Financial incentive interventions Gerd Flodgren, Martin P. Eccles, Anthony Scott, and Sasha Shepperd 3.5 Monitoring knowledge use and evaluating outcomes Sharon E. Straus, Jacqueline Tetroe, Onil Bhattacharyya, Merrick Zwarenstein, and Ian D. Graham 3.6 Sustaining knowledge use Barbara Davies and Nancy Edwards Subsection 3.7 Case examples 3.7.a An Integrated Knowledge Translation Research Approach in Wound Care Ian D. Graham and Margaret B. Harrison 3.7.b Tips on implementation Judith A. Ritchie Section 4: Theories and Models of Knowledge to Action 4.1 Planned action theories Ian D. Graham, Jacqueline Tetroe, and the KT Theories Group 4.2 Cognitive psychology theories of change in provider behavior Alison M. Hutchinson and Carole A. Estabrooks 4.3 Educational theories Alison M. Hutchinson and Carole A. Estabrooks 4.4 Organizational theories Jean-Louis Denis and Pascale Lehoux 4.5 Quality improvement Anne Sales Section 5: Evaluation of Knowledge to Action 5.1 Methodologies to Evaluate Effectiveness of Knowledge Translation Interventions Onil Bhattacharyya, Leigh Hayden, and Merrick Zwarenstein 5.2 Economic evaluation of KTI Emma Quinn, Craig Mitton and Jeanette Ward Section 6: Ethics 6.1 Ethics in the Science Lifecycle: Broadening the Scope of Ethical Analysis Kristiann Allen and Jaime Flamenbaum 6.2 Ethical Issues in Cluster-Randomized Trials in Knowledge Translation Monica Taljaard, Charles Weijer, and Jeremy M. Grimshaw Index

Read more less

Book SynopsisWnt signaling in Development and Disease: Molecular Mechanisms and Biological Functions reviews the core topics in Wnt signaling, from molecular pathway mechanisms to its role in embryogenesis, adult tissue homeostasis, and chronic disease. Written by a team of expert reviewers, the book provides clear and concise coverage of the core foundations of Wnt signaling before advancing to discussion of cutting-edge scientific research. Focused on the biological insights and current scientific questions of Wnt signaling, this book will be a comprehensive and definitive resource for a wide range of researchers and students in cell signaling, cell physiology, developmental biology, and biomedical engineering, as well as anyone interested in learning more about this important and complex protein network. A definitive source of information on Wnt signaling and its role in development and disease, written by leaders in the field. Explores the role of Wnt signalingTable of ContentsContributors vii Preface xi Part 1 Molecular Signaling Mechanisms: From Pathways to Networks 1 1 Wnt Signal Production, Secretion, and Diffusion 3 Madelon M. Maurice and Hendrik C. Korswagen 2 Wnt Signaling at the Membrane 15 Gary Davidson and Christof Niehrs 3 Wnt Signal Transduction in the Cytoplasm: an Introduction to the Destruction Complex 33 Tony W. Chen, Heather A. Wallace, Yashi Ahmed, and Ethan Lee 4 An Overview of Gene Regulation by Wnt/β-Catenin Signaling 51 Chen U. Zhang and Ken M. Cadigan 5 Finding a Needle in a Genomic Haystack: Genome-Wide Approaches to Identify Wnt/TCF Transcriptional Targets 73 Chandan Bhambhani and Ken M. Cadigan 6 Introduction to β-Catenin-Independent Wnt Signaling Pathways 89 Susanne Kühl and Michael Kühl 7 Molecular Mechanisms of Wnt Pathway Specificity 101 Alexandra Schambony, Guido J.R. Zaman, and Folkert Verkaar 8 Modulation of Wnt Signaling by Endocytosis of Receptor Complexes 113 Akira Kikuchi, Shinji Matsumoto, Katsumi Fumoto, and Akira Sato 9 New Insights from Proteomic Analysis of Wnt Signaling 125 Matthew P. Walker, Dennis Goldfarb, and Michael B. Major 10 New Insights about Wnt/β-Catenin Pathway Mechanisms from Global siRNA Screens 137 Tenzin Gocha and Ramanuj DasGupta 11 Mathematical Models of Wnt Signaling Pathways 153 Michael Kühl, Barbara Kracher, Alexander Groß, and Hans A. Kestler 12 The Wnt’s Tale: On the Evolution of a Signaling Pathway 161 Jenifer C. Croce and Thomas W. Holstein Part 2 Selected Key Molecules in Wnt Signaling 177 13 Secreted Wnt Inhibitors or Modulators 179 Paola Bovolenta, Anne-Kathrin Gorny, Pilar Esteve, and Herbert Steinbeisser 14 Frizzleds as G Protein-Coupled Receptors 195 Gunnar Schulte 15 Dishevelled at the Crossroads of Pathways 207 Vítìzslav Bryja and Ondøej Bernatík 16 β-Catenin: a Key Player in Both Cell Adhesion and Wnt Signaling 217 Jonathan Pettitt 17 Evolutionary Diversification of Vertebrate TCF/LEF Structure, Function, and Regulation 225 Stefan Hoppler and Marian L. Waterman 18 Insights from Structural Analysis of Protein–Protein Interactions by Wnt Pathway Components and Functional Multiprotein Complex Formation 239 Zhihong Cheng and Wenqing Xu Part 3 Wnt Signaling in Embryonic Development and Adult Tissue Homeostasis 251 19 Wnt Signaling in Early Vertebrate Development: From Fertilization to Gastrulation 253 Eliza Zylkiewicz, Sergei Y. Sokol, and Stefan Hoppler 20 Wnt/β-Catenin Signaling in Embryonic Stem Cells: Insights into Early Mammalian Development 267 Kathryn C. Davidson 21 Wnt Signaling in Neural Development 279 Richard I. Dorsky 22 Wnt Signaling in Heart Organogenesis 293 Stefan Hoppler, Silvia Mazzotta, and Michael Kühl 23 Wnt Signaling in Kidney Organogenesis 303 Kimmo Halt and Seppo Vainio 24 Wnt Signaling Regulation of Tissue Architecture (EMT and MET) and Morphogenesis: Consequences for Colorectal and Liver Cancer 315 Theodora Fifis, Bang M. Tran, Renate H.M. Schwab, Timothy M. Johanson, Nadia Warner, Nick Barker, and Elizabeth Vincan 25 Wnt Signaling in Adult Stem Cells: Tissue Homeostasis and Regeneration 329 Frank J.T. Staal and Riccardo Fodde 26 Restoring Tissue Homeostasis: Wnt Signaling in Tissue Regeneration After Acute Injury 339 Günes Özhan and Gilbert Weidinger Part 4 Wnt Signaling in Chronic Disease 357 27 Wnt Signaling and Colorectal Cancer 359 Kevin Myant and Owen J. Sansom 28 Wnt Signaling in Melanoma 369 Jamie N. Anastas and Andy J. Chien 29 Wnt Signaling in Mood and Psychotic Disorders 379 Stephen J. Haggarty, Karun Singh, Roy H. Perlis, and Rakesh Karmacharya 30 Neuropsychiatric Disease-Associated Genetic Variation in the Wnt Pathway 393 Stephen J. Haggarty, Karun Singh, Roy H. Perlis, and Rakesh Karmacharya 31 Wnt Signaling in Dementia 411 Stephen J. Haggarty 32 Therapeutic Targeting of the Wnt Signaling Network 421 Felicity Rudge and Trevor Dale Index 445

Read more less

Book SynopsisForensic medicine is a broad and evolving field with areas of rapid progress embracing both clinical and pathological aspects of practice, in which there may be considerable overlap. This is the second volume in a series that provides a unique, in-depth and critical update on selected topics of direct relevance to those practising in the field of clinical forensic medicine and related areas including lawyers, police, medical practitioners, forensic scientists, and students. The chapters endeavour to maintain a relevance to an international, multi-professional audience and include chapters on: DNA decontamination, The toxicity of novel psychoactive substances, The relevance of gastric contents in the timing of death, The effects of controlled energy devices, The main risk factors for driving impairment, The risk factors for harm to health of detainees in short-term custody, Autoerotic deaths, Child malTable of ContentsList of Contributors ix Preface xix Chapter One: DNA contamination – a pragmatic clinical view 1 Contamination considerations 1 DNA profiling 6 DNA deposits 10 Decontamination 11 General approach to DNA decontamination 20 Contamination 20 Cleaning and the DNA laboratory 22 Cleaning and decontamination of forensic examination suites – the way forward 26 References 31 Chapter Two: The toxicity of the novel psychoactive substances 35 Introduction 35 Acute toxicity 35 Chronic toxicity 40 Deaths 41 References 44 Chapter Three: Postmortem gastric content analysis: its role in determining time since death 47 Introduction 47 The physiology of gastric emptying 48 Gastric motility and emptying 49 Methods for measuring gastric emptying 52 Experimental studies 52 Factors affecting gastric emptying (in adults) 53 Analysis of gastric contents 56 Usefulness of gastric contents in time of death estimations 61 Conclusion 62 Acknowledgments 63 References 63 Chapter Four: Conducted energy devices 67 Overview 67 What are conducted energy devices? 67 Modes of use of the TASER ® X26, TASER ® X26P and TASER ® X2 68 The electrical outputs of the TASER ® X26, X26P and X2 68 Operationally exploited effects of TASER ® CEDs: pain and neuromuscular incapacitation 70 Adverse effects associated with use of the TASER ® X26 71 Conclusions 76 References 77 Chapter Five: Autoerotic deaths 81 Historical context 81 Definition 83 Incidence 85 Investigation of autoerotic deaths 86 Typical methods of autoerotic death 88 Atypical methods of autoerotic deaths 91 Typical and atypical victims 92 Summary 94 References 94 Chapter Six: Excited Delirium Syndrome: aetiology, identification and treatment 97 Introduction 97 Aetiology 101 Diagnosis 103 Initial approach and work‐up 104 Medication treatment options for ExDS 106 Supportive treatment 110 Conclusions 112 References 114 Chapter Seven: Automatism – wading through the quagmire 119 Introduction 119 Definitions of automatism 120 The law 121 Medical conditions capable, or possibly capable, of founding a defence of automatism 123 Sentencing and mitigation 134 Proposals for reform in England and Wales 135 Acknowledgments 135 Law reports 135 References 136 Chapter Eight: Classification of personality disorders, clinical manifestations and treatment 139 Introduction 139 What is personality disorder? 139 Dimensional or categorical diagnostic approaches? 141 Prevalence 142 The hybrid model 143 Assessment 143 Specific issues in forensic medicine settings 149 References 150 Chapter Nine: Driving impairment: the main risk factors 153 Introduction 153 Legislative approaches 155 Sobriety assessment 158 Specific drugs 162 Forensic specimens in drug driving cases 168 Medical conditions and fitness to drive 169 Sleep deprivation 171 Conclusions 172 References 172 Chapter Ten: Risk factors for death or harm to health for detainees in short‐term police custody 179 Introduction 179 The background to healthcare in police custody 179 The nature of health problems of detainees 180 Deaths and harm in police custody 185 Excited Delirium Syndrome 190 Broad principles of care 191 Identification and diversion 197 Prevention of death and harm in police custody 202 References 203 Chapter Eleven: The utility of radiological investigation of suspected abusive head trauma in children 207 Introduction 207 Injury patterns 207 Anatomy of the head 208 Scalp injury 209 Skull injury 209 Estimate of time of injury of skull fractures 213 Mimics of skull fractures 214 Tips for investigating suspected skull fracture 217 Intracranial manifestations of head injury 218 Subdural haemorrhage 219 Subarachnoid haemorrhage 233 Extradural haemorrhage 234 Cortical contusions 235 Diffuse axonal injury (shear injury) 235 Brain oedema, swelling and hypoxic ischaemic brain injury 236 Conclusion 240 References 240 Chapter Twelve: Child maltreatment: detection and diagnosis 243 Introduction 243 Defining child abuse and neglect 244 The physician’s role in detecting child abuse 244 Contributing and risk factors for child abuse 246 General signs and symptoms of child abuse 246 Physical signs of child abuse 247 Fabricated or induced illness 257 Specific clinical presentations suspect for child abuse 259 Recognizing neglect 260 Screening instruments for detection of child abuse in Emergency Departments 260 Medical conditions that mimic child abuse 262 Summary and conclusion 262 References 265 Chapter Thirteen: Recovery of remains in potential crimes against humanity investigations – a forensic anthropological approach 269 Forensic anthropology and investigations into human rights violations and crimes against humanity 269 The characteristics of forensic anthropological investigations into human rights violations and crimes against humanity 272 The main mistakes made in forensics 274 Phases of the forensic anthropological investigation in the context of human rights violations 275 A multidisciplinary approach 281 Complex cases 282 Lessons learned and considerations 283 Conclusions 284 Acknowledgments 284 References 285 Chapter Fourteen: Field missions 287 Introduction 287 S: Situation 288 M: Mission 289 E: Execution 289 A: Administration and logistics 291 C: Communications and command 295 S: Security 295 Other mission‐related matters 296 Strategic security assessments 297 Conclusion 311 Appendix A-Mission plan template 312 Appendix B-Example of team functions for personnel required for the exhumation of human remains from a mass grave 314 Index 317

Read more less

Book SynopsisEpilepsy is a complicated neurological condition with variable manifestations, numerous etiologies, and a diverse range of treatments. It is a chronic disease that, in many cases, can be controlled. However, treatment requires accurate clinical evaluation to allow intelligent treatment choices.Table of ContentsContributor List ix Series Foreword xiii Preface xv Part I: Epilepsy Basics 1 Recognizing Seizures and Epilepsy: Insights from Pathophysiology 3 Carl E. Stafstrom 2 Classifying Epileptic Seizures and the Epilepsies 10 Valeria M. Muro and Mary B. Connolly 3 What Causes Epilepsy? 15 Anna Rosati and Renzo Guerrini 4 Epidemiology of Seizures and Epilepsy 28 Aidan Neligan and Josemir W. Sander Part II: Working up Seizures and Epilepsy 5 Diagnosing and Localizing Seizures at the Bedside and in Clinic 35 Joseph I. Sirven 6 Psychogenic Nonepileptic Episodes 42 Vaishali S. Phatak 7 What Can the EEG Tell Us? 45 Mark Quigg 8 What Can Neuroimaging Tell Us? 54 Edward J. Novotny 9 Workup of New-Onset Seizures 61 Jennifer Langer 10 Evaluation of the Patient with Medically Refractory Epilepsy 67 Gregory L. Holmes Part III: Using Antiepileptic Medications 11 Choosing, Initiating, Adjusting, and Changing Antiepileptic Medications 77 John W. Miller 12 Antiepileptic Drug Adverse Effects: What to Watch Out For 84 Jacquelyn L. Bainbridge and Caleb Y. Oh 13 Antiepileptic Drug Interactions 91 Philip N. Patsalos 14 Recognizing Intractability to Antiepileptic Medication 102 Bassel W. Abou-Khalil 15 Optimizing Antiepileptic Drug Therapy in Refractory Epilepsy 107 Nicholas P. Poolos 16 Rescue Medications for Home Treatment of Acute Seizures 112 Peter Wolf and Rûta Mameniškienë 17 When and How to Stop Antiepileptic Drugs 118 John D. Hixson 18 Using Parenteral Antiepileptic Medications 122 Jane G. Boggs 19 Pharmacopeia 126 Gail D. Anderson Part IV: Special Topics in Pediatric Epilepsy 20 Seizures in the Neonate 141 Adam L. Hartman and Frances J. Northington 21 Benign and Malignant Childhood Epilepsies 147 Katherine C. Nickels and Elaine C. Wirrell 22 Epilepsy: When to Perform a Genetic Analysis 159 Heather E. Olson and Annapurna Poduri 23 Metabolic Disorders Not to Miss 167 Phillip L. Pearl and Yuezhou Joe Yu Part V: Special Topics in Adult Epilepsy 24 Juvenile Myoclonic Epilepsy and Other Primary Generalized Epilepsies 177 Shahin Hakimian 25 Epilepsy in Women of Childbearing Age 184 Autumn Klein 26 Epilepsy After Sixty 189 Edward Faught Part VI: What can be done when medication doesn’t work? 27 When Should Epilepsy Neurosurgery Be Considered, and What Can It Accomplish? 199 Paul A. Garcia 28 When Should Vagus Nerve Stimulation Be Considered, and What Can It Accomplish? 205 Pearce J. Korb and Sandra L. Helmers 29 Ketogenic Diet and Alternative Therapies 210 Dana Ekstein and Steven C. Schachter Part VII: How are acute seizures and status epilepticus evaluated and treated in the emergency department and the hospital? 30 acute Symptomatic Seizures in Children and Adults: Evaluation and Treatment 217 J. Stephen Huff and Jessica L. Carpenter 31 Evaluating and Treating Status Epilepticus 222 Jeffrey Bolton and Howard P. Goodkin 32 Recognizing, Assessing, and Treating Seizures and Status Epilepticus in the ICU 227 Nicolas Gaspard and Lawrence J. Hirsch Part VIII: The morbidity and mortality of epilepsy 33 mortality in Epilepsy 243 Elizabeth J. Donner 34 Accidents in Epilepsy 248 Allan Krumholz and Ana M. Sanchez 35 Medical Comorbidity in Epilepsy 253 Kimberly L. Pargeon and Sheryl R. Haut 36 Cognitive Effects of Chronic Epilepsy 260 Daniel L. Drane 37 Recognizing and Treating Psychiatric Comorbidity in Epilepsy 268 Jay Salpekar Index 275 Color plate section between pages 80 and 81

Read more less

Book SynopsisThe ideal revision aid for pre-registration mental health nursing students, this accessible, easy-to-read title first explores the essential clinical skills needed by nurses, using the Essential Skills Clusters as an organising framework. The second section goes on to look at common disorders and approaches.Table of ContentsHow to use your revision guide vii About the companion website x Introduction xii Practice tree example xiv Part 1 Essential skills 1 1 Care, compassion and communication 2 2 Building therapeutic relationships 4 3 Values-based practice 6 4 Managing clinical risk 8 5 Infection prevention and control 10 6 Nutrition and fluid management 12 7 Elimination 14 8 Clinical observations 16 9 Documentation 18 10 Medicines management 20 Part 2 Nursing individuals with mental health needs 23 11 Assessment 24 12 Risk 26 13 Classification 28 14 Psychological interventions 31 15 Schizophrenia 34 16 Depression 36 17 Bipolar affective disorder 38 18 Anxiety 40 19 Eating disorders 42 20 Personality disorders 44 21 Learning disabilities and mental health 46 22 Functional disorders in older adults 48 23 Dementia 50 24 Acute confusional states 52 25 Drug and alcohol misuse 54 26 Children and adolescent mental health 56 27 Recovery 58 28 Physical wellbeing 60 29 Mental health law 62 30 Medication and ECT 66 Part 3 Leadership skills 71 31 Organising care 72 32 Leadership 74 33 Managing people 76 34 Time management 78 35 Decision-making 80 36 Utilising research 82 37 Reflection 84 38 Lifelong learning 86 Appendix: Clinical procedures 88 References and bibliography 92 Glossary 93 Index 95

Read more less

Book SynopsisZoonotic Tuberculosis: Mycobacterium bovis and Other Pathogenic Mycobacteria, Third Edition is a comprehensive review of the state of the art in the control and elimination of infections caused by Mycobacterium tuberculosis complex in animals and humans. This update to the most complete and current reference available on Mycobacterium bovis includes new coverage of the latest molecular techniques; more information on human infection and One Health; updates to the information on the International Union Against Tuberculosis and Lung Disease (IUATLD), the World Health Organization (WHO), Pan American Health Organization (PAHO), and the United States Department of Agriculture's (USDA) National Tuberculosis Eradication Program; and coverage of additional Africancountries. The Third Edition upholds the book's reputation as a truly global resource on M. bovis. Written by an international list of tuberculosis experts, chapters cover the status of tuberculoTrade Review“The third edition complements the previous editions and will be a useful text for readers interested in both human and animal tuberculosis.” (Journal of the American Veterinary Medical Association, 15 September 2014) “Zoonotic Tuberculosis’ is a superb text and should be placed on the shelf alongside the previous editions for anyone wanting to know more about the global management of tuberculosis.” (Veterinary Record, 21 June 2014)Table of ContentsContributors ix Preface xv 1 Tuberculosis in animals and humans: An introduction 3 Charles O. Thoen, Philip A. LoBue, and Donald A. Enarson 2 One Health approach for preventing and controlling tuberculosis in animals and humans 9 John B. Kaneene, Bruce Kaplan, James H. Steele, and Charles O. Thoen 3 Public health significance of zoonotic tuberculosis caused by the Mycobacterium tuberculosis complex 21 Adam J. Langer and Philip A. LoBue 4 Mycobacterium bovis infection in humans and animals with an emphasis on countries in Central and South America 35 Isabel N. de Kantor, Pedro M. Torres, Eliana Roxo, Alfredo Garin, Luis A. Paredes Noack, María D. Sequeira, María Susana Imaz, Nora Morcillo, and María Alice da Silva Telles 5 Pathogenesis of tuberculosis caused by Mycobacterium bovis 51 Charles O. Thoen and Raúl G. Barletta 6 Epidemiology of Mycobacterium bovis 63 Julian A. Drewe, Dirk U. Pfeiffer, and John B. Kaneene 7 Molecular epidemiology of Mycobacterium bovis 79 Julian A. Drewe and Noel H. Smith 8 New and current approaches for isolation, identification, and genotyping of Mycobacterium bovis 89 Suelee Robbe-Austerman and Claude Turcotte 9 Tuberculosis in animals in South Africa 99 Nick Kriek 10 Status and control of bovine tuberculosis in Ethiopia 109 Asseged Bogale, Berhanu Tameru, and Tsegaye Habtemariam 11 Distribution, public health significance, and control status of bovine tuberculosis caused by Mycobacterium bovis in Uganda 133 David Nganwa and Asseged Bogale 12 Bovine tuberculosis: Epidemiology, zoonotic transmission, activities, and challenges toward its control in Nigeria 149 Simeon I.B. Cadmus and F. Olalekan Ayanwale 13 Factors contributing to the transmission of bovine tuberculosis caused by Mycobacterium bovis and its control status in Sudan 159 Ehsan Abdalla and David Nganwa 14 Overview of bovine tuberculosis in Ghana 175 Gregory Banayah Mwinyelle and Andy Alhassan 15 Status and control of tuberculosis in animals in Pakistan 181 M. Tariq Javed 16 Zoonotic tuberculosis in humans, elephants, and other animals in Nepal 191 Mahesh Bhandari and Charles O. Thoen 17 Zoonotic tuberculosis in India 197 Rishendra Verma 18 An overview of Mycobacterium bovis infections in domestic and wild animals in Korea 203 Han Sang Yoo and Kyoungjin J. Yoon 19 Mycobacterium bovis infection and control in China 213 Aizhen Guo, Yingyu Chen, and Huanchun Chen 20 Zoonotic tuberculosis in Australia and New Zealand 221 Graham Nugent and Debra V. Cousins 21 Bovine tuberculosis eradication in the United States: A century of progress 235 Alecia Larew Naugle, Mark Schoenbaum, C. William Hench, Owen L. Henderson, and Jack Shere 22 The occurrence of M. bovis cases in U.S. cattle, 2001–2011 253 Katie Portacci, Jason Lombard, Mark Schoenbaum, Kathleen Orloski, and Mark Camacho 23 The importance of M. bovis infection in cervids on the eradication of bovine tuberculosis in the United States 263 Michael J. Gilsdorf and John B. Kaneene 24 Evaluation of antemortem diagnostic tests for detecting bovine tuberculosis infection in the United States 277 Mark Schoenbaum, María Celia Antognoli, and Kathleen Orloski 25 Canada’s bovine tuberculosis eradication program: Past and present 287 Noel Harrington, Krista Howden, and Claude Turcotte 26 Bovine tuberculosis eradication program in Mexico 291 Alejandro Perera Ortiz, José Alfredo Gutiérrez-Reyes, Estela Flores Velázquez, Guillermo Agustín Reyes Escalona, and Eli Tonatiuh Selva Hernández 27 Epidemiology of bovine tuberculosis in the Republic of Serbia with a brief overview of the current epidemiological situation in the region 309 Dejan Krnjaic, Budimir Plavsic, and Slavoljub Stanojevic 28 The impact of an integrated wildlife and bovine tuberculosis eradication program in Ireland 323 Michael Sheridan, Margaret Good, Simon J. More, and Eamonn Gormley 29 Bovine tuberculosis eradication in France 341 María Laura Boschiroli and Jean-Jacques Bénet 30 Animal tuberculosis in Spain: A multihost system 349 Christian Gortazar and Mariana Boadella 31 Tuberculosis eradication in Italy 357 Laura Chiavacci, Alessandro Dondo, Maria Goria, Giuliana Moda, Luigi Ruocco, Patrizia Vignetta, and Simona Zoppi 32 Status of bovine tuberculosis control in countries of Central Europe and countries of the former Soviet Union 369 Ivo Pavlik 33 Zoonotic tuberculosis in nonhuman primates 383 Pat A. Frost, Paul P. Calle, Hilton Klein, and Charles O. Thoen Index 399

Read more less

Book SynopsisFollowing the popular and accessible at a Glance format, Vascular and Endovascular Surgery at a Glance demystifies the important concepts of vascular disease and vascular surgery.Trade Review“This is a good resource for those studying vascular medicine and vascular surgery. It is easy to read and drives home key points with paired illustrations.” (Doody’s, 6 February 2015) “This is a must-read for any specialist at all levels who has an on-going commitment to vascular disease management and medical education.” (Kingbook73's Medical Ebook and Video Collection, 5 September 2014)Table of ContentsPreface 6 List of abbreviations and symbols 7 About the companion website 9 Part 1 Vascular principles 1 Overview of vascular disease 10 2 Arterial anatomy 12 3 Venous anatomy 14 4 Vascular biology 16 5 Vascular pathobiology 18 6 Vascular physiology 20 7 Vascular pharmacology 22 8 Coagulation and thrombosis 24 9 Cardiovascular risk factors 26 10 Best medical therapy 28 11 Vascular history taking 30 12 Examination of the vascular system 32 13 Ankle Brachial Pressure Index measurement 34 14 Vascular examination: Varicose veins 36 15 Interpreting vascular scars 38 16 Vascular investigations: Overview 40 17 Vascular ultrasound I 42 18 Vascular ultrasound II 44 19 Vascular ultrasound III: Specific parameters 46 20 Angiography I: Overview 48 21 Angiography II: Access and imaging 50 22 Angiography III: Angiointervention 53 23 Principles of vascular surgery 56 24 Perioperative care of the vascular patient 58 25 Post-operative complications and management 60 Part 2 Disease-specific topics 26 Carotid disease: Assessment and treatment 62 27 Carotid surgery 64 28 Aneurysms 66 29 Abdominal aortic aneurysm I: Overview 68 30 Abdominal aortic aneurysm II: Treatment 70 31 Other aneurysms 72 32 Thoracic aortic disease I: Dissection 74 33 Thoracic aortic disease II: Aneurysms 76 34 Peripheral vascular disease I: Overview 78 35 Peripheral vascular disease II: Assessment 80 36 Peripheral vascular disease III: Management 82 37 The acute limb 84 38 Amputation and rehabilitation 88 39 Vascular trauma: Neck and chest 90 40 Vascular trauma: Abdomen and pelvis 92 41 Peripheral vascular injury 94 42 Compartment syndrome and fasciotomy 96 43 Vascular complications from IVDU 98 44 Upper limb vascular disease 100 45 Thoracic outlet syndrome 102 46 Vasculitis I: Overview 106 47 Vasculitis II: Specific conditions 108 48 Raynaud’s and cold injury 110 49 Primary hyperhidrosis 112 50 Coagulopathy and thrombophilia 114 51 Deep venous thrombosis 116 52 Complications of DVT 120 53 Varicose veins and venous hypertension 122 54 Varicose veins: Treatment 124 55 Vascular ulceration 126 56 General wound care 128 57 Lymphoedema 130 58 The diabetic foot 132 59 Haemodialysis access 134 60 Mesenteric ischaemia I 136 61 Mesenteric ischaemia II 138 62 Renal vascular disease 140 63 Congenital vascular malformations 142 64 Rare and eponymous vascular disorders 144 65 High-yield vascular facts 148 66 Vascular trials 150 Appendix 1: Wires commonly used during angiography and angiointervention 152 Appendix 2: Catheters commonly used during angiography and angiointervention 153 Index 154

Read more less

Book SynopsisDeveloped by the American Cancer Society this new textbook designed for a wide range of learners and practitioners comprehensively addresses all aspects of clinical management for cancer taking a balanced, authoritative and, -where possible- evidence-based stance and may be used in conjunction with the book, The American Cancer Society''s Principles of Oncology: Prevention to Survivorship. Edited by leading clinicians in the field and a stellar contributor list from the US and Europe, this book is written in an easy to understand style by multidisciplinary teams of medical oncologists, radiation oncologists and other specialists, reflecting day-to-day decision-making and clinical practice. Input from pathologists, surgeons, radiologists, and other specialists is included wherever relevant and comprehensive treatment guidelines are provided by expert contributors where there is no standard recognized treatment. This book is an ideal resource for anyone seeking a practiTable of ContentsEditorial Board and Reviewers List of Contributors Introduction Section 1 Thoracic Cancers 1 Lung CancerSuresh S. Ramalingam and Fadlo R. Khuri 2 Other Thoracic MalignanciesBrandon H. Tieu, Mehee Choi, Kyle Robinson, and Charles R. Thomas, Jr Section 2 Digestive System Cancers 3 Esophageal CancerRavi Shridhar, Khaldoun Almhanna, Sarah E. Hoffe, Matthew Biagioli, Domenico Coppola, and Kenneth L. Meredith 4 Gastric AdenocarcinomaRoger H. Kim, Quyen D. Chu, and Benjamin D. Li 5 Small Bowel Cancer (Excluding Gastrointestinal Stromal Tumors and Carcinoid)Alireza Hamidian Jahromi, Roger H. Kim, Quyen D. Chu, and Benjamin D. Li 6 Adenocarcinoma of the PancreasQuyen D. Chu, Erkut Borazanci, Roger H. Kim, and Guillermo Sangster 7 Liver CancersCelina Ang, Sonia Reichert, and Randall F. Holcombe 8 Biliary Tract Cancers/CholangiocarcinomasCelina Ang, Sonia Reichert, and Randall F. Holcombe 9 Colon and Rectal CancerLauren Kosinski, Ben George, Kiran K. Turaga, Candice A. Johnstone, and Mohammad Mahmoud 10 Anal CancerCathy Eng, Ravi Shridhar, Emily Chan, Nataly Silva, Liana Tsikitis, Susan Hedlund, Michael D. Chuong, and Charles R. Thomas, Jr 11 Gastrointestinal Stromal TumorsRian M. Hasson Charles, Stanley W. Ashley, and Chandrajit P. Raut Section 3 Head and Neck 12 Oral Cavity and Oropharyngeal CancerAvinash V. Mantravadi and Michael G. Moore 13 Salivary Gland CancerDaniel Brickman and Neil D. Gross 14 Larynx CancerEmma B. Holliday, Blaine D. Smith, Neil D. Gross, Clifton D. Fuller, and David I. Rosenthal 15 Nasal and Paranasal Sinus CancerEmma B. Holliday, Michael E. Kupferman, Clifton D. Fuller, and Ehab Hanna 16 Nasopharyngeal CancerJamie M. Pawlowski, Emma B. Holliday, and Clifton D. Fuller Section 4 Urinary System 17 Renal Cell CarcinomaJonathan Mathias and Brian Rini 18 Bladder Cancer and Other Urothelial SitesMichael C. Risk, Ayman Soubra, and Badrinath R. Konety Section 5 Female Reproductive Cancer 19 Ovarian, Fallopian Tube, and Primary Peritoneal CancerMichael L. Pearl, Erin E. Stevens, and Joyce Varughese 20 Uterine Corpus CancerMario Javier Pineda and John R. Lurain 21 Cervical CancerMerieme Klobocista, Mark H. Einstein, and Carolyn D. Runowicz 22 Vaginal CancerChristina Gauthreaux, Anna Kuan]Celarier, and Carolyn D. Runowicz 23 Vulvar CancerCarolyn D. Runowicz 24 Gestational Trophoblastic DiseaseAlok Pant and John R. Lurain Section 6 Male Reproductive Cancers 25 Testicular CancerCostantine Albany, Nasser Hanna, and Lawrence H. Einhorn 26 Prostate CancerBobby C. Liaw and William K. Oh 27 Penile CancerDavid Bowes and Juanita Crook Section 7 Breast Cancer 28 Breast Cancer, Including Brief Discussion of Male Breast CancerElisavet Paplomata and Ruth O’Regan Section 8 Hematologic Cancers 29 Myeloid MalignanciesJoshua F. Zeidner, Darshan Roy, Alexander Perl, and Ivana Gojo 30 Lymphoid Leukemias in AdultsNilanjan Ghosh, Jocelyn L. Wozney, and Michael R. Grunwald 31 Hodgkin Lymphoma in AdultsSatish Shanbhag and Richard Ambinder 32 Non]Hodgkin Lymphoma in AdultsLoretta J. Nastoupil, Jean L. Koff, Leon Bernal]Mizrachi, and Christopher R. Flowers 33 Multiple MyelomaGiada Bianchi and Kenneth C. Anderson Section 9 Skin Cancer 34 MelanomaJustin M. Ko, Alan C. Geller, and Susan M. Swetter 35 Non]Melanoma Skin CancersH. William Higgins, II and Martin A. Weinstock Section 10 Endocrine Cancers 36 Thyroid CancerMaria E. Cabanillas, Steven P. Weitzman, Ramona Dadu, Ted Gansler, and Mark Zafereo 37 Adrenal Cortical Carcinoma and PheochromocytomaRobert Dreicer, Moshe C. Ornstein, Kriti Mittal, Jordan Reynolds, Joseph Klink, Christopher Przybycin, and Jorge A. Garcia 38 Pituitary TumorsAdriana G. Ioachimescu and Nelson M. Oyesiku 39 Gastroenteropancreatic Neuroendocrine TumorsJonathan Strosberg Section 11 Cancer of the Nervous System and Eye 40 Central Nervous System and Peripheral NervesD. Ryan Ormond, Alexandros Bouras, Michael Moore, Matthew Gary, Paula Province Warren, Roshan Prabhu, Kathleen M. Egan, Srikant Rangaraju, Christina Appin, Constantinos Hadjipanayis, Burt Nabors, Alfredo Voloschin, and Jeffrey J. Olson 41 Malignant Tumors of the EyeDevron H. Char and Tia B. Cole Section 12 Bone and Soft Tissue Tumors 42 Sarcomas of Bone in AdultsMrinal Gounder, Yoshiya Yamada, and Nicola Fabbri 43 Sarcoma of Soft TissueMrinal Gounder, Vinod Ravi, Yoshiya Yamada, Richard Carvajal, and Aimee Crago Section 13 Cancer of Unknown Primary, Paraneoplastic Syndromes, and Peritoneal Carcinomatosis 44 Cancer of Unknown Primary SiteJohn D. Hainsworth and F. Anthony Greco 45 Paraneoplastic SyndromesLorraine C. Pelosof and David E. Gerber 46 Peritoneal Surface MalignanciesKiran K. Turaga Section 14 Pediatric and Adolescent Oncology 47 Pediatric CancersStephanie B. Dixon, Lisa M. Force, Pratiti Bandopadhayay, Peter Manley, Carlos Rodriguez]Galindo, Lewis B. Silverman, and Karen J. Marcus Index

Read more less

Book SynopsisFeaturing chapters from specialists in endocrinology, physiology, pathology, and nuclear medicine, this book provides a multidisciplinary approach to a wide variety of issues concerning somatostatin and its analogues. The book: Provides the most up-to-date coverage of somatostatin analog use in diagnostic and therapy Integrating the specialties of endocrinology, physiology, pathology, and nuclear medicine, providing the multidisciplinary approach to the topic Focuses on future applications, novel compounds, and areas for further research Covers topics by authors who are renowned experts and researchers in the field Table of ContentsContributors viii Preface xii Acknowledgements xv 1 Somatostatin: The History of Discovery 1Malgorzata Trofimiuk‐Müldner and Alicja Hubalewska‐Dydejczyk 2 Physiology of Endogenous Somatostatin Family: Somatostatin Receptor Subtypes, Secretion, Function and Regulation, and Organ Specific Distribution 6Marily Theodoropoulou 3 Somatostatin Receptors in Malignancies and Other Pathologies 21Marco Volante, Adele Cassenti, Ida Rapa, Luisella Righi, and Mauro Papotti 4 The Use of Radiolabeled Somatostatin Analogue in Medical Diagnosis: Introduction 31Alberto Signore 4.1 Somatostatin Receptor Scintigraphy‐SPECT 35Renata Mikołajczak and Alberto Signore 4.2 Molecular Imaging of Somatostatin Receptor‐Positive Tumors Using PET/CT 55 Richard P. Baum and Harshad R. Kulkarni4.3 Other Radiopharmaceuticals for Imaging GEP‐NET 75Klaas Pieter Koopmans, Rudi A. Dierckx, Philip H. Elsinga, Thera P. Links, Ido P. Kema, Helle-Brit Fiebrich, Annemieke M.E. Walekamp, Elisabeth G.E. de Vries, and Adrienne H. Brouwers 4.4 The Place of Somatostatin Receptor Scintigraphy in Clinical Setting: Introduction 86Alicja Hubalewska‐Dydejczyk 4.4.1 Somatostatin Receptor Scintigraphy in Management of Patients with Neuroendocrine Neoplasms 90Anna Sowa‐Staszczak, Agnieszka Stefańska, Agata Jabrocka‐Hybel, and Alicja Hubalewska‐Dydejczyk 4.4.2 The Place of Somatostatin Receptor Scintigraphy and Other Functional Imaging Modalities in the Setting of Pheochromocytoma and Paraganglioma 112Alicja Hubalewska‐Dydejczyk, Henri J.L.M. Timmers, and Malgorzata Trofimiuk‐Müldner 4.4.3 Somatostatin Receptor Scintigraphy in Medullary Thyroid Cancer 127Anouk N.A. van der Horst‐Schrivers, Adrienne H. Brouwers, and Thera P. Links 4.4.4 Somatostatin Receptor Scintigraphy in Other Tumors Imaging 135Malgorzata Trofimiuk‐Müldner and Alicja Hubalewska‐Dydejczyk 4.4.5 Somatostatin Receptor Scintigraphy in Inflammation and Infection Imaging 153Alberto Signore, Kelly Luz Anzola Fuentes, and Marco Chianelli 5 Somatostatin Analogues in Pharmacotherapy: Introduction 164Wouter W. de Herder 5.1 Somatostatin Analogues in Pharmacotherapy 166Wouter W. de Herder 5.2 Pituitary Tumor Treatment with Somatostatin Analogues 169Alicja Hubalewska-Dydejczyk, Aleksandra Gilis-Januszewska, and Malgorzata Trofimiuk-Müldner 5.3 Somatostatin Analogues in Pharmacotherapy of Gastroenteropancreatic Neuroendocrine Tumors 189Frédérique Maire and Philippe Ruszniewski 5.4 Somatostatin Analogue Use in Other than Endocrine Tumor Indications 198Aleksandra Gilis‐Januszewska, Malgorzata Trofimiuk‐Müldner, Agata Jabrocka‐Hybel,, and Dorota Pach 6 Peptide Receptor Radionuclide Therapy Using Radiolabeled Somatostatin Analogues: An Introduction 207John Buscombe 6.1 Somatostatin Analogues and Radionuclides Used in Therapy 214Esther I. van Vliet, Boen L.R. Kam, Jaap J.M. Teunissen, Marion de Jong, Eric P. Krenning, and Dik J. Kwekkeboom 6.2 PRRT Dosimetry 230Mark Konijnenberg 6.3 Peptide Receptor Radionuclide Therapy (PRRT): Clinical Application 252Lisa Bodei, and Giovanni Paganelli 6.4 Duo‐PRRT of Neuroendocrine Tumors Using Concurrent and Sequential Administration of Y‐90‐ and Lu‐177‐Labeled Somatostatin Analogues 264Richard P. Baum and Harshad R. Kulkarni 6.5 N onsystemic Treatment of Liver Metastases from Neuroendocrine Tumor 273Daniel Putzer, Gerlig Widmann, Dietmar Waitz, Werner Jaschke, and Irene J. Virgolini 6.6 Peptide Receptor Radionuclide Therapy: Other Indications 282Agnieszka Stefańska, Alicja Hubalewska‐Dydejczyk, Agata Jabrocka‐Hybel, and Anna Sowa‐Staszczak 7 Somatostatin Analogs: Future Perspectives and Preclinical Studies—Pansomatostatins 291Aikaterini Tatsi Berthold A. Nock, Theodosia Maina, and Marion de Jong 8 Radiolabeled Somatostatin Receptor Antagonists 305Melpomeni Fani and Helmut R. Maecke 9 Cortistatins and Dopastatins 321Manuela Albertelli and Diego Ferone Index 000

Read more less

Book SynopsisTable of ContentsList of Contributors, x Preface, xxi Section 1 Malignant Hematology and Hematopoietic Cell Transplantation Part 1 Acute Lymphoblastic Leukemia in Adults 1 Diagnosis of acute lymphoblastic leukemia, 5 Frederick G. Behm, Agatha Bogard, Syed A. Abutalib, and Sujata S. Gaitonde 2 Prognostic markers and models in acute lymphoblastic leukemia, 18 Dieter Hoelzer 3 Management of B-cell acute lymphoblastic leukemia, 22 Hady Ghanem, Hagop Kantarjian, Nitin Jain, and Elias Jabbour 4 Management of T-cell acute lymphoblastic leukemia, 29 Daniel J. DeAngelo 5 Minimal residual disease in acute lymphoblastic leukemia, 35 Meir Wetzler 6 Hematopoietic cell transplantation in adult acute lymphoblastic leukemia, 40 Netanel A. Horowitz and Jacob M. Rowe Part 2 Acute Myeloid Leukemia in Adults 7 Prognosis in acute myeloid leukemia: cytogenetics and beyond, 51 Gordana Raca, Madina Sukhanova, and Lucy A. Godley 8 Induction therapy in acute myeloid leukemia, 58 Tapan Kadia and Farhad Ravandi 9 Consolidation therapy in acute myeloid leukemia, 67 Gregory K. Behbehani and Bruno C. Medeiros 10 Management of acute promyelocytic leukemia, 71 Eytan M. Stein and Martin S. Tallman 11 Minimal residual disease in acute myeloid leukemia, 76 Hans Beier Ommen, Line Nederby, Marie Toft-Petersen, Charlotte Guldborg Nyvold, and Peter Hokland 12 Relapsed and refractory acute myeloid leukemia, 82 Stefan H. Faderl 13 Hematopoietic cell transplantation in acute myeloid leukemia, 89 Antonio M. Jimenez and Stefan O. Ciurea Part 3 Myelodysplastic Syndromes and Related Disorders 14 Pitfalls in the diagnosis of myelodysplastic syndromes, 99 Jay Yang, Gail Bentley, and Charles A. Schiffer 15 Cytogenetics and prognostic models in myelodysplastic syndromes, 106 Uma Borate and Harry P. Erba 16 Management of myelodysplastic syndromes, 113 Vu H. Duong, Alan F. List, and Rami S. Komrokji 17 Management of therapy-related myeloid neoplasms, 120 Jagoda K. Jasielec and Richard A. Larson 18 Hematopoietic cell transplantation in myelodysplastic syndromes, 126 Antonio Di Stasi, Armin Ghobadi, and Partow Kebriaei 19 Acquired aplastic anemia, 131 Valeria Visconte and Ramon V. Tiu Part 4 Myeloproliferative Neoplasms 20 Diagnostic approach in myeloproliferative neoplasms, 137 Ayalew Tefferi 21 Chronic myeloid leukemia: chronic phase, 142 Jerald P. Radich 22 Blast crisis of chronic myeloid leukemia, 147 Michael J. Mauro 23 Chronic myeloid leukemia and pregnancy, 150 Michael J. Mauro 24 Polycythemia vera, 152 Constantine S. Tam and Srdan Verstovsek 25 Essential thrombocytosis, 156 Paola Guglielmelli and Alessandro M. Vannucchi 26 Primary myelofibrosis, 162 Ayalew Tefferi 27 Eosinophilic myeloproliferative disorders, 167 Jason Gotlib 28 Chronic myelomonocytic leukemia, 176 Mrinal M. Patnaik 29 Hematopoietic cell transplantation in chronic myeloid leukemia, 180 Jerald P. Radich 30 Hematopoietic cell transplantation in primary myelofibrosis, 187 Irum Khan and Damiano Rondelli Part 5 Chronic Lymphocytic and Other Leukemias 31 Prognostic markers and management of chronic lymphocytic leukemia, 195 Courtney D. DiNardo and Susan O’Brien 32 Hematopoietic cell transplantation in chronic lymphocytic leukemia, 201 Michael R. Bishop 33 Prolymphocytic leukemia, 207 Claire Dearden 34 Hairy cell leukemia, 220 Justin M. Watts and Martin S. Tallman Part 6 Hodgkin Lymphoma 35 Management of classical Hodgkin lymphoma, 229 Kristen Sanfi lippo and Nancy L. Bartlett 36 Nodular lymphocyte-predominant Hodgkin lymphoma, 235 Dennis A. Eichenauer 37 Hematopoietic cell transplantation in Hodgkin lymphoma, 240 Tsiporah Shore and Koen van Besien Part 7 Non-Hodgkin’s Lymphomas 38 Pitfalls in the diagnosis of non-Hodgkin’s lymphomas, 247 Carmen Barcena and Laurence de Leval 39 Follicular lymphoma, 257 Myron S. Czuczman 40 Diffuse large B-cell lymphoma, 263 Andrew D. Zelenetz 41 Mantle cell lymphoma, 270 Stephen Smith and John Sweetenham 42 Marginal zone lymphoma, 275 Sarah Rutherford, Wayne Tam, and Peter Martin 43 Primary mediastinal large B-cell lymphoma, 282 Pier Luigi Zinzani 44 Burkitt lymphoma, 286 Mark Roschewski and Wyndham Wilson 45 Gray zone lymphoma, 290 Caron A. Jacobson and Ann S. LaCasce 46 Transformed lymphoma, 295 Stephane Doucet and Jane N. Winter 47 HIV-associated lymphoma, 304 Kieron Dunleavy 48 Primary CNS lymphoma, 308 Nicholas A. Blondin, Joachim M. Baehring, and Fred H. Hochberg 49 Primary cutaneous lymphoma, 316 Thomas M. Habermann 50 Mycosis fungoides and Sézary syndrome, 323 Stephane Dalle, Marie Perier-Muzet, Brigitte Balme, and Luc Thomas 51 Hematopoietic cell transplantation in indolent non-Hodgkin’s lymphoma, 327 Saurabh Chhabra and Ginna G. Laport 52 Hematopoietic cell transplantation in diffuse large B-cell lymphoma, 332 Syed A. Abutalib and Istvan Redei 53 Hematopoietic cell transplantation in T-cell non-Hodgkin’s lymphomas, 339 Lori S. Muffly and Sonali M. Smith Part 8 Plasma Cell Neoplasms and Related Disorders 54 Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance, 347 Robert A. Kyle 55 Risk stratification and response assessment in multiple myeloma and Waldenström’s macroglobulinemia, 352 Silvia Gentili and Sagar Lonial 56 Treatment of multiple myeloma, 358 Cindy Varga, Claudia Paba Prada, Kenneth Anderson, and Paul Richardson 57 Light-chain amyloidosis, 366 David C. Seldin 58 Waldenström’s macroglobulinemia, 371 Anita D’Souza and Morie A. Gertz 59 Autologous hematopoietic cell transplantation in multiple myeloma, 376 Jean-Luc Harousseau and Mohamad Mohty 60 Allogeneic hematopoietic cell transplantation in multiple myeloma, 381 Jasleen Randhawa, Veerpal Singh, and Parameswaran Hari Part 9 Special Issues in Hematology 61 Role of PET scan in lymphomas, 391 Matthew A. Lunning and James O. Armitage 62 Radioimmunotherapy in lymphomas, 398 Reem Karmali and Stephanie A. Gregory 63 Radiation oncology consultation for hematologic malignancies, 403 Chris R. Kelsey and Leonard R. Prosnitz Part 10 Special Issues in Hematopoietic Cell Transplantation 64 Donor and graft selection in allogeneic hematopoietic cell transplantation, 411 Jose Leonel Ochoa-Bayona and Claudio Anasetti 65 Preparative regimens in allogeneic hematopoietic cell transplantation for malignant hematological diseases, 417 Robert J. Soiffer 66 T-cell depletion in allogeneic hematopoietic cell transplantation, 421 Jenna D. Goldberg and Miguel-Angel Perales 67 Prevention and treatment of relapse following hematopoietic cell transplantation, 426 Robert Chen, Sandra Thomas, and Stephen J. Forman 68 Acute graft-versus-host disease, 432 Andrew C. Harris and John E. Levine 69 Chronic graft-versus-host disease, 438 Carrie L. Kitko and Daniel R. Couriel Section 2 Oncology Part 1 Central Nervous System Tumors 70 Primary brain tumors, 449 Barbara J. O’Brien and Mark R. Gilbert 71 Secondary brain and spinal cord tumors, 457 Rimas V. Lukas, Patrik Gabikian, and Steven J. Chmura Part 2 Head and Neck Cancers and Thoracic Malignancies 72 Medical management of head and neck cancers, 467 Tobenna Nwizu and David Adelstein 73 Endocrine malignancies, 476 Ann W. Gramza 74 Methodological and practical challenges for personalized therapies in non-small-cell lung cancer, 480 Ignacio I. Wistuba 75 Screening, staging, and stage I non-small-cell lung cancer, 486 Tarek M. Mekhail 76 Stage II and III non-small-cell lung cancer, 493 Grzegorz Korpanty and Natasha B. Leighl 77 Recurrent and metastatic non-small-cell lung cancer and novel targets, 500 Evan Pisick and Ravi Salgia 78 Small-cell lung cancer, 503 Stephen V. Liu and Glen J. Weiss 79 Mesothelioma, 506 Christopher W. Towe and Harvey I. Pass Part 3 Breast Cancer 80 Immunohistochemistry testing and beyond in breast cancer, 515 Alejandro A. Gru and D. Craig Allred 81 Prevention and adjuvant therapy in breast cancer, 523 Faithlore P. Gardner and Edith A. Perez 82 Preoperative systemic therapy for breast cancer, 532 Virginia Kaklamani and William J. Gradishar 83 Recurrent and metastatic breast cancer, 540 Dennis L. Citrin 84 Special issues in the young and pregnant patient with breast cancer, 546 Hatem A. Azim Jr. and Fedro A. Peccatori Part 4 Gastrointestinal Oncology 85 Early-stage esophageal and stomach cancers, 555 M. Naomi Horiba and Yixing Jiang 86 Metastatic esophagogastric cancer: controversies, consensus, and new targets, 562 Geoffrey Y. Ku and David H. Ilson 87 Early-stage colorectal cancer, 567 Vaibhav Sahai and Al B. Benson III 88 Recurrent and metastatic colorectal cancer: controversies, consensus, and new targets, 573 Davendra Sohal and Robert J. Pelley 89 Pancreatic cancer, 581 Katherine Van Loon and Margaret Tempero 90 Hepatobiliary cancer, 590 Keith Stuart 91 Neuroendocrine tumors, 595 Anya Litvak and Leonard Saltz 92 Transarterial liver-directed therapies in oncology, 601 Divyesh G. Mehta and Jeffery Choh 93 Anal cancer, 606 Rob Glynne Jones Part 5 Genitourinary Oncology 94 Renal cancer: tumor diversity, molecular taxonomy, and prognostic algorithms, 615 Henry J. Conter and Eric Jonasch 95 Medical management of renal cancer, 621 Gary R. MacVicar and Timothy M. Kuzel 96 Medical management of bladder cancer, 628 Gary R. MacVicar and Timothy M. Kuzel 97 Prostate cancer: Screening, surveillance, prognostic algorithms and independent pathologic predictive parameters, 634 Megan G. Lockyer and Thomas M. Wheeler 98 Medical management of prostate cancer, 638 Elizabeth K. O’Donnell and Philip Kantoff 99 Germ cell tumors, 645 Timothy Gilligan Part 6 Skin Malignancies 100 Medical management of melanoma, 653 Ana M. Ciurea and Kim Margolin 101 Nonmelanoma skin cancers, 661 Daniel Christiansen and Anna Sancho Clayton PART 7 Gynecological Malignancies 102 Ovarian cancer: neoadjuvant, adjuvant, and surgical issues, 669 Alpa M. Nick and Robert L. Coleman 103 Ovarian cancer: second-line treatment strategies, 675 Maurie Markman 104 Endometrial and cervical cancers, 681 Maurie Markman PART 8 Sarcomas 105 Bone sarcomas, 689 Nicole Larrier, William C. Eward, and Richard F. Riedel 106 Soft tissue sarcomas, 696 Neeta Somaiah and Shreyaskumar Patel PART 9 Multidisciplinary Approach: Consultation with Surgical Oncology Team 107 Surgical aspects of head and neck cancers, 707 Constance E.H. Teo and Randal S. Weber 108 Surgical aspects of thoracic malignancies, 711 Albert S.Y. Chang, Thomas A. D’Amico, and David C. White 109 Surgical aspects of upper gastrointestinal cancers, 719 Sabha Ganai and Mitchell C. Posner 110 Surgical aspects of pancreatic cancer, 723 Amanda B. Cooper, Ching-Wei D. Tzeng, and Matthew H.G. Katz 111 Surgical aspects of hepatobiliary tumors, 729 Subhasis Misra and Leonidas Koniaris 112 Surgical aspects of lower gastrointestinal cancers, 735 Anthony J. Senagore 113 Surgical aspects of renal cancer, 739 Michael E. Woods and Matthew C. Raynor 114 Surgical aspects of bladder cancer, 744 Michael B. Williams 115 Surgical aspects of prostate cancer, 747 Peter Pinto 116 Surgical aspects of melanoma, 754 Thomas Velancia PART 10 Multidisciplinary Approach: Consultation with Radiation Oncology Team 117 Radiotherapy for head and neck cancers, 761 Shiyu Song 118 Radiotherapy for ductal carcinoma in situ (DCIS), 767 Beryl McCormick 119 Radiotherapy for early-stage invasive breast cancer, 771 Julia White 120 Radiotherapy for thoracic malignancies, 778 Meredith E. Giuliani and Andrea Bezjak 121 Radiotherapy for gastrointestinal malignancies, 785 Manisha Palta, Christopher Willett, and Brian Czito 122 Radiotherapy for genitourinary malignancies, 789 Christina H. Chapman and Curtiland Deville PART 11 Hereditary Cancer Syndromes and Genetic Testing in Oncology 123 When to suspect hereditary cancer syndromes, 795 Emily Dalton and Kathy Schneider 124 Hereditary breast cancer syndromes, 800 Kathy Schneider and Emily Dalton 125 Genetic testing in gastrointestinal tumors, 804 Kristen M. Shannon and Daniel C. Chung 126 Hereditary urogenital cancer syndromes, 810 Melanie Corbman and Eric Fowler PART 12 Special Issues in Hematology and Oncology 127 Carcinoma of unknown primary (CUP), 817 Isabella C. Glitza and Gauri R. Varadhachary 128 Geriatric oncology, 822 Nayana Kamath and Supriya Gupta Mohile 129 Nuts and bolts of cancer immunotherapy, 826 Christopher R. Heery and James L. Gulley 130 Controversies related to oncology clinical trial development, 831 Elihu H. Estey 131 PET scan in oncology, 835 Shaunagh McDermott and Michael A. Blake 132 Hematopoietic growth factors, 841 LeAnn B. Norris, Jametta Magwood, and Charles L. Bennett 133 Anticoagulation issues in oncology, 844 Steven M. Corsello and Jean Marie Connors 134 Symptom management and palliative care, 851 Rony Dev and Eduardo D. Bruera 135 Metabolic and nutritional issues in oncology, 860 Julia Fechtner, Carolyn Lammersfeld, Carol Ireton-Jones, and Pankaj Vashi 136 Bone-related issues in oncology, 867 S. Mujtaba Rizvi, Helen Collins, and Alan Lipton 137 Integrative medicine in oncology, 872 Weidong Lu and David S. Rosenthal 138 Naturopathic medicine in oncology, 879 Christina M. Shannon, Tracey Thomas, and Shauna Birdsall 139 Anesthesiology consultation for localized cancer pain, 884 Abed Rahman, Magdalena Anitescu, and Raed Rahman 140 Musculoskeletal care in oncology, 893 James E. Rosenberg and Charles A. McDonald 141 Cancer survivorship and psychosocial issues in oncology, 896 Jabeen Abutalib, Shahid Raza, and Laura Sunn Index, 902 Color plate section facing p.522

Read more less

Book SynopsisMount Sinai Expert Guides: Neurology provides trainees in neurology with an extremely clinical and accessible handbook covering the major neurologic disorders and symptoms, their diagnosis and clinical management. Perfect as a point-of-care resource on the hospital wards and also as a refresher for board exam preparation, the focus throughout is on providing rapid reference, essential information on each disorder to allow for quick, easy browsing and assimilation of the must-know information. All chapters follow a consistent template including the following features: An opening bottom-line/key points section Classification, pathogenesis and prevention of disorder Evidence-based diagnosis, including relevant algorithms, laboratory and imaging tests, and potential pitfalls when diagnosing a patient Disease management including commonly used medications with dosages, management algorithms and how to prevent complications How to maTable of ContentsContributors xxx Series foreword xxx Preface xxx About the Companion Website xxx Section 1: Introduction 1 Neurologic history and examinationStuart Sealfon 2 NeuroradiologyThomas P. Naidich, Ruby J. Lien, Reade De Leacy 3 Neurophysiologic and other neurodiagnostic testsSusan Shin , Deborah Horowitz, David M. Simpson Section 2: Diagnosis of patients with neurologic symptoms 4 Delirium and ComaStephen Krieger 5 Episodic collapse, loss of consciousness, seizuresLara V. Marcuse, Madeline C. Fields 5 Dysphasias, dyspraxias, and dysexecutive syndromes: the non-memory cognitive impairmentsMartin Goldstein 7 Memory Loss and DementiaSam Gandy 8 HeadacheMark Green 9 Abnormal movements and incoordinationWinona Tse 10 Sleep Disorders, Somnolence, and FatigueCharles B Stacy 11 Visual loss and double visionJanet C Rucker 12 Vertigo, Dizziness and Hearing LossBernard Cohen, Eric Smouha 13 Facial weakness, slurred speech and difficulty swallowingHailun Wang, Kenneth Altman 14 Difficulty walkingRuth H Walker 15 Muscle weakness and paralysisRajeev Motiwala 16 Tingling and loss of sensationLan Zhou 17 Low back pain and neck painCharles B Stacy 18 Suspected spinal cord dysfunctionAaron Miller 19 Bladder and sexual dysfunctionSteven Weissbart and Jonathan M. Vapnek Section 3: Neurologic Diseases and Therapeutics 20 Vascular diseases-ischemic stroke, intracerebral and subarachnoid hemorrhage, cerebral venous thrombosis, arterio-venous malformationsStanley Tuhrim 21 Neurologic complications of systemic diseaseMichelle T. Fabian 22 NeurooncologyIsabelle Germano 23 Multiple sclerosis and other inflammatory diseasesFred D Lublin 24 Infections of the nervous systemMichael P. Mullen, Geena Varghese 25 Parkinson disease and related disordersBarbara Kelly Changizi 26 Hyperkinetic movement disordersRitesh A. Ramdhani, Steven J. Frucht 27 Alzheimer’s disease and frontotemporal dementiaSam Gandy 28 Cerebellar and brain stem disordersFlorence Ching-Fen Chang, Catherine Cho 29 Inborn errors of metabolismShannon E. Babineau 30 EpilepsyMadeline C. Fields, Lara V. Marcuse, Isabelle Germano 31 Autonomic disordersJessica Robinson-Papp 32 Peripheral neuropathiesRaj Motiwala 33 MyopathyLan Zhou 34 Neuromuscular junction disordersMark A. Sivak 35 Motor neuron diseaseMark A. Sivak 36 Metabolic encephalopathy, hypoxic-ischemic encephalopathy, and brain deathMandip S. Dhamoon 37 Pain disordersCharles B Stacy 38 Migraine and other headache syndromesMark W. Green 39 Sleep disordersSteven H. Feinsilver 40 Neurocritical careErrol L. Gordon 41 TraumaJeremy M Steinberger, Margaret Pain, Jamie S. Ullman 42 The postoperative Care of Neurosurgical PatientsJustin Mascitelli, Asha Iyer, Joshua Bederson Index

Read more less

Book SynopsisThe Visual Guide to Neonatal Cardiology is a comprehensive, highly illustrated, reference covering the evaluation, diagnosis and management of cardiac disease in the newborn. Contains over 900 color illustrations, including patient photographs, chest roentgenograms, electrocardiograms, echocardiograms, angiocardiograms, 3D computed tomogramphy, magnetic resonance imaging, pathologic specimens, and other relevant visual aidsDiscusses the natural history of fetal heart disease and the rationale, indications, technique, and impact of fetal cardiac interventionReviews the anatomy and physiology of the neonatal cardiovascular system, including differences within the fetal, transitional, neonatal, child and adult circulatory systemHighlights key steps for taking a patient history, including detailed discussion of the cardiac examination (inspection, palpation and auscultation of heart sounds and murmurs)Presents over 35 morphologic conditions with sections covering introduction, epidemiolTable of ContentsSection 1. Prenatal and Perinatal Issues Chapter 1. Cardiac embryology and embryopathy.Robert H. Anderson, MD, Nigel A. Brown, MD, Timothy J. Mohun, MD Chapter 2. Maternal, familial and non-cardiac fetal conditions affecting the fetal and neonatal heart.Miwa K. Geiger, MD, Anita J. Moon-Grady, MD Chapter 3. The natural and unnatural history of fetal heart disease.Karim Diab, MD, Samer Masri, MD Section 2. General Neonatal Issues Chapter 4. Epidemiology of heart defects.Gregory H. Tatum, MD, Pierce C.A. Barker, MD Chapter 5. The Transitional and Neonatal Heart and Cardiovascular System. Timothy M. Cordes, MD Chapter 6. History and Physical Examination.Ernerio T. Alboliras, MD Chapter 7. The Cyanotic Newborn.Ernerio T. Alboliras, MD Chapter 8. The Tachypneic Newborn.Ernerio T. Alboliras, MD Chapter 9. The Hypoperfused Newborn.Deepti Bhat, MD Chapter 10. The Dysmorphic Newborn.Stephanie Burns Wechsler, MD, Marie McDonald, MD Section 3. Diagnostic Procedures Chapter 11. Chest RoentgenogramRandy Richardson, MD, Darshit Tharkar, MD, Deepak Kaura, MD Chapter 12. ElectrocardiogramBrian Cannon, MD Chapter 13. EchocardiogramMichael D. Quartermain, MD Chapter 14. Cardiac Catheterization and AngiocardiographyHowaida El-Said, MD, Sergio Bartakian, MD Chapter 15. Computed TomographyRandy Richardson, MD Chapter 16. Magnetic Resonance ImagingShaine A. Morris, MD, MPH, Timothy C. Slesnick, MD Chapter 17. Electrophysiologic Testing, Transesophageal Pacing and PacemakersBrian Cannon, MD Section 4. Specific Morphologic Conditions Chapter 18. Total Anomalous Pulmonary Venous ConnectionDavid W. Brown, MD, Tal Giva, MD Chapter 19. Other Anomalies of pulmonary and systemic venous connectionsMark V. Zilberman, MD, Clifford L. Cua, MD Chapter 20. Anomalies of Atrial SeptationDarren Hutchinson, MD, Lisa Hornberger, MD Chapter 21. Atrial Chamber Obstruction – Cor Triatriatum Dexter; Cor TriatriatumLisa Hornberger, MD Chapter 22. Common Atrioventicular Canal DefectsMeryl S. Cohen, MD Chapter 23. Ventricular Septal DefectLowell Frank, MD Chapter 24. Tricuspid AtresiaNathaniel W. Taggart, MD Chapter 25. Ebstein Malformation and Tricuspid valve DysplasiasSameh M. Said, MD, Donald J. Hagler, MD, Joseph A. Dearani, MD Chapter 26. Pulmonary Valve and Pulmonary Arterial StenosisEvan M. Zahn, MD, Darren Berman, MD Chapter 27. Pulmonary Atresia with Intact Ventricular SeptumKiran K. Mallula, MD, Zahid Amin, MD Chapter 28. Tetralogy of Fallot with Pulmonary Stenosis and AtresiaMuhammad Yasir Qureshi, MD, Frank Cetta, MD Chapter 29. Absent Pulmonary Valve SyndromeBrieann Muller, MD, Sawsan Awad, MD Chapter 30. Transposition of the Great ArteriesAdam L Dorfman, MD Chapter 31. Congenitally Corrected Transposition of the Great ArteriesCamden L. Hebson, MD, William L. Border, MD Chapter 32. Common Arterial Trunk (Truncus Arteriosus)Michael C. Mongé, MD, Osama Eltayeb, MD, Andrada Popescu, MD, Carl L. Backer, MD Chapter 33. Mitral Valve Apparatus AnomaliesShubhika Srivastava, MD Chapter 34. Hypoplastic Left Heart SyndromeAaron Bell, MD, Hannah Bellsham-Revell, MD Chapter 35. Aortic StenosisSalwa Gendi, MD, Ra-id Abdulla, MD Chapter 36. Coronary Artery AnomaliesGrace Choi, MD, Peter Koenig, MD Chapter 37. Aorto-Left Ventricular TunnelPatrick W. O’Leary, MD Chapter 38. Coronary-Cameral FistulasGareth J Morgan, MD, Shakeel A Qureshi, MD Chapter 39. Aorticopulmonary WindowCarl L. Backer, MD, Michael C. Mongé, MD, Andrada R. Popescu, MD, Osama Eltayeb, MD Chapter 40. Anomalous Origin of a Branch Pulmonary Artery from the Ascending Aorta (Hemitruncus)Michael C. Mongé, MD, Osama Eltayeb, MD, Andrada R. Popescu, MD, Carl L. Backer, MD Chapter 41. Interrupted Aortic ArchMichael C. Mongé, MD, Hyde M. Russell, MD, Carl L. Backer, MD Chapter 42. Coarctation of AortaHitesh Agrawal, MD; John W. Bokowski, PhD, RDCS; Damien Kenny, MD Chapter 43. Vascular Rings and Pulmonary Sling.Donald J. Hagler, MD, Jessica Bowman, MD Chapter 44. Double Outlet Right VentricleIrene D. Lytrivi, MD, H. Helen Ko, BS, RDMS, RDCS Chapter 45. Double Outlet Left VentricleLeo Lopez, MD Chapter 46. Single Ventricle and Biventricular Hearts with Hypoplasia of One Ventricle.Denise A. Hayes, MD, Sujatha Budde, MD, MS, Wyman W. Lai, MD, MPH Chapter 47. Dextrocardia and the Heterotaxy SyndromesSowmya Balasubramanian, MD, MSc and Rajesh Punn, MD Chapter 48. Ectopia Cordis and Thoracopagus TwinsSawsan Awad, MD Chapter 49. Patent Ductus ArteriosusRobert Puntel, MD Chapter 50. Neonatal Hypertrophic Cardiomyopathy and Syndromes with Infantile Cardiac HypertrophyJ. Martijn Bos, MD, PhD, Michael J. Ackerman, MD, PhD Chapter 51. Dilated Cardiomyopathy and MyocarditisJonathan N. Johnson, M.D. Chapter 52. Cardiac Chambers Diverticula & AneurysmsLisa Hornberger, MD Chapter 53. Neonatal Cardiac TumorsNadine Choueiter, MD, Rebecca S. Beroukhim, MD Chapter 54. Arteriovenous MalformationsAllison K. Cabalka, M.D. Chapter 55. Pericardial DefectsDonald J Hagler, MD Chapter 56. Miscellaneous Chest Abnormalities Affecting the Heart– Diaphragmatic Hernia and Eventration; Congenital Cystic Adenomatoid Malformation of the LungMark Wylam, MD Chapter 57. Persistent Pulmonary Hypertension of the NewbornAmish Jain MD, Mark K. Friedberg, MD Chapter 58. Hydrops FetalisJames Huhta, MD Section 5. Rhythm Disturbances in the Newborn. Chapter 59. Structural, Metabolic and Genetic Abnormalities Affecting the Neonatal Conduction System.Supaluck Kanjanauthai, MD, Ira Shetty, MD Chapter 60. TachydysrhythmiasBarbara J. Deal, MD Chapter 61. Bradydysrhythmias.Gregory Webster, MD, Barbara J. Deal, MD Chapter 62. Atrial and Ventricular Ectopies.Sabrina Tsao, MBBS, Barbara J. Deal, MD Section 6. Special Issues in the Newborn Chapter 63. Balloon Atrial SeptostomyNeil D. Patel, MD, Damien Kenny, MD Chapter 64. Interventional Therapeutic Procedures in the NewbornSalwa M Gendi, MD, Qi-Ling Cao, MD, Ziyad M Hijazi , MD Chapter 65. The Hybrid ProcedureRalf J. Holzer, MD Chapter 66. Neonatal Cardiac Surgical ProceduresHarold M. Burkart, MD Chapter 67. Extracorporeal Membrane Oxygenation and Ventricular Assist DevicesVikas Sharma MBBS, Gregory J Schears M.D, Joseph A Dearani, MD Chapter 68. Neonatal Cardiac TransplantationStephen Pophal MD, Justin Ryan PhD, John J Nigro MD Chapter 69. Postoperative Care of the NewbornAnthony F Rossi, MD Section 7. Neonatal Formulary Chapter 70. Medications and FormularyEnrique Oliver Aregullin, MD, Anthony F. Rossi, MD. Chapter 71. NutritionNicole Sutton, MD

Read more less

Book SynopsisRare gynecological cancers kill all too commonly Gynecological cancer is a frightening prospect for women. It is terrifying also for physicians who need, but often can t find, guidance on how to investigate and appropriately treat the tumors.Table of ContentsList of Contributors vi Preface viii Part 1 General Principles 1 1 Molecular Targets in Gynecologic Cancers 3 Whitfield Growdon, Rosemary Foster, and Bo Rueda 2 Imaging of Rare Gynecologic Tumors 18 Hima B. Prabhakar and Dinushi S. Perera 3 Pathology Overview of Rare Gynecologic Tumors 35 Robert H. Young Part 2 Rare Ovarian Cancers 51 4 Ovarian Clear Cell Carcinoma 53 Rachel M. Clark and John O. Schorge 5 Mucinous Epithelial Ovarian Cancer 64 Marcela G. del Carmen 6 Pseudomyxoma Peritonei 70 Leslie S. Bradford and Annekathryn Goodman 7 Squamous Cell Carcinoma of the Ovary 81 Ryan J. Spencer and Laurel W. Rice 8 Endometriosis-Associated Ovarian Cancer 94 Leslie A. Garrett and Marcela G. del Carmen 9 Carcinosarcoma of the Ovary 109 J. Alejandro Rauh-Hain and Marcela G. del Carmen 10 Malignant Germ Cell Tumors of the Ovary 120 Marcela G. del Carmen 11 Malignant Sex Cord-Stromal Tumors of the Ovary 132 Marcela G. del Carmen and Richard T. Penson 12 Small Cell and Neuroendocrine Cancers of the Ovary 139 Ariel A. Kaphan and Cesar M. Castro 13 Carcinoid Tumors of the Ovary 148 Michael J. Worley Jr., and Michael G. Muto Part 3 Rare Uterine Cancers 157 14 Uterine Carcinosarcoma 159 Premal H. Thaker and Don S. Dizon 15 Uterine Leiomyosarcoma 167 Marcela G. del Carmen 16 Mucinous Tumors of the Uterine Corpus 178 Rachel M. Clark and Marcela G. del Carmen 17 Uterine Clear Cell Carcinoma 186 J. Alejandro Rauh-Hain, Alexander B. Olawaiye, and David M. Boruta 18 Updates on the Management of Uterine Serous Carcinoma 195 Amanda Ramos and Amanda Nickles Fader 19 Endometrial Stromal Sarcomas 205 Kathleen M. Schmeler, J. Alejandro Rauh-Hain, and Marcela G. del Carmen Part 4 Rare Cancers of the Cervix, Vulva and Vagina 217 20 Small Cell Neuroendocrine Carcinoma of the Cervix 219 Olivia W. Foley, Leslie S. Bradford, and Marcela G. del Carmen 21 Primary Malignant Melanoma of the Vagina and Vulva 228 Alexander B. Olawaiye 22 Sarcomas of the Vulva and Vagina 236 Rachel M. Clark, J. Alejandro Rauh-Hain, and Marcela G. del Carmen 23 Gestational Trophoblastic Disease 245 Whitfield Growdon Index 260

Read more less

Book SynopsisClinical Problems in Oncology: A Practical Guide to Management is an easy-to-use, compact reference with essential, practical information on managing oncological emergencies, as well as the side effects and complications of cancer and its treatment. Because patient responses can vary widely, depending on the type of treatment prescribed, this resource offers medical professionals the specific information they need to improve the evaluation and treatment of cancer patients at the point of care. The compact format includes a wide range of clinical information, from the dose of drugs that would typically be used, through guidance on the practical procedures that are frequently used to treat oncology patients. Some of the book's highlights include: Toxicity grading and management, including at-a-glance summaries of the most common toxicities associated with chemotherapy Prescribing guidelines, including how to write Trade Review“Clinical Problems in Oncology: A Practical Guide to Management is an easy–to–use, compact reference with essential, practical information on managing oncological emergencies, as well as the side effects and complications of cancer and its treatment.” (Kingbook73's Medical Ebook and Video Collection, 7 October 2014) Table of ContentsList of contributors, ix Preface, xi Acknowledgements xii List of abbreviations xiii 1 Introduction to clinical problems in oncology 1 Sing Yu Moorcraft General approach to the management of oncology patients 2 Performance status 6 Tumour markers 6 2 Oncological emergencies 13 Daniel L.Y. Lee Anaphylaxis and hypersensitivity reactions 13 Bleeding 16 Central airway obstruction and stridor 19 Extravasation 23 Febrile neutropenia 28 Hypercalcaemia 30 Non-neutropenic sepsis 34 Raised intracranial pressure and seizures 36 Spinal cord compression 41 Superior vena cava obstruction 45 Transfusion reactions 48 Tumour lysis syndrome 50 3 Side effects and complications of cancer and its treatment 53 Alexandra Pender, Sing Yu Moorcraft and Daniel L.Y. Lee Overview of toxicity management 54 Abnormal liver function tests 57 Alopecia 60 Anaemia 62 Anorexia and nutrition 66 Ascites 69 Bone metastases and osteoporosis 71 Bowel obstruction 75 Breathlessness 77 Chest pain and other cardiac complications 81 Confusion and decreased conscious level 86 Constipation 91 Dental disorders 93 Diarrhoea 95 Dysphagia 100 Fatigue 104 Fertility and pregnancy 106 Haematuria 113 Hearing loss 115 Hiccups 117 Hyperglycaemia and hypoglycaemia 119 Hypertension and hypotension 123 Lymphoedema 127 Mucositis 129 Nausea and vomiting 133 Neuropathy 138 Neutropenia 142 Proteinuria 145 Pruritus 146 Psychiatric disorders 149 Rash 154 Renal failure and hydronephrosis 163 Sexual dysfunction 166 Thrombocytopenia 170 Thromboembolism 173 Vaccinations and immunoglobulin 178 Visual symptoms 180 4 Introduction to radiotherapy 185 Emma Dugdale, Alexandra Gilbert and Robin Prestwich Introduction to radiotherapy 185 Methods of delivery of radiotherapy 186 5 Radiotherapy side effects and their management 193 Alexandra Gilbert, Emma Dugdale and Robin Prestwich Overview of radiotherapy toxicity 193 Overview of radical radiotherapy treatment and side effect management by anatomical treatment site 195 Brain 195 Head and neck 196 Breast 200 Thorax 200 Abdomen 204 Pelvis 205 Skin toxicities 211 Total body irradiation 214 6 Endocrine therapy, immunotherapy and targeted therapies 215 Samantha Turnbull Endocrine therapy 215 Immunotherapy 218 Targeted therapies 220 7 Electrolyte abnormalities 225 Sing Yu Moorcraft Hypocalcaemia 225 Hyperkalaemia and hypokalaemia 227 Hypermagnesaemia and hypomagnesaemia 231 Hypernatraemia and hyponatraemia 234 Hyperphosphataemia and hypophosphataemia 237 8 Palliative care and pain management 241 Karen Neoh Pain management 241 Overview of pain management 241 Opioid prescribing in palliative care 245 Opioid toxicity 251 Syringe pumps 252 End-of-life care 253 9 Oncology procedures and their complications 257 Juanita Lopez Ascitic drains (paracentesis) 257 Biliary drains and stents 259 Central venous access devices 261 Chemoembolisation 265 Chest drains and pleurodesis 266 Enteral feeding tubes 269 Nephrostomies and ureteric stents 270 Oesophageal stents and dilatation 272 Radioembolisation (SIR-spheres®) 273 Radiofrequency ablation (RFA) 275 10 Cancer drug development and funding 277 Sing Yu Moorcraft Clinical trials 277 Funding of cancer drugs 280 Personalised medicine 282 Appendices 287 Sing Yu Moorcraft and Daniel L.Y. Lee Chemotherapy regimes 287 Drug toxicities 287 Useful resources 296 Index 301

Read more less

Book SynopsisWith a focus on case studies of R&D programs in a variety of disease areas, the book highlights fundamental productivity issues the pharmaceutical industry has been facing and explores potential ways of improving research effectiveness and efficiency.Trade Review"Innovative drug discovery can only be partially guided by knowledge from known chemical and pharmacological space, so a level of attrition is therefore inevitable. This refreshingly readable book provides an engaging combination of background historical and current reasons for attrition, combined with a panorama of some of the possible ways to covert “attrition” into the informed risk-taking necessary for innovative drug discovery. The book is very logically presented across the phases of drug discovery out across the technologies an across the phases of drug discovery and thus builds in depth reference source especially for those entering the challenging environment of drug discovery. As the authors point out, converting molecules into drugs remains difficult and engaging in more projects as a way to ensure a minimal level of success is not sustainable, so challenging and understanding better the reasons for attrition are of fundamental importance. The reasons for attrition change over time as some factors, notably AMDE and PK are better understood. But an inability to accurately predict still hampers the industry. This book makes a very useful reference source by highlighting where progress is being made, for example, the AstraZeneca 5Rs approach or the translational data analysis by Pfizer showing three parameters which correlate combined confidence in pharmacology an exposure with confidence in Phase II success. The book then nicely moves the reader on from the improvements in Phase II attrition by asking the critical question, “Why do drugs fail in Phase III if efficacy failures in Phase II are being better managed?” One of the advantages of this book is that it not only provides a well written background review, but that it combines this with examples of where progress it still needed, something of particular importance as regulators increasingly place emphasis on safety profiles. Although the book does make some comments to other modalities, it focuses on small molecule drug discovery, for which the authors take the reader through all stages of drug discovery form target identification to post-marketing attrition with extensive use of informative case studies. These case studies are used to highlight where attrition has been reduced, where improvements are still needed, and for preclinical research in particular where attrition isn’t necessarily bad, but rather a consequence of innovative drug discovery, that is best managed in a structured approach where knowledge can be transferred between projects. As the pharmaceutical industry moves to a more fragmented but networked environment changes in the ways in which knowledge is acquired and transferred between companies will significantly change the ways in which attrition is confronted. This book is therefore an excellent source material that will be of great value to all those embarking in drug discovery in smaller more agile companies. As evidenced in Chapter 2, preclinical research has made significant inroads in managing attrition with structured approaches to ADME profiling and PK/PD modelling. This is picked up and integrated into more detailed discussion later in Chapters 7–10, covering reasons for attrition associated with the various technologies employed in preclinical research. Whilst attrition in preclinical research can be mitigated and to varying extents managed, attrition in clinical studies represent failure of a project or mechanism. Clinical and post-marketing failures continue to limit the overall efficiency of the drug discovery industry. The reasons are many and starting in chapter 3 with Phase I this book systematically reviews the factors influencing attrition in each phase, combined with examples of how some may be reduced. Attrition due to PK and tolerability issues remain the main causes of Phase I attrition, although PK attrition can be attenuated by preclinical in vitro CYP profiling combined with in vivo PK studies. Phase I oncology studies are more susceptible to tolerability problems and in general tolerability issues are a common reason for termination of dose escalation studies across disease areas. The chapter finishes with an interesting discussion on the addition of Target Occupancy readouts in Phase I studies for a range of different target classes. Determining the Target Occupancy required for efficacy significantly improves the probability of a success in subsequent Phase II studies. In the following Chapter, the discussion moves to attrition in Phase II/III studies with a detailed series of well-chosen case studies that highlight that despite improving Phase II success rates, lack of efficacy in some cases compounded by addition toxicological issues remains the main reason for Phase II/III failures. Failure is evenly spread across small molecules, antibodies, and biologics, though some disease areas such as Alzheimer’s disease are more difficult. Well-selected case histories are also used to highlight post-marketing attrition arising from both on- and off-target pharmacologies, where unacceptable benefit– risk scenarios have led to drugs being removed from the market or subject to restricting label restrictions. And as highlighted in Chapter 5 some off-target side effects are only revealed in large (postmarketing) populations which show highlight second target or other side effects. Whilst not perhaps directly as source of attrition, changes in the regulatory environment are presented in Chapter 6 as they have a significant retroactive effect on drug discovery. For example, no project today would be progressed without extensive studies on liability for drug-induced QTc prolongation. Drug withdrawals due to safety are thankfully relatively rare, nevertheless FA and EMA guidance impact significantly on introducing additional parameters in pre-clinical and clinical research that need to be effectively controlled to avoid attrition. Chapter 9 contrasts the different attrition scenarios contained in phenotypic screening and target-based drug discovery projects, using key case studies from anti-infective and CNS projects. The values of each approach and the associated potential attrition factors, such as; complex SAR in phenotypic screening or the disconnection from pharmacological relevance in target-based approaches are compared. Attrition is also affected in each approach by technological factors and implications for data-driven compound optimization and translation into clinical studies. As screening technologies advance the distinction between the two approaches becomes less clear, and for now the combination of both approaches coupled with in silico modelling appears to best method for project progression and mitigation of downstream attrition. As discussed in Chapter 10 of the book, data integration and interpretation via in silico modelling has significantly helped reduce pre-clinical attrition. ADME and toxicity profiling in particular have benefitted from ability to predict compound properties via iterative cycles of in silico modelling. Indeed, knowledge sharing of compound data and properties either by public databases or industry-academic collaborations has proven an effective route to help further reduce attrition. The book closes with two chapters looking to the future and to emerging new approaches to tackle attrition rates that are emerging from pre-competitive collaborative research and new business models and above all the continued need for highly motivated knowledge seeking researchers that make the drug discovery business successful. As highlighted in the conclusion, “if there were no attrition, it would not be research”. Attrition in drug discovery will always be a factor as new targets and new mechanisms are investigated. Attrition is a necessary element of innovation, and through constant improvements in our understanding of the causes of attrition continued reduction of failures due to lack of efficacy and in particular safety issues can be expected."Prof. Roberto Pellicciari, TES Pharma, Perugia (ChemMedChem, July 2017)Table of ContentsContributors xiiiIntroduction 1Alexander Alex C. John Harris and Dennis A. SmithReferences 41 Attrition in Drug Discovery and Development 5Scott Boyer Clive Brealey and Andrew M. Davis1.1 “The Graph” 51.2 The Sources of Attrition 71.3 Phase II Attrition 91.3.1 Target Engagement 111.3.2 Clinical Trial Design 111.4 Phase III Attrition 121.4.1 Safety Attrition in Phase III 141.5 Regulation and Attrition 171.6 Attrition in Phase IV 191.7 First in Class Best in Class and the Role of the Payer 321.8 Portfolio Attrition 341.9 “Avoiding” Attrition 361.9.1 Drug Combinations and New Formulations 361.9.2 Biologics versus Small Molecules 371.9.3 Small-Molecule Compound Quality 381.10 Good Attrition versus Bad Attrition 391.11 Summary 40References 422 Compound Attrition at the Preclinical Phase 46Cornelis E.C.A. Hop2.1 Introduction: Attrition in Drug Discovery and Development 462.2 Target Identification HTS and Lead Optimization 502.3 Resurgence of Covalent Inhibitors 552.4 In Silico Models to Enhance Lead Optimization 562.5 Structure-Based and Property-Based Compound Design in Lead Optimization 592.5.1 Risks Associated with Operating in Nondrug-Like Space 622.6 Attrition Due to ADME Reasons 642.6.1 Metabolism Bioactivation and Attrition 682.6.2 PK/PD Modeling in Drug Discovery to Reduce Attrition 692.6.3 Human PK Prediction Uncertainties 702.7 Attrition Due to Toxicity Reasons 722.8 Corporate Culture and Nonscientific Reasons for Attrition 752.9 Summary 76References 763 Attrition in Phase I 83Dennis A. Smith and Thomas A. Baillie3.1 Introduction 833.2 Attrition in Phase I Studies and Paucity of Published Information 843.3 Drug Attrition in not FIH Phase I Studies 853.4 Attrition in FIH Studies Due to PK 863.4.1 Attrition due to Pharmacogenetic Factors 883.5 Attenuation of PK failure 903.5.1 Preclinical Methods (In Vivo) 903.5.2 Preclinical Methods (In Vitro) 913.5.3 Phase 0 Microdose Studies in Humans 923.5.4 Responding to Unfavorable PK Characteristics 943.6 Phase I Oncology Studies 953.7 Toleration and Attrition in Phase I Studies 973.7.1 Improving the Hepatic Toleration of Compounds 983.7.2 Rare Severe Toxicity in Phase I Studies 983.8 Target Occupancy and Go/No]Go Decisions to Phase II Start 993.9 Conclusions 102References 1024 Compound Attrition in Phase II/III 106Alexander Alex C. John Harris Wilma W. Keighley and Dennis A. Smith4.1 Introduction 1064.2 Attrition Rates: How Have they Changed? 1074.3 Why do Drugs Fail in Phase II/III? Lack of Efficacy or Marginal Efficacy Leading to Likely Commercial Failure 1084.4 Toxicity 1114.5 Organizational Culture 1124.6 Case Studies for Phase II/III Attrition 1124.6.1 Torcetrapib 1124.6.2 Dalcetrapib 1134.6.3 Onartuzumab 1144.6.4 Bapineuzumab 1154.6.5 Gantenerumab 1154.6.6 Solanezumab 1164.6.7 Pomaglumetad Methionil (LY]2140023) 1164.6.8 Dimebon (Latrepirdine) 1174.6.9 BMS]986094 1174.6.10 TC]5214 (S]Mecamylamine) 1184.6.11 Olaparib 1184.6.12 Tenidap 1194.6.13 NNC0109]0012 (RA) 1204.6.14 Omapatrilat 1204.6.15 Ximelagatran 1214.7 Summary and Conclusions 122References 1235 Postmarketing Attrition 128Dennis A. Smith5.1 Introduction 1285.2 On-Target Pharmacology-Flawed Mechanism 1305.2.1 Alosetron 1305.2.2 Cerivastatin 1305.2.3 Tegaserod 1335.3 Off-Target Pharmacology Known Receptor: An Issue of Selectivity 1355.3.1 Fenfluramine and Dexfenfluramine 1355.3.2 Rapacuronium 1365.3.3 Astemizole Cisapride Grepafloxacin and Thioridazine 1385.4 Off-Target Pharmacology Unknown Receptor: Idiosyncratic Toxicology 1425.4.1 Benoxaprofen 1425.4.2 Bromfenac 1425.4.3 Nomifensine 1435.4.4 Pemoline 1445.4.5 Remoxipride 1445.4.6 Temafloxacin 1455.4.7 Tienilic acid 1455.4.8 Troglitazone 1465.4.9 Tolcapone 1465.4.10 Trovafloxacin 1475.4.11 Valdecoxib 1485.4.12 Zomepirac 1485.5 Conclusions 150References 1516 Influence of the Regulatory Environment on Attrition 158Robert T. Clay6.1 Introduction 1586.1.1 How the Regulatory Environment has Changed Over the Last Two Decades 1596.1.2 Past and Current Regulatory Attitude to Risk Analysis and Risk Management 1616.2 Discussion 1626.2.1 What Stops Market Approval? 1626.2.2 Impact of Black Box Warnings 1666.2.3 Importance and Impact of Pharmacovigilance 1676.2.4 Prospects of Market Withdrawals for New Drugs 1686.2.5 What are the Challenges for the Industry Given the Current Regulatory Environment? 1736.2.6 Future Challenges for Both Regulators and the Pharmaceutical Industry 1746.3 Conclusion 175References 1767 Experimental Screening Strategies to Reduce Attrition Risk 180Marie-Claire Peakman Matthew Troutman Rosalia Gonzales and Anne Schmidt7.1 Introduction 1807.2 Screening Strategies in Hit Identification 1837.2.1 Screening Strategies and Biology Space 1837.2.2 Screening Strategies and Chemical Space 1877.2.3 High-Throughput Screening Technologies 1917.2.4 Future Directions for High-Throughput Screening 1947.3 Screening Strategies in Hit Validation and Lead Optimization 1947.4 Screening Strategies for Optimizing PK and Safety 1977.4.1 High-Throughput Optimization of PK/ADME Profiles 1987.4.2 Early Safety Profiling 2027.4.3 Future Directions for ADME and Safety in Lead Optimization 2047.5 Summary 205References 2068 Medicinal Chemistry Strategies to Prevent Compound Attrition 215J. Richard Morphy8.1 Introduction 2158.2 Picking the Right Target 2168.3 Finding Starting Compounds 2168.4 Compound Optimization 2188.4.1 Drug-Like Compounds 2188.4.2 Structure-Based Drug Design 2198.4.3 The Thermodynamics and Kinetics of Compound Optimization 2208.4.4 PK 2208.4.5 Toxicity 2228.5 Summary 225References 2269 Influence of Phenotypic and Target]Based Screening Strategies on Compound Attrition and Project Choice 229Andrew Bell Wolfgang Fecke and Christine Williams9.1 Drug Discovery Approaches: A Historical Perspective 2299.1.1 Phenotypic Screening 2299.1.2 Target-Based Screening 2309.1.3 Recent Changes in Drug Discovery Approaches 2319.2 Current Phenotypic Screens 2339.2.1 Definition of Phenotypic Screening 2339.2.2 Recent Anti-infective Projects 2339.2.3 Recent CNS Projects 2359.3 Current Targeted Screening 2379.3.1 Definition of Targeted Screening 2379.3.2 Recent Anti-infective Projects 2379.3.3 Recent CNS Projects 2399.4 Potential Attrition Factors 2419.4.1 Technical Doability and Hit Identification 2419.4.2 Compound SAR and Properties 2469.4.3 Safety 2489.4.4 Translation to the Clinic 2509.5 Summary and Future Directions 2529.5.1 Summary of Impact of Current Approaches 2529.5.2 Future Directions 2549.5.3 Conclusion 255References 25510 In Silico Approaches to Address Compound Attrition 264Peter Gedeck Christian Kramer and Richard Lewis10.1 In Silico Models Help to Alleviate the Process of Finding Both Safe and Efficacious Drugs 26410.2 Use of In Silico Approaches to Reduce Attrition Risk at the Discovery Stage 26510.3 Ligand-Based and Structure-Based Models 26510.4 Data Quality 26810.5 Predicting Model Errors 27010.6 Molecular Properties and their Impact on Attrition 27210.7 Modeling of ADME Properties and their Impact of Reducing Attrition in the Last Two Decades 27510.8 Approaches to Modeling of Tox 27610.9 Modeling PK and PD and Dose Prediction 27610.10 Novel In Silico Approaches to Reduce Attrition Risk 27810.11 Conclusions 280References 28011 Current and Future Strategies for Improving Drug Discovery Efficiency 287Peter Mbugua Njogu and Kelly Chibale11.1 General Introduction 28711.2 Scope 28811.3 Neglected Diseases 28911.3.1 Introduction 28911.3.2 Control of NTDs 29011.3.3 Drug Discovery Potential of Neglected Diseases 29011.4 Precompetitive Drug Discovery 29211.4.1 Introduction 29211.4.2 Virtual Discovery Organizations 29311.4.3 Collaborations with Academic Laboratories 29511.4.4 CoE and Incubators 29611.4.5 Screening Data and Compound File Sharing 29711.5 Exploitation of Genomics 29711.5.1 Introduction 29711.5.2 Target Identification and Validation 29811.5.3 Target-Based Drug Discovery 29811.5.4 Phenotypic Whole-Cell Screening 30111.5.5 Individualized Therapy and Therapies for Special Patient Populations 30211.6 Outsourcing Strategies 30411.6.1 Introduction 30411.6.2 Research Contracting in Drug Discovery 30511.7 Multitarget Drug Design and Discovery 30511.7.1 Introduction 30511.7.2 Rationale for Multitargeted Drugs 30611.7.3 Designed Multitarget Compounds for Neglected Diseases 30711.8 Drug Repositioning and Repurposing 31511.8.1 Introduction 31511.8.2 Cell Biology Approach 31711.8.3 Exploitation of Genome Information 31811.8.4 Compound Screening Studies 31811.8.5 Exploitation of Coinfection Drug Efficacy 31811.8.6 In Silico Computational Technologies 31911.9 Future Outlook 319References 31912 Impact of Investment Strategies Organizational Structure and Corporate Environment on Attrition and Future Investment Strategies to Reduce Attrition 329Geoff Lawton12.1 Attrition 32912.2 Costs 33112.2.1 The Costs of Creating a New Medicine 33112.2.2 The Costs of Not Creating a New Medicine 33212.3 Investment Strategies 33412.3.1 RoI 33412.3.2 Investment in a Portfolio of R&D Projects 33512.3.3 Asset-Centered Investment 33512.3.4 Sources of Funds 33612.4 Business Models 33712.4.1 FIPCO 33712.4.2 Fully Integrated Pharmaceutical Network (FIPNET) 33812.4.3 Venture-Funded Biotech 33912.4.4 Fee-for-Service CRO 33912.4.5 Hybrids 33912.4.6 Academic Institute 34012.4.7 Social Enterprise 34112.5 Portfolio Management 34112.5.1 Portfolio Construction 34112.5.2 Project Progression 34312.5.3 The Risk Transition Point 34312.6 People 34412.6.1 Motivation 34412.6.2 Culture and Leadership 34412.6.3 Sustainability 34412.7 Future 34512.7.1 Business Structures 34512.7.2 Skilled Practitioners 34712.7.3 Partnerships 34812.7.4 A Personal View of the Future 349References 351Index 353

Read more less

Book SynopsisCan you adapt to the wide variety of learning environments in medicine? Can you show your best abilities in the exams at the same time as learning to be a doctor? This book provides an insight into what to expect from the start of medical school right through to the start of your medical career.Trade Review"This should be the gift of choice for any just entering medical school: it will pinpoint and help students overcome many potential barriers to success." (Midwest Book Review 2016) Table of ContentsAbout the authors vii Foreword to the first edition ix Introduction 1 Chapter 1 What kind of learner are you? 5 Chapter 2 Learning knowledge 19 Chapter 3 Learning clinical skills 47 Chapter 4 Learning clinical communication skills 68 Chapter 5 Working in a group 100 Chapter 6 Developing your academic writing skills 117 Chapter 7 Portfolios and reflection 125 Chapter 8 Life–work balance 138 Chapter 9 Revision 151 Chapter 10 Exam technique: general rules 162 Chapter 11 Exam technique: specific examples 174 Chapter 12 Teaching, mentoring and coaching: helping others to learn and develop 203 Chapter 13 Professionalism: not as straightforward as you think 224 Chapter 14 Thinking ahead: student-selected components, careers and electives 242 Index 253

Read more less

Book SynopsisHighly Commended at the British Medical Association Book Awards 2016 Clinical Communication in Medicine brings together the theories, models and evidence that underpin effective healthcare communication in one accessible volume.Trade Review"From being proactive to skills that come into play when handling emergencies, Clinical Communication in Medicine discusses all kinds of scenarios and options, contrasting different coping strategies and approaches, and should be required reading for any medical student." (California Bookwatch, 2016)"The result is a scholarly yet accessible blend of history, social science, and medical and psychological insights recommended for anyone working in a clinical medical setting." (Donovan's Literary Services 2016)Table of ContentsContributors viii Foreword xi 1 Introduction 1 Jane Kidd Part 1: The doctor‐patient relationship Section lead editor: Lorraine M. Noble 2 Introduction to the Doctor–Patient Relationship 5 Lorraine M. Noble 3 History of the Doctor–Patient Relationship 6 Annie Cushing 4 Models of the Doctor–Patient Consultation 21 Alexia Papageorgiou 5 What Is Effective Doctor–Patient Communication? Review of the Evidence 30 Gregory Makoul and Sandra van Dulmen 6 Patient‐Centredness 40 Rosie Illingworth 7 The Impact of Training 49 John Skelton 8 The Future of the Doctor–Patient Relationship 57 Lorraine M. Noble Part 2: Components of Communication Section lead editor: Alexia Papageorgiou Part 2A: Core Tasks in Clinical Communication 9 Overview of Core Tasks in Clinical Communication 69 Jonathan Silverman 10 Relationship Building 72 Jonathan Silverman 11 Information Gathering and Clinical Reasoning 76 Jonathan Silverman 12 Information Sharing and Shared Decision Making 81 Jonathan Silverman Copyrighted Material 13 Communicating about Risk and Uncertainty 87 Katherine Joekes 14 Responding to Emotions 91 Theano V. Kalavana 15 Breaking Bad News 98 Rob Lane 16 Facilitating Behaviour Change through Motivational Interviewing 104 Eva Doherty 17 Responding to Medical Error and Complaints 108 Lucy Ambrose and Lindsey Pope Part 2B: Diversity Issues in Clinical Communication and Cultural Diversity 18 Overview of Diversity Issues in Clinical Communication 117 Costas S. Constantinou 19 Diversity Issues in Clinical Communication 119 Margot Turner and Nisha Dogra 20 The Family Consultation 127 Xavier Coll 21 Consulting with Children and Young People 131 Xavier Coll 22 The Older Patient 138 Andrew Tarbuck 23 End of Life Issues 147 Vinnie Nambisan and Jennifer Balls 24 Mental Health Matters 151 Jonathan Wilson Part 2C: Interprofessional Communication 25 Interprofessional Communication and Its Challenges 159 Susanne Lindqvist Part 3: Learning Teaching and Assessment Section lead editor: Jo Brown 26 Introduction to Learning Teaching and Assessment 171 Jo Brown 27 The History of Clinical Communication Teaching 172 Victoria Bates Jonathan Reinarz and Connie Wiskin Part 3A: Models of Learning 28 Behaviourism as a Way of Learning 181 Jo Brown 29 Situated and Work‐Based Learning 186 Jo Brown 30 Experiential Learning 193 Jan van Dalen 31 Transformative Learning and High‐Fidelity Simulation 200 Wesley Scott‐Smith 32 Reflective Practice 206 Sally Quilligan 33 Models of Feedback 211 Catherine J. Williamson Jill Dales and John Spencer Part 3B: The Assessment of Communication 34 Introduction to Assessment in Communication 221 Jane Kidd 35 Assessing Performance 233 Connie Wiskin and Janet Lefroy 36 Workplace‐Based Assessment 241 Jane Kidd and Janet Lefroy Part 4: Afterword 37 Afterword 251 Jo Brown Lorraine M. Noble Alexia Papageorgiou and Jane Kidd Index 252

Read more less

Book SynopsisWith contributions from leading, international academics and industrial practitioners, Bioprocessing for Cell-Based Therapies explores the very latest techniques and guidelines in bioprocess production to meet safety, regulatory and ethical requirements, for the production of therapeutic cells, including stem cells. An authoritative, cutting-edge handbook on bioprocessing for the production of therapeutic cells with extensive illustrations in full colour throughout An authoritative, cutting-edge handbook on bioprocessing for the production of therapeutic cells with extensive illustrations in full colour throughout In depth discussion of the application of cell therapy including methods used in the delivery of cells to the patient Includes contributions from experts in both academia and industry, combining a practical approach with cutting edge research The only handbook currently available to provide a state of the art guide toTable of ContentsList of Contributors xi Preface xv 1 Overview of the Cell Therapy Field 1 Michael Whitaker, Lucy Foley and Stephen Ward 1.1 The Context of Cell Therapies and Their Manufacturing Challenges 1 1.1.1 Regulation of Cell Therapies 4 1.1.2 Manufacturing Challenges in Cell Therapy 5 1.2 The Cell Therapy Landscape 5 1.2.1 Licensed Cell Therapy Products 7 1.2.2 Companies, Clinicians, Products and Procedures 8 1.2.3 Cell Therapy Clinical Trials 8 1.3 Operations in Cell Therapy Manufacture 11 1.3.1 Cells for Cell Therapy Production 12 1.3.1.1 Cell Source 12 1.4 Upstream Processing of Cellular Therapies 13 1.4.1 Cell Separation 13 1.4.2 Cell Expansion 13 1.4.3 Tissue Expansion 15 1.4.4 Adherent Cell Expansion 15 1.4.4.1 Multi-layer Reactors 15 1.4.4.2 Hollow Fibre Reactors 16 1.4.4.3 Scaffolds 17 1.4.5 Suspension Cell Expansion 18 1.4.5.1 Stirred Tank Bioreactors 18 1.4.5.2 Rocking Platforms 19 1.4.5.3 Perfusion Cell Culture 19 1.4.6 Differentiation 19 1.5 Downstream Processing of Cellular Therapies 20 1.5.1 Harvest, Washing and Concentration 20 1.5.1.1 Centrifugation 21 1.5.1.2 Filtration 21 1.5.2 Separation and Purification 22 1.5.2.1 Centrifugation 22 1.5.2.2 Magnetic Separation 24 1.6 Formulation, Fill and Finish of Cellular Therapies 24 1.6.1 Formulation 25 1.6.2 Fill and Finish 25 1.6.3 Preservation and Shipment 26 1.7 Administration of the Cell Therapy to a Patient 27 1.8 Cell Therapy Manufacturing Facilities of the Future 28 1.8.1 Factory of the Future Requirements 31 1.9 Conclusion 31 References 32 2 Structured Methodology for Process Development in Scalable Stirred Tank Bioreactors Platforms 35 Huaqing Wang, Daniel Kehoe, Julie Murrell and Donghui Jing 2.1 Introduction 35 2.2 Understanding the Engineering of the Stirred Tank Bioreactors 36 2.2.1 Mixing Phenomena in Stirred Tank Bioreactors 37 2.2.2 Understanding Oxygen Transfer Rate (kLa) with Different Sparging Methodologies 40 2.2.3 Heat Transfer in STB (Minimum Volume, Sensor/Sensing Control) 42 2.2.4 How to Choose a Microcarrier for Adherent Cells (hMSCs) 43 2.3 Understanding the Biology of the Cells in Stirred Tank Bioreactors (STB) 45 2.3.1 Cell Types (Adherent and Suspension Cells) 45 2.3.2 Assays for Comparability, Nutrients, Senescence and Doubling Dime 46 2.4 Process Development of Adherent Cells in STB Platforms 47 2.4.1 Standard Comparison to Cell Factory 47 2.4.2 Methodology for Screening of Microcarriers 49 2.4.3 Process Development in Small-scale Bioreactors (3L) 50 2.4.3.1 Cell Seeding Density 51 2.4.3.2 Microcarrier Concentrations (Cells:Bead Ratio) 52 2.4.3.3 Operation Ranges of pH and Dissolved Oxygen 53 2.4.3.4 Feeding Strategy 54 2.4.4 Process Development in Medium-scale Bioreactors (50L) 55 2.4.5 Case Study for Expansion of Bone Marrow Derived MSCs in Stirred Tank Bioreactors 59 2.5 Future Directions 60 References 61 3 The Effect of Scale-up on Cell Phenotype: Comparability Testing to Optimize Bioreactor Usage and Manufacturing Strategies 65 Jason Hamilton and Bart Vaes 3.1 Introduction 65 3.1.1 Cell Characterization in the Development Path 66 3.1.2 The MultiStem® Allogeneic Cell Therapy Product: Mechanisms of Benefit and Target Cells Numbers 69 3.2 Challenges in Cell Product Development 72 3.2.1 Effect of Large-scale Expansion on Stem Cell Properties 72 3.2.2 Serum-free and Xeno-free Media Development 74 3.3 Stem Cell Characterization 75 3.3.1 ISCT Requirements 75 3.3.2 Potency Assays 77 3.3.3 Omics Screens for Therapeutic Stem Cell Characterization 78 3.4 Next-generation Stem Cell Development 80 References 83 4 The Scale-up of Human Mesenchymal Stem Cell Expansion and Recovery 91 Thomas R. J. Heathman, Qasim A. Rafiq, Karen Coopman, Alvin W. Nienow and Christopher J. Hewitt 4.1 Introduction 91 4.2 Scale-up or Scale-out 93 4.3 Understanding the Small Scale 96 4.4 Microcarrier Screening 103 4.5 Spinner Flask Culture 108 4.6 Large-scale Expansion in Conventional Stirred Tank Bioreactors 111 4.7 Cell Recovery from Microcarriers 117 4.8 Conclusions 120 References 121 5 Challenges of Scale-up of Cell Separation and Purification Techniques 127 Marieke A. Hoeve, Paul A. De Sousa and Nicholas A. Willoughby 5.1 Introduction 127 5.1.1 Cell Separation for Cell-based Therapeutics 127 5.1.2 Separation Methodology Design 128 5.1.3 Objective of this Chapter 128 5.1.3.1 Cell Yield 129 5.1.3.2 Standardisation 129 5.1.3.3 Economical viability 129 5.2 Scalable Cell Separation for Cell Therapy 130 5.2.1 Label Requiring versus Label-free Separation 130 5.2.2 Active versus Passive Method 133 5.2.3 Isolated Purification (Including Off-the-Shelf) versus Embedded Integrated Process 133 5.2.4 Low versus High Resolution 133 5.2.5 Open versus Closed Systems 134 5.2.6 Batch versus Continuous Separation 134 5.3 Currently Developed Cell Separation Techniques 135 5.3.1 Acoustophoresis 135 5.3.2 Aqueous Two-Phase System (ATPS) 137 5.3.3 Centrifugal Techniques 138 5.3.3.1 Centrifugal Counterflow Elutriation (CCE) 138 5.3.3.2 Centrifuge Systems with Integrated Filters 139 5.3.4 Dielectrophoresis (DEP) 140 5.3.5 Deterministic Lateral Displacement (DLD) 141 5.3.6 Genetic Engineering 141 5.3.7 Hydrodynamic Filtration (HDF) 142 5.3.8 Immunoadsorption 142 5.3.9 Immunomagnetic Cell Sorting 145 5.3.10 Inertial Migration 145 5.3.11 Magnetic Cell Sorting – Label-free 147 5.3.11.1 Magnetophoretic Cell Separation 147 5.3.11.2 Magnetic Solution-based Separation 148 5.3.12 Microscale Vortices 150 5.3.13 Normal Flow Filter (NFF) 150 5.3.14 Optical – Label-free 151 5.3.15 Tangential Flow Filters (TFF) 155 5.3.16 Weir and Pillar 156 5.4 Conclusion 157 Acknowledgements 159 References 159 6 Fundamental Points to Consider in the Cryopreservation and Shipment of Cells for Human Application 167 Glyn N. Stacey, Lyn Healy, Jennifer Man, Charles J. Hunt and John Morris 6.1 Introduction 167 6.2 The Role of Cryoprotective Agents (CPA) 168 6.3 Vitrification versus Cryopreservation 169 6.4 Points to Consider in the Development of Cryopreservation Protocols 169 6.4.1 General Considerations 169 6.4.2 Cellular Characteristics and Selection of Appropriate CPAs and Cooling Protocols 170 6.4.3 Key Events in Cryopreservation 172 6.4.3.1 Ice Nucleation 174 6.4.3.2 CPAs: Concentration and Composition 174 6.4.3.3 Cooling Rate 174 6.4.3.4 Storage of Cryopreserved Cells 176 6.4.3.5 Thawing and Recovery of Frozen Cells 177 6.5 Large-volume Freezing 178 6.6 Cryopreservation as Part of Manufacturing Processes 179 6.6.1 Containers for Cryopreserved Cells 179 6.6.2 Controlled Rate Freezers and Storage Systems 179 6.6.3 The Cold-chain: Challenges and Solutions 180 6.6.4 Biobanking and Regulatory Requirements 181 6.7 Conclusions 181 Acknowledgements 182 References 182 7 Short-term Storage of Cells for Application in Cell-based Therapies 187 Stephen Swioklo and Che J. Connon 7.1 Introduction 187 7.1.1 Advances in Cell-based Therapies 188 7.1.2 The Logistical Landscape for CTPs and the Requirement for Short-term Storage of Cells 188 7.2 Hypothermia and Mammalian Cell Storage 193 7.2.1 Hypothermic Storage of Mesenchymal Stem Cells (MSCs) 194 7.2.2 Optimal Temperature for Cell Storage 202 7.3 The Application of Hypothermic Storage in Cell-based Therapies 204 7.4 Concluding Remarks 205 References 205 8 Cell Therapy in Practice 211 Gustavo S. Figueiredo, Julian R. De Havilland, Majlinda Lako and Francisco C. Figueiredo 8.1 Introduction 211 8.2 The Classification of ATMPs 212 8.3 European Regulations 216 8.3.1 Hospital Exemption (HE) and “Specials” Manufacturing 219 8.3.2 Orphan Medicinal Product Designation 220 8.3.3 Committee for Advanced Therapies 221 8.3.4 Good Manufacturing Practice (GMP) 221 8.3.5 European Union Tissue and Cells Directives (EUTCD) 223 8.4 ATMP Case Study: Autologous Limbal Stem Cell Therapy: the Newcastle Experience 224 8.5 Conclusion 233 References 234 Index 237

Read more less

Book SynopsisThe first comprehensive, clinically focused guide to help hospitalists and other hospital-based clinicians provide quality palliative care in the inpatient setting.Table of ContentsContributors viii 1. Hospital Care for Seriously Ill Patients and Their Families 1 Steven Z. Pantilat, Wendy G. Anderson, Matthew J. Gonzales, and Eric W. Widera Section 1 Symptom Management 2. Pain Management: A Practical Approach for Hospital Clinicians 11 Solomon Liao, Kira Skavinski, Jamie Capasso, and Rosene D. Pirrello 3. Dyspnea: Management in Seriously Ill Hospitalized Patients 37 Margaret L. Campbell and Michael A. Stellini 4. Nausea and Vomiting: Evaluation and Management in Hospitalized Patients 49 Katherine Aragon and Matthew J. Gonzales 5. Delirium: Identification and Management in Seriously Ill Hospitalized Patients 61 Marieberta Vidal and Eduardo Bruera 6. Depression and Anxiety: Assessment and Management in Hospitalized Patients with Serious Illness 71 Nathan Fairman, Jeremy M. Hirst, and Scott A. Irwin Section 2 Communication and Decision Making 7. Effective Communication with Seriously Ill Patients in the Hospital: General Principles and Core Skills 95 Kristen A. Chasteen and Wendy G. Anderson 8. Family Meetings and Caring for Family Members 108 Sara K. Johnson 9. Assessing Goals of Care: A Case-Based Discussion 121 Elizabeth Lindenberger and Amy S. Kelley 10. Documenting Goals of Care and Treatment Preferences in the Hospital: A Case-Based Discussion 133 Lynn A. Flint, Rebecca L. Sudore, and Brook Calton 11. Prognostication: Estimating and Communicating Prognosis for Hospitalized Patients 143 Joshua R. Lakin and Eric W. Widera 12. Managing Conflict over Treatment Decisions 160 Robert M. Arnold and Eva Reitschuler-Cross Section 3 Practice 13. Palliative Care Emergencies in Hospitalized Patients 171 Paul Glare, Yvona Griffo, Alberta Alickaj, and Barbara Egan 14. Withdrawing Life-Sustaining Interventions 195 James M. Risser and Howard Epstein 15. Artificial Nutrition and Hydration in Patients with Serious Illness 206 Thomas T. Reid 16. Last Days of Life: Care for the Patient and Family 223 Jason Morrow 17. Palliative Care after Discharge: Services for the Seriously Ill in the Home and Community 237 Amy M. Corcoran, Neha J. Darrah, and Nina R. O’Connor 18. Interdisciplinary Team Care of Seriously Ill Hospitalized Patients 250 Dawn M. Gross and Jane Hawgood 19. Self-Care and Resilience for Hospital Clinicians 260 Sarah M. Piper, B.J. Miller, and Michael W. Rabow Index 273

Read more less

Book SynopsisA masterful and thorough revision of the only single-source, authoritative reference on cutaneous lymphoproliferative disease.Table of ContentsAcknowledgments, viii 1 Introduction to the Classification of Lymphoma 1 Kiel Lukes–Collins, and Working Formulation classifications 1 WHO, REAL, EORTC, and the Combined WHO/EORTC classifications 2 Summary 7 References 8 Appendix: Definitions of key terms and techniques 9 2 The Therapy of Cutaneous T Cell Lymphoma 14 Benjamin H. Kaffenberger, Mark A. Bechtel, and Pierluigi Porcu Introduction 14 Diagnostic work-up and staging procedures 14 CTCL therapies 15 Goals of therapy in advanced-stage CTCL 16 Extracorporeal photopheresis (ECP) 17 Interferons 17 Retinoids 17 Immunotoxins 18 Monoclonal antibodies 18 Histone deacetylase inhibitors (HDACi) 19 Antibody drug conjugates (ADC) 19 Cytotoxic chemotherapy 19 Investigational therapies 20 TLR agonists and cytokines 20 Allogeneic hematopoietic stem cell transplantation (allo-HSCT) 20 References 21 3 Molecular Analysis in Cutaneous Lymphoid Proliferation 23 Shabnam Momtahen, Cynthia Magro, and Carl Morrison Introduction 23 Immunoglobulin and T cell receptor structure 23 PCR design for determination of clonality 24 Detection of PCR products for clonality 24 Evaluation of results 25 The value and utility of molecular diagnostics in primary cutaneous lymphomas 26 Limitations of clonality assessment by PCR 27 Case vignettes 29 References 36 4 Benign Lymphocytic Infiltrates 37 Introduction 37 Spongiotic and eczematous dermatitis 37 Other spongiotic/eczematous tissue reactions 40 Other causes of subacute eczematous dermatitis 40 Interface dermatitis: cell-poor vacuolar interface dermatitis 42 Interface dermatitis: lichenoid pattern 46 Diffuse and nodular lymphocytic dermal infiltrates without atypia 51 Diffuse and nodular lymphocytic infiltrates associated with autoimmune disease 53 References 57 5 Reactive Lymphomatoid Tissue Reactions Mimicking Cutaneous T and B Cell Lymphoma 59 Lymphomatoid drug eruptions 59 Molecular profile of lymphomatoid drug eruptions 61 Pathogenetic basis of lymphomatoid drug reactions 62 Reactive lymphomatoid lesions encountered in lesions of collagen vascular disease 63 Angiomatous Variants of Pseudolymphoma 67 Case vignettes 69 References 86 6 Precursor Lesions of Cutaneous T Cell Lymphoma 89 Cutaneous T cell lymphoid dyscrasia 89 Large plaque parapsoriasis 90 Hypopigmented interface T cell dyscrasia: a unique indolent T cell dyscrasia 91 Pigmented purpuric dermatosis (PPD) 92 Pityriasis lichenoides 94 Idiopathic erythroderma (pre-Sézary) 96 Syringolymphoid hyperplasia with alopecia 96 Folliculotropic T cell lymphocytosis/pilotropic T cell dyscrasia 97 Idiopathic follicular mucinosis/alopecia mucinosa 98 Keratoderma-like T cell dyscrasia 99 Atypical lymphocytic lobular panniculitis 100 Case vignettes 102 References 132 7 Marginal Zone Lymphoma and Other Related Post Germinal Center B Cell Lymphoproliferative Disorders of The Skin 134 Marginal zone lymphoma 134 Blastic marginal zone lymphoma 140 Epidermotropic marginal zone lymphoma 140 Castleman disease 141 Primary cutaneous plasmacytoma 142 Case vignettes 145 References 166 8 Primary Cutaneous Follicle Center Cell Lymphoma 169 Clinical features 169 Pathology 169 Phenotypic profile 171 Molecular studies 172 Pathogenesis 172 Cytogenetics 172 Case vignettes 174 Additional molecular and cytogenetic study 185 References 186 9 Primary Cutaneous Diffuse Large B-Cell Lymphoma Including the Leg Type and Precursor B Cell Lymphoblastic Lymphoma 187 Primary cutaneous diffuse large B cell lymphoma 187 Systemic diffuse large B cell lymphomas with a propensity to involve the skin 197 Case vignettes 200 Additional light microscopic, phenotypic, molecular, cytogenetic studies 210 References 215 10 Intravascular Lymphoma 218 Clinical features 218 Light microscopic findings 219 Phenotypic profile 219 Molecular and cytogenetic studies 219 Pathogenesis 219 Differential diagnosis 219 Intravascular anaplastic large cell lymphoma 219 Benign intravascular proliferations of histiocytes and reactive T cells 220 Case vignettes 221 References 224 11 Cutaneous Mantle Cell Lymphoma 225 Clinical features 225 Light microscopic findings 225 Phenotypic profile 226 Molecular studies 227 Cytogenetic profile 227 Pathogenesis 227 Case vignettes 229 Additional molecular and cytogenetic studies 233 References 234 12 Mycosis Fungoides and Sézary Syndrome 236 Definition 236 Mycosis fungoides 236 Sézary syndrome and erythrodermic mycosis fungoides 243 Large cell transformation of mycosis fungoides 251 Extracutaneous involvement in mycosis fungoides 254 Case vignettes 259 References 271 13 CD30-Positive Lymphoproliferative Disorders Including Lymphomatoid Papulosis, Borderline CD30-Positive Lymphoproliferative Disease, Anaplastic Large Cell Lymphoma, and T-Cell-Rich CD30-Positive Large B Cell Lymphoma 274 Introduction 274 Lymphomatoid papulosis 274 CD8+ lymphomatoid papulosis, including the type D variant 278 Type E lymphomatoid papulosis (Case vignette 15) 278 Borderline CD30-positive lymphoproliferative disorders (type C LYP) (Case vignette 9) 279 Lymphomatoid papulosis with a rearrangement of chromosome 6p25.3 279 Cutaneous anaplastic large cell lymphoma 280 Small cell ALCL 282 Additional unusual histologic variants of anaplastic large cell lymphoma 282 Breast-implant-associated anaplastic large cell lymphoma 282 Intravascular anaplastic large cell lymphoma 282 Sarcomatoid anaplastic large cell lymphoma (Case vignette 14) 283 CD30-positive large B cell lymphoma 285 Case vignettes 286 References 309 14 CD4+ Peripheral T Cell Lymphoma, Not Otherwise Specified, Including Primary Cutaneous Cd4+ Small/Medium-Sized Pleomorphic T Cell Lymphoma 312 Introduction 312 Primary cutaneous CD4+ small/medium-sized pleomorphic T cell lymphoma 312 CD30-negative large cell T cell lymphoma 313 Cutaneous follicular helper T cell lymphoma 314 Overview of overall prognosis of primary cutaneous peripheral T cell lymphoma, unspecified 315 Evolution of the nomenclature of primary cutaneous CD4+ small/medium-sized pleomorphic T cell lymphoma 319 Case vignettes 320 References 333 15 Subcutaneous Panniculitis-Like T Cell Lymphoma 334 Clinical features 334 Morphology 336 Phenotype 337 Molecular studies 337 Differential diagnosis 337 Case vignettes 340 References 349 16 CD8 T Cell Lymphoproliferative Disease of the Skin 351 Overview 351 Introduction 351 Classification of primary CD8+ cutaneous T cell lymphomas 352 Histomorphology of primary cutaneous CD8+ T cell lymphoma: primary cutaneous aggressive epidermotropic CD8+ T cell lymphoma, and CD8+ variants of peripheral T cell lymphoma, NOS, including primary cutaneous CD8+ granulomatous T cell lymphoma 353 CD8 variant of lymphomatoid papulosis and other related CD30-positive T cell lymphoproliferative disorders of CD8 subtype 354 Light microscopic findings 354 Indolent CD8 positive lymphoid proliferation of the face and other body sites including acral surfaces 355 CD8 prolymphocytic leukemia 355 CD8 pseudolymphoma related to underlying HIV disease 356 Drug-associated CD8+ pseudolymphoma 356 Actinic reticuloid as a unique form of CD8+pseudolymphoma 356 Case vignettes 357 References 375 17 Nasal and Related Extranodal Natural Killer Cell/T Cell Lymphomas and Blastic Plasmacytoid Dendritic Cell Neoplasm 377 Introduction 377 Biology of NK and NK-like T cells 377 NK/T-cell lymphoma 379 Nasal NK/T cell lymphoma 379 Nasal type NK/T cell lymphoma 380 Aggressive NK cell lymphoma 380 Role of Epstein–Barr virus in the evolution of NK/T cell lymphomas 382 Blastic plasmacytoid dendritic cell neoplasm 382 CD56-positive γ δ lymphoma involving the subcutaneous fat 383 Chronic granular lymphocytosis/large granular cell leukemia 384 Natural killer-like CD4+ T cell lymphoma 384 EBV-associated NK/T cell lymphomas of the elderly 385 Hydroa vaccineforme (HV)-like lymphoma 385 Cutaneous intravascular NK T cell lymphoma 386 Case vignettes 387 References 401 18 Primary Cutaneous γ δ T Cell Lymphoma 404 Introduction 404 Case vignettes 409 Additional supplemental figures 411 References 414 19 Epstein–Barr Virus-Associated Lymphoproliferative Disease 415 Introduction 415 Hydroa vacciniforme-like EBV-associated T cell lymphoproliferative disease/mosquito bite hypersensitivity 416 EBV+ cutaneous B cell lymphoproliferative disorder of the elderly 420 EBV-associated mucocutaneous ulcer 421 EBV + T cell lymphoproliferative disease of the elderly 421 General principles regarding EBV-associated lymphomagenesis 421 Pathogenetic link between EBV-associated B cell lymphoma and iatrogenic immune dysregulation related to either methotrexate or cyclosporine 421 Case vignettes 423 References 432 20 Hodgkin Lymphoma of the Skin 435 Clinical features 435 Subtypes of Hodgkin lymphoma 436 References 447 21 Chronic Lymphocytic Leukemia of B Cell and T Cell Prolymphocytic Leukemia 449 B cell chronic lymphocytic leukemia 449 T cell prolymphocytic leukemia 452 Case vignettes 455 References 471 22 Adult T Cell Leukemia/Lymphoma 473 Clinical features 473 Pathology 474 Phenotypic studies 475 Pathogenesis 475 Infective dermatitis of childhood 476 Case vignettes 477 References 484 23 Angioimmunoblastic Lymphadenopathy/Angioimmunoblastic T Cell Lymphoma 486 Clinical features 486 Light microscopic findings 487 Phenotypic studies 488 Molecular studies 488 Pathogenesis 489 Case vignettes 491 References 497 24 Lymphomatoid Granulomatosis 499 Introduction 499 Clinical features 499 Histopathology 500 Histogenesis 501 Clonality studies 501 Differential diagnosis 501 Treatment 502 Case vignette 503 References 506 25 Cutaneous Infiltrates of Myeloid Derivation 507 Introduction 507 Leukemia cutis 507 Clonal histiocytopathy syndromes 509 Histiocytopathy of factor XIIIA perivascular dermal dendritic cell origin 514 Case vignettes 517 References 537 Index 541

Read more less

Book SynopsisJONES' CLINICAL PAEDIATRIC SURGERY Jones' Clinical Paediatric Surgery provides clear-sighted advice on the surgical options available for young patients. Building on the popular and successful style of previous editions, this fully revised seventh edition employs a systematic approach to the childhood diseases that need surgical treatment. It includes more case vignettes and colour photographs, expanded coverage on the use of imaging, and updated approaches to management including laparoscopic operations. Key subject areas are supported by case vignettes in a familiar format similar to what might appear in an OSCE viva. Jones' Clinical Paediatric Surgery is the ideal guide for paeditricians, surgeons and trainees, as well as primary care physicians, junior doctors and medical students.Table of ContentsContributors vii Foreword to the first edition by Mark M Ravitch viii Tribute to Mr Peter Jones ix Preface to the seventh edition x Acknowledgements xi Part I: Introduction 1 Antenatal Diagnosis: Surgical Aspects 3 2 The care and transport of the newborn 7 3 The Child in Hospital 13 Part II: Neonatal Emergencies 4 Respiratory distress in the newborn 19 5 Congenital Diaphragmatic Hernia 26 6 Oesophageal Atresia and Tracheo-oesophageal Fistula 30 7 Bowel Obstruction 35 8 Abdominal Wall Defects 45 9 Spina Bifida 50 10 Disorders of sex development 57 11 Anorectal Malformations 62 Part III: Head and Neck 12 The Scalp Skull and Brain 69 13 The Eye 80 14 The Ear Nose and Throat 91 15 Cleft Lip Palate and Craniofacial Anomalies 97 16 Abnormalities of the Neck and Face 106 Part IV: Abdomen 17 The Umbilicus 117 18 Vomiting in the First Months of Life 121 19 Intussusception 126 20 Abdominal Pain: Appendicitis? 130 21 Recurrent Abdominal Pain 136 22 Constipation 139 23 Bleeding from the Alimentary Canal 142 24 Inflammatory Bowel Disease 147 25 The Child with an Abdominal Mass 153 26 Spleen, Pancreas and Biliary Tract 158 27 Anus, Perineum and Female Genitalia 164 28 Undescended Testes and Varicocele 171 29 Inguinal Region and Acute Scrotum 175 30 The Penis 183 Part V: Urinary Tract 31 Urinary Tract Infection 191 32 Vesico-ureteric Reflux (VUR) 197 33 Urinary Tract Dilatation 202 34 The Child with Wetting 209 35 The Child with Haematuria 215 Part VI: Trauma 36 Trauma in Childhood 221 37 Head Injuries 228 38 Abdominal and Thoracic Trauma 235 39 Foreign Bodies 241 40 The Ingestion of Corrosives 247 41 Burns 249 Part VII: Orthopaedics 42 Neonatal Orthopaedics 257 43 Orthopaedics in the Infant and Toddler 262 44 Orthopaedics in the Child 267 45 Orthopaedics in the Teenager 275 46 The Hand 280 Part VIII: Chest 47 The Breast 287 48 Chest Wall Deformities 290 49 Lungs, Pleura and Mediastinum 294 Part IX: Skin and Soft Tissues 50 Vascular and Pigmented Naevi 303 51 Soft Tissue Lumps 308 52 Answers to Case Questions 311 Index 317

Read more less

Book SynopsisPerioperative Medicine for the Junior Clinician is the first easy-to-read resource, featuring a digital component, on how to manage a diverse range of patients in the perioperative period, providing up-to-date practical knowledge and advice from a broad range of medical specialists caring for surgical patients.Trade Review'Perioperative Medicine for the Junior Clinician is a succinct, high-yield entry point into perioperative health. Written primarily by Australian clinicians from a wide number of specialties and institutions, the book provides an overview of key topics in perioperative medicine. whether used as a primary text for medical students on their clinical anesthesia or surgery rotations, or for practicing clinicians as an on-the-fly reference, the book meets its proposed purpose of informing on the assessment of perioperative patient care issues and treatment....In summary, Perioperative Medicine for the Junior Clinician is a concise primer of perioperative medicine, and it provides a practical resource for many clinicians and allied health personnel who care for patients in the surgical pathway.' Anesthesia & Analgesia'...the authors have achieved their aim of delivering an easy-to-read book, covering a diverse range of relevant and interesting topics. Important themes are well covered, and practical advice given with reference to evidence based guidelines and protocols. The chapters are interesting and contain plentiful figures and images to maintain engagement. The text is well-referenced throughout ... there is sufficient breadth to stimulate interest for more senior clinicians. This book will undoubtedly be a useful starting point for any clinician involved in perioperative care.' European Journal of Anaesthesiology (EJA)Table of ContentsContributors (Online Only) Foreword xxivMichael (Monty) Mythen Preface xxvPaul Myles Acknowledgements xxvii Abbreviations (Online Only) About the companion website xxxvii Part I Introduction 1 1 The role of the perioperative medicine physician 3Mike Grocott 2 The role of the preadmission clinic 6James Tomlinson 3 Consent 11Justin Burke 4 The early postoperative round 15Debra Devonshire and Paul Myles 5 Quality improvement and patient safety 18Stuart Marshall 6 Intraoperative and postoperative monitoring 22Philip Peyton 7 Drugs used for anaesthesia and sedation 28Alex Konstantatos 8 The recovery room 33Arvinder Grover 9 Perioperative genomics 38Christopher Bain and Andrew Shaw Part II Preoperative risk assessment 43 10 Perioperative medication management 45Paul Myles 11 The cardiac patient for non]cardiac surgery 51Howard Machlin 12 Cardiovascular risk assessment in cardiac surgery 57Christopher Duffy 13 Preoperative cardiac testing 61Joshua Martin and Peter Bergin 14 Airway assessment and planning 68Pierre Bradley and Joel Symons 15 Pulmonary risk assessment 74David Daly 16 Preoperative cardiopulmonary exercise testing 79Chris Snowden and Serina Salins17 Anaemia 85Amanda Davis and Angus Wong 18 Central nervous system risk assessment 90Richard Stark 19 Risk assessment for perioperative renal dysfunction 94David McIlroy 20 Medical futility and end]of]life care 98Mark Shulman and Matthew Richardson 21 The surgical safety checklist 102Pedro Guio]Aguilar and Russell Gruen Part III Perioperative investigations 107 22 Preoperative investigations (non]cardiac surgery) 109Arvinder Grover 23 Postoperative investigations 114Arvinder Grover Part IV Specific medication management and prophylaxis 119 24 Thromboprophylaxis 121Amanda Davis 25 Anticoagulants and antiplatelet agents 128David Daly 26 Diabetes medication 136Shane Hamblin 27 Steroid medication 144Shane Hamblin 28 Opioids and opioid addiction 148Meena Mittal, Nicholas Christelis and David Lindholm 29 Antibiotic prophylaxis 154Allen Cheng 30 Antibiotic prophylaxis for endocarditis 158Denis Spelman Part V Perioperative management of organ dysfunction and specific population groups 163 31 Coronary artery disease and coronary stents 165Sesto Cairo 32 Hypertension 170Steven Fowler and Terry Loughnan 33 Arrhythmias 175Andrew Robinson 34 Pacemakers and implanted defibrillators 182Andrew Robinson 35 Heart failure 188Vanessa van Empel and Dion Stub 36 Aortic stenosis 193Rishi Mehra 37 Pulmonary hypertension 198Mark Buckland 38 Endocarditis, myocarditis and cardiomyopathy 203Enjarn Lin 39 Acute lung injury 212Paul Nixon and David Tuxen 40 Obstructive sleep apnoea 217Matthew Naughton 41 Asthma 223Alan Young 42 Chronic obstructive pulmonary disease 229Jeremy Wrobel and Trevor Williams 43 Non]small cell lung cancer 235Robert Stirling 44 Gastrointestinal disease 242Lauren Beswick and William Kemp 45 Hepatic disease 245Lauren Beswick and William Kemp 46 Oliguria 249Paul Myles 47 Acute kidney injury 254Lloyd Roberts and Owen Roodenburg 48 Renal transplantation 259Solomon Menahem 49 Diabetes mellitus 264David Story 50 Thyroid disorders 268Shane Hamblin 51 Parathyroid disorders 272Shane Hamblin 52 Adrenal disorders 277Jonathan Serpell 53 Carcinoid syndrome 281Alexandra Evans 54 Intracranial surgery 286Hilary Madder 55 Carotid surgery 292Matthew Claydon 56 Epilepsy 301Richard Stark 57 Neuromuscular disease 304Erik Andersen and Andrew Kornberg 58 Trauma: pretheatre management 309John Moloney 59 Traumatic brain injury 314Winifred Burnett 60 Maxillofacial injuries 322Joel Symons and Charles Baillieu 61 Spinal injuries (excluding cervical spine) 329Susan Liew 62 Cervical spine injuries 337Peter Hwang and Jin Tee 63 Chest injuries 343Silvana Marasco 64 Abdominal injuries 349Katherine Martin 65 Burns 354Jamie Smart 66 Bleeding disorders 360Paul Coughlan 67 Human immunodeficiency virus infection 366Anna Pierce 68 Exposure to blood]borne viruses 370Anna Pierce 69 The patient with psychiatric illness 374Steven Ellen and James Olver 70 Obstetric patients having non]obstetric surgery 377Maggie Wong 71 The elderly patient 382Yana Sunderland 72 Allergies and anaphylaxis 386Helen Kolawole 73 Obesity 390Jennifer Carden 74 Goal]directed therapy 395Andrew Toner and Mark Hamilton 75 Fluids and electrolytes 400David Story 76 Electrolyte abnormalities 404Lloyd Roberts and Carlos Scheinkestel 77 Blood transfusion 410Amanda Davis 78 Organ donation 416Steve Philpot and Joshua Ihle Part VI Early postoperative care 421 79 Postoperative nausea and vomiting 423Joel Symons 80 Postoperative fluid therapy 430Dashiell Gantner 81 Ventilation strategies 435John Botha 82 Sepsis and the inflammatory response to surgery 440Tomás Corcoran and Kajari Roy 83 Nutritional support 445Craig Walker 84 Postoperative surgical complications 449Katherine Martin 85 Postoperative chest pain 453Shane Nanayakkara and Peter Bergin 86 Postoperative shortness of breath 459KJ Farley and Deirdre Murphy 87 Postoperative hypotension 467Steven Fowler 88 Myocardial injury after non]cardiac surgery 472Fernando Botto and PJ Devereaux 89 Aspiration 476Alan Kakos 90 Postoperative delirium and postoperative cognitive dysfunction 480Brendan Silbert and Lisbeth Evered 91 Postoperative hyperthermia 485Glenn Downey 92 Perioperative hypothermia 493John Monagle and Shashikanth Manikappa Part VII Pain management 499 93 Acute pain 501Alex Konstantatos 94 Neuropathic pain 507Tim Hucker 95 The chronic pain patient 511Carolyn Arnold

Read more less

Book SynopsisThe first three editions of this acclaimed book presented a much-needed conceptual synthesis of this rapidly moving field. Now, Cancer Cytogenetics, Fourth Edition, offers a comprehensive, expanded, and up-to-date review of recent dramatic advances in this area, incorporating a vast amount of new data from the latest basic and clinical investigations. New contributors reflecting broader international authorship and even greater expertise Greater emphasis throughout on the clinical importance and application of information about cytogenetic and molecular aberrations Includes a complete coverage of chromosome aberrations in cancer based on an assessment of the 60,000 neoplasms cytogenetically investigated to date Now produced in full color for enhanced clarity Covers how molecular genetic data (PCR-based and sequencing information) are collated with the cytogenetic data where pertinent Discusses how molecular cytogeTable of ContentsContributors vii Preface to the Fourth Edition ix 1 How it all began: cancer cytogenetics before sequencing 1Felix Mitelman and Sverre Heim 2 Cytogenetic methods 11David Gisselsson 3 Cytogenetic nomenclature 19Sverre Heim and Felix Mitelman 4 Nonrandom chromosome abnormalities in cancer: an overview 26Sverre Heim and Felix Mitelman 5 From chromosomes to genes: searching for pathogenetic fusions in cancer 42Ioannis Panagopoulos 6 Acute myeloid leukemia 62Bertil Johansson and Christine J. Harrison 7 Myelodysplastic syndromes 126Harold J. Olney and Michelle M. Le Beau 8 Chronic myeloid leukemia 153Thoas Fioretos 9 Chronic myeloproliferative neoplasms 175Peter Vandenberghe and Lucienne Michaux 10 Acute lymphoblastic leukemia 198Christine J. Harrison and Bertil Johansson 11 Mature B] and T]cell neoplasms and Hodgkin lymphoma 252Reiner Siebert and Sietse M. Aukema 12 Tumors of the upper aerodigestive tract 332Susanne M. Gollin 13 Tumors of the lung 361Penny Nymark, Eeva Kettunen and Sakari Knuutila 14 Tumors of the digestive tract 373Georgia Bardi and Sverre Heim 15 Tumors of the urinary tract 401Paola Dal Cin 16 Tumors of the breast 426Manuel R. Teixeira, Nikos Pandis and Sverre Heim 17 Tumors of the female genital organs 447Francesca Micci and Sverre Heim 18 Tumors of the male genital organs 481Manuel R. Teixeira and Sverre Heim 19 Tumors of endocrine glands 497Jörn Bullerdiek and David Gisselsson 20 Tumors of the nervous system 515Petter Brandal and Sverre Heim 21 Tumors of the eye 538Karen Sisley 22 Tumors of the skin 555Fredrik Mertens, Felix Mitelman and Sverre Heim 23 Tumors of bone 566Fredrik Mertens and Nils Mandahl 24 Soft tissue tumors 583Nils Mandahl and Fredrik Mertens Index 615

Read more less

Book SynopsisTable of ContentsForeword 1 xxix Foreword 2 xxxi Foreword 3 xxxiii Preface to the Third Edition xxxv Preface to the Second Edition xxxix Acknowledgments xliii H.K. Huang Short Biography xlv List of Acronyms xlvii Part 1 The Beginning: Retrospective 1 1 Medical Imaging, PACS and Imaging Informatics: Retrospective 3 PART I TECHNOLOGY DEVELOPMENT AND PIONEERS 4 1.1 Medical Imaging 4 1.2 PACS and its Development 8 1.3 Key Technologies: Computer and Software, Storage, and Communication Networks 15 1.4 Key Technologies: Medical Imaging Related 17 PART II COLLABORATIONS AND SUPPORTS 22 1.5 Collaboration with Government Agencies, Industry and Medical Imaging Associations 22 1.6 Medical Imaging Informatics 29 1.7 Summary 32 1.8 Acknowledgments 34 References 35 Part 2 Medical Imaging, Industrial Guidelines, Standards, and Compliance 37 2 Digital Medical Imaging 39 2.1 Digital Medical Imaging Fundamentals 39 2.2 Two-Dimensional Medical Imaging 46 2.3 Three-Dimensional Medical Imaging 55 2.4 Four-Dimensional, Multimodality, and Fusion Imaging 78 2.5 Image Compression 85 Further Reading 93 3 PACS Fundamentals 97 3.1 PACS Components and Network 97 3.2 PACS Infrastructure Design Concept 101 3.3 Generic PACS-Based Multimedia Architecture and Workflow 103 3.4 PACS-Based Architectures 105 3.5 Communication and Networks 110 Further Reading 121 4 Industrial Standards: Health Level 7 (HL7), Digital Imaging and Communications in Medicine (DICOM) and Integrating the Healthcare Enterprise (IHE) 123 4.1 Industrial Standards 124 4.2 The Health Level 7 (HL7) Standard 124 4.3 From ACR-NEMA to DICOM 127 4.4 DICOM 3.0 Standard 129 4.5 Examples of Using DICOM 136 4.6 DICOM Organizational Structure and New Features 138 4.7 IHE (Integrating the Healthcare Enterprise) 142 4.8 Some Operating Systems and Programming Languages useful to HL7, DICOM and IHE 151 4.9 Summary of Industrial Standards: HL7, DICOM and IHE 153 References 153 Further Reading 154 5 DICOM-Compliant Image Acquisition Gateway and Integration of HIS, RIS, PACS and ePR 155 5.1 DICOM Acquisition Gateway 156 5.2 DICOM-Compliant Image Acquisition Gateway 157 5.3 Automatic Image Data Recovery Scheme for DICOM Conformance Device 162 5.4 Interface PACS Modalities with the Gateway Computer 164 5.5 DICOM Compliance PACS Broker 166 5.6 Image Preprocessing and Display 167 5.7 Clinical Operation and Reliability of the Gateway 168 5.8 Hospital Information System (HIS), Radiology Information System (RIS), and PACS 169 References 178 6 Web-Based Data Management and Image Distribution 179 6.1 Distributed Image File Server: PACS-Based Data Management 179 6.2 Distributed Image File Server 179 6.3 Web Server 181 6.4 Component-based Web Server for Image Distribution and Display 183 6.5 Performance Evaluation 188 6.6 Summary of PACS Data Management and Web]based Image Distribution 189 Further Reading 189 7 Medical Image Sharing for Collaborative Healthcare Based on IHE XDS-I Profile 191 7.1 Introduction 192 7.2 Brief Description of IHE XDS/XDS-I Profiles 193 7.3 Pilot Studies of Medical Image Sharing and Exchanging for a Variety of Healthcare Services 194 7.4 Results 206 7.5 Discussion 209 Acknowledgements 212 References 212 Part 3 Informatics, Data Grid, Workstation, Radiotherapy, Simulators, Molecular Imaging, Archive Server, and Cloud Computing 215 8 Data Grid for PACS and Medical Imaging Informatics 217 8.1 Distributed Computing 217 8.2 Grid Computing 219 8.3 Data Grid 222 8.4 Fault-Tolerant Data Grid for PACS Archive and Backup, Query/Retrieval, and Disaster Recovery 226 References 230 Further Reading 230 9 Data Grid for Clinical Applications 233 9.1 Clinical Trials and the Data Grid 233 9.2 Dedicated Breast MRI Enterprise Data Grid 239 9.3 Administrating the Data Grid 247 9.4 Summary 250 References 251 Further Reading 251 10 Display Workstations 253 10.1 PACS-Based Display Workstation 254 10.2 Various Types of Image Workstation 260 10.3 Image Display and Measurement Functions 263 10.4 Workstation Graphic User Interface (GUI) and Basic Display Functions 267 10.5 DICOM PC-Based Display Workstation Software 269 10.6 Post-Processing Workflow, PACS-Based Multidimensional Display, and Specialized Post-Processing Workstation 276 10.7 DICOM-Based Workstations in Progress 277 References 289 11 Multimedia Electronic Patient Record (EPR) System in Radiotherapy (RT) 291 11.1 Multimodality 2-D and 3-D Imaging in Radiotherapy 292 11.2 Multimedia ePR System in Radiation Treatment 298 11.3 Radiotherapy Planning and Treatment 301 11.4 Radiotherapy Workflow 302 11.5 The ePR Data Model and DICOM-RT Objects 303 11.6 Infrastructure, Workflow and Components of the Multimedia ePR in RT 306 11.7 Database Schema 309 11.8 Graphical User Interface Design 311 11.9 Validation of the Concept of Multimedia ePR System in RT 312 11.10 Advantages of the Multimedia ePR system in RT for Daily Clinical Practice 319 11.11 Use of the Multimedia ePR System in RT For Image-Assisted Knowledge Discovery and Decision Making 320 11.12 Summary 321 Acknowledgement 321 References 321 12 PACS-Based Imaging Informatics Simulators 325 12.1 Why Imaging Informatics Simulators? 326 12.2 PACS–ePR Simulator 328 12.3 Data Grid Simulator 329 12.4 CAD–PACS Simulator 331 12.5 Radiotherapy (RT) ePR Simulator 335 12.6 Image]assisted Surgery (IAS) ePR Simulator 338 12.7 Summary 344 Acknowledgements 344 References 344 13 Molecular Imaging Data Grid (MIDG) 347 13.1 Introduction 348 13.2 Molecular Imaging 348 13.3 Methodology 351 13.4 Results 358 13.5 Discussion 360 13.6 Summary 361 Acknowledgements 361 References 362 14 A DICOM-Based Second-Generation Molecular Imaging Data Grid (MIDG) with the IHE XDS-i Integration Profile 365 14.1 Introduction 366 14.2 Methodology 369 14.3 System Implementation 371 14.4 Data Collection and Normalization 375 14.5 System Performance 378 14.6 Data Transmission, MIDG Implementation, Workflow and System Potential 380 14.7 Summary 383 Acknowledgements 386 References 386 15 PACS-Based Archive Server and Cloud Computing 389 15.1 PACS-Based Multimedia Biomedical Imaging Informatics 390 15.2 PACS-Based Server and Archive 390 15.3 PACS-Based Archive Server System Operations 396 15.4 DICOM-Compliant PACS-Based Archive Server 397 15.5 DICOM PACS-Based Archive Server Hardware and Software 399 15.6 Backup Archive Server and Data Grid 400 15.7 Cloud Computing and Archive Server 403 Acknowledgements 414 References 414 Part 4 Multimedia Imaging Informatics, Computer-Aided Diagnosis (CAD), Image-Guide Decision Support, Proton Therapy, Minimally Invasive Multimedia Image-Assisted Surgery, Big Data 417 Prologue – Chapters 16, 17 and 18 417 16 DICOM-Based Medical Imaging Informatics and CAD 419 16.1 Computer]Aided Diagnosis (CAD) 420 16.2 Integration of CAD with PACS-Based Multimedia Informatics 425 16.3 The CAD–PACS Integration Toolkit 429 16.4 Data Flow of the three CAD–PACS Editions Integration Toolkit 432 References 433 Further Reading 434 17 DICOM-Based CAD: Acute Intracranial Hemorrhage and Multiple Sclerosis 435 17.1 Computer]Aided Detection (CAD) of Small Acute Intracranial Hemorrhage on CT of the brain 435 17.2 Development of the CAD Algorithm for AIH on CT 436 17.3 CAD-PACS Integration 452 17.4 Multiple Sclerosis (MS) on MRI 456 References 461 Further Reading 461 18 PACS-Based CAD: Digital Hand Atlas and Bone Age Assessment of children 463 18.1 Average Bone Age of a Child 464 18.2 Bone Age Assessment of Children 466 18.3 Method of Analysis 473 18.4 Integration of CAD with PACS-Based Multimedia Informatics for Bone Age Assessment of Children: The CAD System 479 18.5 Validation of the CAD and the Comparison of CAD Result with Radiologists’ Assessment 483 18.6 Clinical Evaluation of the CAD System for Bone Age Assessment (BAA) 489 18.7 Integrating CAD for Bone Age Assessment with Other Informatics Systems 493 18.8 Research and Development Trends in CAD–PACS Integration 497 Acknowledgements 499 References 499 Further Reading 500 19 Intelligent ePR System for Evidence-Based Research in Radiotherapy 503 19.1 Introduction 503 19.2 Proton Therapy Clinical Workflow and Data 506 19.3 Proton Therapy ePR System 508 19.4 System Implementation 511 19.5 Results 512 19.6 Conclusion and Discussion 520 Acknowledgements 522 References 522 20 Multimedia Electronic Patient Record System for Minimally Invasive Image]Assisted Spinal Surgery 525 20.1 Integration of Medical Diagnosis with Image]Assisted Surgery Treatment 526 20.2 Minimally Invasive Spinal Surgery Workflow 535 20.3 Multimedia ePR System for Image]Assisted MISS Workflow and Data Model 536 20.4 ePR MISS System Architecture 538 20.5 Pre-Op Authoring Module 543 20.6 Intra-Op Module 547 20.7 Post-Op Module 553 20.8 System Deployment, User Training and Support 554 20.9 Summary 557 References 557 21 From Minimally Invasive Spinal Surgery to Integrated Image-Assisted Surgery in Translational Medicine 559 21.1 Introduction 560 21.2 Integrated Image-Assisted Minimally Invasive Spinal Surgery 561 21.3 IIA-MISS EMR System Evaluation 565 21.4 To Fulfill some Translational Medicine Aims 569 21.5 Summary 571 21.6 Contribution from Colleagues 572 Acknowledgement 572 References 572 22 Big Data in PACS-Based Multimedia Medical Imaging Informatics 575 22.1 Big Data in PACS-Based Multimedia Medical Imaging Informatics 575 22.2 Characters and Challenges of Medical Image Big Data 577 22.3 Possible and Potential Solutions of Big Data in DICOM PACS-Based Medical Imaging and Informatics 581 22.4 Research Projects Related to Medical Imaging Big Data 586 22.5 Summary of Big Data 587 Acknowledgements 588 References 588 Index 591

Read more less

Book SynopsisTrauma and Orthopaedics at a Glance is an easy-to-read, highly visual guide to orthopaedics. It comprehensively covers relevant basic science and clinically-oriented anatomy of the musculoskeletal system, and the diagnosis and management of trauma, sports injuries, paediatric orthopaedics, degenerative disease, and musculoskeletal tumours.Table of ContentsPreface vii Acknowledgements viii How to Use Your Revision Guide ix About the Companion Website x Part 1 Basic sciences 1 1 Musculoskeletal tissues 2 2 Bone metabolism 4 3 Osteoarthritis 6 4 Rheumatoid arthritis 8 5 Imaging in orthopaedics: X‐rays 10 6 Imaging in orthopaedics: other modalities 12 7 Infection 14 8 Clinical anatomy of the upper limb 16 9 Clinical anatomy of the lower limb 19 10 Clinical anatomy of the spine 22 11 Examination of the upper limb 24 12 Examination of the lower limb 26 13 Examination of the spine 28 14 The brachial plexus 30 Part 2 Adult orthopaedics 33 Upper limb 34 15 Shoulder 1 34 16 Shoulder 2 36 17 Elbow 38 18 Wrist and hand 1 40 19 Wrist and hand 2 42 20 Wrist and hand 3 44 Lower limb 46 21 Hip 46 22 Hip replacement 48 23 Knee 1 50 24 Knee 2 52 25 Foot and ankle 54 26 Spine 56 27 Tumours 58 28 Rehabilitation 60 Part 3 Paediatric orthopaedics 63 29 Developmental dysplasia of hip (DDH) 64 30 Other paediatric hip conditions 66 31 Paediatric spinal disorders 68 32 Paediatric foot conditions 70 33 Neuromuscular conditions 72 34 Lower limb alignment 74 Part 4 Trauma 77 35 General principles 1 78 36 General principles 2 80 37 Advanced trauma life support (ATLS) 82 38 Upper limb trauma 1 84 39 Upper limb trauma 2 86 40 Upper limb trauma 3 88 41 Lower limb trauma 1 90 42 Lower limb trauma 2 92 43 Lower limb trauma 3 94 44 Proximal femoral fracture 1 96 45 Proximal femoral fracture 2 98 46 Cervical spine trauma 100 47 Thoracolumbar spine trauma 102 48 Trauma in children 1 104 49 Trauma in children 2 106 50 Compartment syndrome 108 51 Non‐union and malunion 110 Part 5 Working as a junior doctor in orthopaedics 113 52 Being an orthopaedic F2 114 53 Assessment of patients 116 54 The operating theatre 118 Part 6 Practical procedures 121 55 Practical procedures 1 122 56 Practical procedures 2 124 Index 126

Read more less

Book SynopsisIn vivo magnetic resonance imaging (MRI) has evolved into a versatile and critical, if not gold standard', imaging tool with applications ranging from the physical sciences to the clinical -ology'. In addition, there is a vast amount of accumulated but unpublished inside knowledge on what is needed to perform a safe, in vivo MRI. The goal of this comprehensive text, written by an outstanding group of world experts, is to present information about the effect of the MRI environment on the human body, and tools and methods to quantify such effects. By presenting such information all in one place, the expectation is that this book will help everyone interested in the Safety and Biological Effects in MRI find relevant information relatively quickly and know where we stand as a community. The information is expected to improve patient safety in the MR scanners of today, and facilitate developing faster, more powerful, yet safer MR scanners of tomorrow. This book is arranged in three sections. The first, named Static and Gradient Fields' (Chapters 1-9), presents the effects of static magnetic field and the gradients of magnetic field, in time and space, on the human body. The second section, named Radiofrequency Fields' (Chapters 10-30), presents ways to quantify radiofrequency (RF) field induced heating in patients undergoing MRI. The effect of the three fields of MRI environment (i.e. Static Magnetic Field, Time-varying Gradient Magnetic Field, and RF Field) on medical devices, that may be carried into the environment with patients, is also included. Finally, the third section, named Engineering' (chapters 31-35), presents the basic background engineering information regarding the equipment (i.e. superconducting magnets, gradient coils, and RF coils) that produce the Static Magnetic Field, Time-varying Gradient Magnetic Field, and RF Field. The book is intended for undergraduate and post-graduate students, engineers, physicists, biologists, clinicians, MR technologists, other healthcare professionals, and everyone else who might be interested in looking into the role of MRI environment on patient safety, as well as those just wishing to update their knowledge of the state of MRI safety. Those, who are learning about MRI or training in magnetic resonance in medicine, will find the book a useful compendium of the current state of the art of the field. Table of ContentsContributors Series Preface Preface Acknowledgments Part A: Static and Gradient Fields 1 Static and Low Frequency Electromagnetic Fields and Their Effects in MRIs 3Zhenyu Zhang and Stuart Feltham 2 Magnetic-field-induced Vertigo in the MR Environment 23Paul Glover 3 Effects of Magnetic Fields and Field Gradients on Living Cells 33Jarek Wosik, Martha Villagran, Ahmed Uosef, Rafik M. Ghobrial, John H. Miller Jr., and Malgorzata Kloc 4 Effect of Strong Time-varying Magnetic Field Gradients on Humans 53John Nyenhuis and David Gross 5 Peripheral Nerve Stimulation Modeling for MRI 67Mathias Davids, Bastien Guérin, Lothar R. Schad, and Lawrence L. Wald 6 Magnetically Induced Force and Torque on Medical Devices 87Terry O. Woods 7 A Review of MRI Acoustic Noise and its Potential Impact on Patient and Worker Health 95Michael C. Steckner 8 Modeling Blood Flow 119Michael Keith Sharp 9 Effect of Magnetic Field on Blood Flow 133G.C. Shit and Sreeparna Majee Part B: Radiofrequency Fields 10 Safety Standards for MRI 161Michael C. Steckner 11 On the Choice of RF Safety Metric in MRI: Temperature, SAR, or Thermal Dose 173Devashish Shrivastava 12 RF Coil and MR Safety 181J. Thomas Vaughan 13 Local SAR Assessment for Multitransmit Systems: A Study on the Peak Local SAR Value as a Function of Magnetic Field Strength 195Alexander J.E. Raaijmakers and Bart R. Steensma 14 Radio Frequency Safety Assessment for Open Source Pulse Sequence Programming 207Sairam Geethanath, Julie Kabil, and J. Thomas Vaughan 15 RF Heating Due to a 3T Birdcage Whole-body Transmit Coil in Anesthetized Sheep 219Samat Turdumamatov, Ça˘gda¸s Oto, Oktay Algın, Hamza Ergüder, and Tahir Malas 16 In Vivo Radiofrequency Heating due to 1.5, 3, and 7 T Whole-body Volume Coils 227Shuo Song, Ji Chen, Rongxing Zhang, Qiang He, J. Thomas Vaughan, and Devashish Shrivastava 17 Temperature Management and Radiofrequency Heating During Pediatric MRI Scans 239Stanley Thomas Fricke, Marjean H. Cefaratti, and Andrew Matisoff 18 Failure to Monitor and Maintain Thermal Comfort During an MRI Scan: A Perspective from a Thermal Physiologist Turned Patient 245Christopher J. Gordon 19 MR Thermometry to Assess Heating Induced by RF Coils Used in MRI 251Henrik Odéen, John Rock Hadley, Dylan Palomino, Katelynn Stroth, and Dennis L. Parker 20 Heating of RF coil 273Joseph Murphy-Boesch 21 RF-Induced Heating in Bare and Covered Stainless Steel Rods: Effect of Length, Covering, and Diameter 289Sunder Rajan, Peter Serano, Joshua Guag, Tayeb Zaidi, Kyoko Fujimoto, Maria Ida Iacono, and Leonardo M. Angelone 22 On the Development of a Novel Leg Phantom for RF Safety Assessment for Circular Ring External Fixation Devices in 1.5 T 295Xing Huang and Ji Chen 23 RF Safety of Active Implantable Medical Devices 311Berk Silemek, Volkan Açıkel, and Ergin Atalar 24 An Analysis of Factors Influencing MRI RF Safety for Patients with AIMDs 333Jingshen Liu, Jianfeng Zheng, Qingyan Wang, and Ji Chen 25 On Using Fluoroptic Thermometry to Measure Time-varying Temperatures in MRI 345Devashish Shrivastava, Mykhaylo Nosovskyy, and Charles A. Lemaire 26 On Using Magnetic Resonance Thermometry to Measure ‘Strong’ Spatio-temporal Tissue Temperature Variations and Compute Thermal Dose 351Devashish Shrivastava 27 The Use and Safety of Iron-Oxide Nanoparticles in MRI and MFH 361Hattie L. Ring, John C. Bischof, and Michael Garwood 28 Numerical Simulation for MRI RF Coils and Safety 379Julie M. Kabil and Anand Gopinath 29 Integral Equation Approach to Modeling RF Fields in Human Body in MRI Systems for Safety 399Anand Gopinath 30 Safety Practices and Protocols in the MR Research Center of the Columbia University in the City of New York 407Kathleen Durkin, Dania Elder, and David H. Gultekin Part C: Engineering 31 History, Physics, and Design of Superconducting Magnets for MRI 423Bruce Breneman 32 Fabrication of Superconducting Magnets for MRI 447Bruce Breneman 33 Magnet Field Shimming and External Ferromagnetic Influences on the Homogeneity and Site Shielding of Superconducting MRI Magnets 469Bruce Breneman 34 Gradient Coils 489Maxim Zaitsev, Philipp Amrein, Feng Jia, and Sebastian Littin 35 RF Coil Construction for MRI 504J. Thomas Vaughan and Russell Lagore Index 521

Read more less

Book SynopsisThe analysis and interpretation of data is fundamental to the subject of genetics and forms a compulsory part of the undergraduate genetics curriculum.Table of ContentsPreface ix Acknowledgements xi How to Use this Book xiii Section 1: Introductory 1.1 Grandma’s Secret 3 1.2 Tiger! Tiger! 7 1.3 Anticipation 13 1.4 Budgie Hell 17 1.5 Friends Reunited 21 1.6 The Footballer, his Wife, their Kids and her Lover 25 1.7 Give Peas a Chance 29 1.8 Noah’s ARC 35 1.9 The Mysterious Disappearance of Midnight 39 1.10 RANCID 45 Section 2: Intermediate 2.1 Otto’s Finger 51 2.2 The Mystery of Muckle Morag 57 2.3 Drosophila hogwashii 63 2.4 The Curse of Lilyrot 69 2.5 Strawberry Fields Forever 75 2.6 The Mystery of Trypton Fell 81 2.7 Sir Henry’s Enormous Chest 89 2.8 Pandemonium 93 2.9 My Imperfect Cousin 101 2.10 The Curse of the WERE Rabbits 107 Section 3: Advanced 3.1 The Legend of Neptune’s Cutlass 117 3.2 The Devil’s Pumpkin 129 3.3 Gravity 141 3.4 Kate and William, a Love Story 151 3.5 The Titanians 163 3.6 Once Bitten, Twice Shy 175 3.7 Red‐Crested Dragons of Mythological Island 185 3.8 I Scream! 197 3.9 The Nuns of Gaborone 209 3.10 Poissons Sans Yeux 221 Answers 233 List of Figures 361

Read more less

Book SynopsisA groundbreaking, evidence-based text to the growing field of evolutionary medicine Evidence-Based Evolutionary Medicine offers a comprehensive review of the burgeoning field of evolutionary medicine and explores vital topics such as evolution, ecology, and aging as they relate to mainstream medicine. The text integrates Darwinian principles and evidence-based medicine in order to offer a clear picture of the underlying principles that reflect how and why organisms have evolved on a cellular level. The authorsnoted authorities in their respective fieldsaddress evolutionary medicine from a developmental cell-molecular perspective. They explore the first principles of physiology that explain the generation of existing tissues, organs, and organ systems. The text offers an understanding of the overall biology as a vertically integrated whole, from unicellular to multicellular organisms. In addition, it addresses clinical diagnostic and therapeutic approachesTable of ContentsPreface xiii 1 A Brief History of Evolutionary Thinking 1 Summary 1 Introduction 2 Darwin 3 Darwin’s Theory 6 The Modern Synthesis 7 The Darkest Chapter 9 Conclusions 14 References 14 2 Outlining the Major Transitions in the History of Life 17 Summary 17 Introduction 18 The Major Transitions 20 Conclusions 29 References 30 3 One Central Mystery: Why Did Eukaryotes Only Evolve Once? 31 Summary 31 Introduction 32 Conclusions 45 References 45 4 A Levels‐of‐Selection View of Evolutionary Physiology 49 Summary 49 Conclusions 59 References 59 5 The Cell as the Smallest Functional Unit of Biology/Physiology 63 Summary 63 In the Beginning 64 The Advent of Multicellularity 65 Evolution: Cellular Style 69 The Water–Land Transition and Vertebrate Evolution 70 The Cellular Approach to Evolution Is Predictive 74 We Are Not Just in This Environment, We Are of It 77 Bioethics Based on Evolutionary Ontology and Epistemology, Not Descriptive Phenotypes, and Genes 78 The Theory of Everything (TOE) 79 Coda 81 References 81 6 Development of Tissues and Organs 83 Summary 83 Introduction 83 Lung Alveolar Morphogenesis 85 Parathyroid Hormone‐Related Protein 86 Stretch‐Induced Cell–Cell Interactions 88 References 89 7 When Homeostasis Fails 91 Summary 91 Introduction 91 Peroxisome Proliferator Activated Receptor Gamma as a Connection to the Evolution of the LIF 93 PPARγ, Statins, and TOR as Mechanisms for Homeostasis 93 Homeostatic Control of What? 93 Pleiotropy: The Deus ex Machina (Ghost in the Machine) 95 Rubik’s Cube as a Metaphor for Pleiotropic Evolution 96 The Lung as the Prototypical Pleiotropic Mechanism 99 The Lung as an Interactive Barrier: Homolog of the Plasma Membrane, Skin, and Brain 102 NKX2.1, Thyroid, Pituitary, and Lung Pleiotropy 104 The Phylogeny of the Thyroid 105 An Evolutionary Vertical Integration of the Phylogeny and Ontogeny of the Thyroid 105 A Retrospective Understanding of Evolution 107 Denouement 109 Conclusions 111 References 112 8 Wnt Signaling During Development 113 Summary 113 Introduction 113 Role of Growth Factors in Alveolar Homeostasis 114 The Kidney Glomerulus as a Homolog of the Lung Alveolus 116 Pathologic Consequences of Failed Paracrine Signaling 117 Reference 117 9 Integrated Regulation of Homeostasis – Vascular, Nervous, Endocrine, Neuroendocrine, Autonomic 119 Summary 119 Introduction 119 Water–Land Transition as the Catalyst for Vertebrate Evolution 121 Parathyroid Hormone‐Related Protein Signaling Is Key to Understanding the Evolution of the Lung 121 The Physics of Lung Evolution 122 Functional Homology between Membrane Lipids and Oxygenation 124 Atmospheric Oxygen, Physiologic Stress, Gene Duplication, and Lung Evolution 125 Duplication of the β Adrenergic Receptor and the Glucocorticoid Receptor Genes 127 Evolution of Endothermy/Homeothermy as Evidence for the Effect of Stress on Vertebrate Physiologic Evolution 127 Hibernation as Reverse Evolution 129 Predictive Power of the Cellular–Molecular Approach to Evolution 131 Conclusions 133 References 136 10 Endogenous and Exogenous Mechanisms for Healing 137 Summary 137 Introduction 138 Endogenous Mechanisms for Healing 138 A Fine Homeostatic Balance between the Differentiated Interstitial Fibroblast and the Myofibroblast 138 Universality of Wnt/β‐catenin in Myofibroblast Proliferation and Scarring: DKK, Shh, Alphabet Soup 140 Prostanoids, Homeostasis, and Regeneration 140 PGJ2 141 ApoE4 143 Evolutionary versus Traditional Medicine 144 Exogenous Mechanisms for Healing Using Evolutionary Principles 145 Summary 145 Cholesterol and Homeostasis 145 Pathophysiology of Hypercholesterolemia 145 Statins as Anti‐Inflammatory Agents 146 PPARγ and Homeostasis 146 TOR and Homeostasis 148 References 148 11 Systems Biology as Recapitulation of Ontogeny and Phylogeny 151 Summary 151 Introduction 151 A Paradigm Shift in Evolution 152 Endothermy as “Proof of Principle” for the Evolution of Serial Exaptations 154 Endothermy Defies Physics, Fostering Migration 155 Conclusions 157 References 158 12 Terminal Addition as Physiologic Homeostasis and Regeneration, or Evolutionary Medicine 159 Summary 159 Introduction 160 Conflicting Viewpoints 161 Terminal Addition as a Perpetual Cellular Link with the Environment 163 Terminal Addition as Layered Cell–Cell Signaling 164 Epigenetic Impacts and Terminal Addition 167 Physiologic Stress, Vascular Shear Stress, Radical Oxygen Species, and Mutation within Constraints = The Mechanism of Terminal Addition 168 Homeobox Genes, Colinearity, and Terminal Addition 169 The Alveolar Lipofibroblast as Terminal Addition 170 The Participation of Glomerular Mesangial Cells 170 PTHrP Effects on the Anterior Pituitary, Adrenal Cortex, and Adrenal Medulla 171 Catecholamines, Lung, and Heart Biology 171 Oxytocin, Endothermy, and the Retina 171 Central Nervous System 172 Terminal Addition, “Reverse Evolution,” and Evolutionary Medicine 172 Discussion 173 Terminal Addition: The Fundament of Haeckel’s Biogenetic Law 173 Somewhere between Gene and Phenotype Lies the Process of Evolution 174 Conclusions 178 References 179 13 Phantom Limbs: Imagination and Epigenetics 181 Summary 181 Introduction 181 Background to Phantom Limb Sensation 182 Relevance of Phantom Limb Sensation to Terminal Addition 183 Phantom Limb Sensation as Non‐Localization 183 Limbs and Hearts 184 Relationship of Limbs to Bipedalism and the Evolution of Birds and Mammals 185 Of Limbs and Consciousness 186 Life as Fractals 186 Consciousness, the Epitome of the Continuum from Inanimate to Animate 188 References 188 14 Man’s Place in the Universe 191 Summary 191 Introduction 192 Anthropomorphisms Subvert the Biologic Imperative to Cooperate 193 Euphysiology 193 References 200 15 Evolution, Deception, and Public Health 203 Summary 203 Part I. Deception Is Deceiving: The Exception that Proves the Rule 203 Introduction 204 In the Beginning 204 Epigenetics and Niche Construction 205 The Deception Proves the Rule 205 Our Own Personal Heliocentrism 206 Deception and Social Pathology 207 Physiologic Stress 208 Ambiguities in Biology 211 Part II. Resolution of the Ambiguities by Assimilating the Deception 214 Introduction 214 The Cell as the First Niche Construction – Self‐Organization Overcomes the Ambiguity 214 The Evolution of Endothermy as Internal Niche Construction; or, Self‐Organization Overcomes Biologic Ambiguities 215 Stress‐Induced Evolution of Endothermy by Stepwise Changes in Physiology Predicts Bipedalism, Evolution of the Avian and Hominid Forelimbs, and Higher Consciousness 217 Cold Stress and DRD4–7: Did Risk‐Taking Drive Us Out of Africa? 218 How Androgens Act to Reduce Ambiguities of Life 220 How Art Seemingly Resolves the Deception of Life 221 How Music Resolves the Deception of Life 221 Literature (Deceptively) Resolves the Ambiguities of Life 222 Liturgy Resolves the Ambiguities of Life: Back to the Garden? 222 Part III. Deception and Public Health 222 Cognitive Dissonance: Scientific Principles, Disease, and Health 223 Part IV. Prediction: Bioethics Based on First Principles of Physiology 224 References 226 Index 227

Read more less

Book SynopsisThe first comprehensive, authoritative review of one of the most fundamental and important issues in infection control and patient safety, hand hygiene. Developed and presented by the world''s leading scholar-clinicians, Hand Hygiene is an essential resource for all medical professionals. Developed and presented by the world leaders in this fundamental topic Fully integrates World Health Organization (WHO) guidelines and policies Offers a global perspective in tackling hand hygiene issues in developed and developing countries Coverage of basic and highly complex clinical applications of hand hygiene practices Includes novel and unusual aspects and issues in hand hygiene such as religious and cultural aspects and patient participation Offers guidance at the individual, institutional, and organizational levels for national and worldwide hygiene promotion campaigns Trade Review"In their new textbook, Hand Hygiene: A Handbook for Medical Professionals, Didier Pittet, John Boyce, and Benedetta Allegranzi turn to leading experts on patient safety and infection control to produce an impressive book with 45 chapters focusing on every aspect of hand hygiene. But, as Pittet asks in the preface, “Does hand hygiene deserve a textbook?” It is refreshing for a textbook writer to ask this question about his own book, and the answer, as the foreword suggests, is a resounding “yes.”While hand hygiene is essential, compliance is complicated. Additionally, actual rates of compliance are difficult to measure as are the number of HAIs that can be prevented with high hand hygiene compliance rates. With these issues in mind, Pittet and colleagues present this new work with a noble objective, “to save many more millions of lives every year worldwide.”The edition includes many important, but often overlooked, areas in chapters covering topics such as handhygiene promotion strategies, human factors, barriers to compliance, and skin reaction to hand hygiene. Ofparticular importance, the book includes chapters on the safety climate as well as personal accountability. Of note, a chapter on religion and cultural practices sheds light on interesting issues that are often marginalised. The book is organised logically, beginning with a review of the data on HAI......We have a real problem with hand hygiene among medical professionals, and now is the time to embrace change. This handbook takes an important step in that direction. Pittet believes that a renewed commitment by providers will “drive excellence in hand hygiene practices, research, and attitudes for many years to come.” The editors and authors should be commended for this laudable goal and outstanding handbook" (The Lancet Vol 17 August 17)"This well-written book, coupled with its excellent editing, is easy to read. It succeeds in appealing to a diverse population of healthcare professionals. All healthcare facility leaders in patient safety and infection prevention would be well served by this guide and reference to improving hand hygiene" Doodys, Sept 2017Table of ContentsContributors xi Preface xv Foreword xvii 1. The Burden of Healthcare-Associated Infection 1Benedetta Allegranzi, Sepideh Bagheri Nejad, and Didier Pittet 2. Historical Perspectives 8Andrew J. Stewardson and Didier Pittet 3. Flora and Physiology of Normal Skin 12Gürkan Kaya and Didier Pittet 4. Dynamics of Hand Transmission 18Andrew J. Stewardson, Benedetta Allegranzi, and Didier Pittet 5. Mathematical Models of Handborne Transmission of Nosocomial Pathogens 28Ben S. Cooper and Nantasit Luangasanatip 6. Methodological Issues in Hand Hygiene Science 36Matthew Samore and Stephan Harbarth 7. Statistical Issues: How to Overcome the Complexity of Data Analysis in Hand Hygiene Research? 42Angèle Gayet-Ageron and Eli Perencevich 8. Hand Hygiene Agents 51Pascal Bonnabry and Andreas Voss 9. Methods to Evaluate the Antimicrobial Efficacy of HandHygiene Agents 58Manfred L. Rotter, Syed A. Sattar, and Miranda Suchomel 10. Hand Hygiene Technique 70Marie-Noëlle Chraïti and Andreas F. Widmer 11. Compliance with Hand Hygiene Best Practices 76Benedetta Allegranzi, Andrew J. Stewardson, and Didier Pittet 12. Barriers to Compliance 85John M. Boyce, Benedetta Allegranzi, and Didier Pittet 13. Physicians and Hand Hygiene 89Benedetta Allegranzi, Andrew J. Stewardson, and Didier Pittet 14. Surgical Hand Preparation 94Andreas F. Widmer and Joseph Solomkin 15. Skin Reaction to Hand Hygiene 101Elaine Larson 16. Alcohol-Based Handrub Safety 105John M. Boyce and M. Lindsay Grayson 17. Rinse, Gel, Foam, Soap … Selecting an Agent 109Andreas Voss 18. Behavior and Hand Hygiene 115Mary-Louise McLaws and Hugo Sax 19. Hand Hygiene Promotion Strategies 123Benedetta Allegranzi and Didier Pittet 20. My Five Moments for Hand Hygiene 134Hugo Sax, Benedetta Allegranzi, and Didier Pittet 21. System Change 144Benedetta Allegranzi, Andreas Voss, and Didier Pittet 22. Education of Healthcare Professionals 152Elaine Larson, Marie-Noëlle Chraïti, and Wing-Hong Seto 23. Glove Use and Hand Hygiene 156Marie-Noëlle Chraïti, Benedetta Allegranzi, and Elaine Larson 24. Monitoring Hand Hygiene Performance 162Hugo Sax and John M. Boyce 25. Performance Feedback 172Andrew J. Stewardson and Hugo Sax 26. Marketing Hand Hygiene 180Julie Storr and Hugo Sax 27. Human Factors Design 185Lauren Clack and Hugo Sax 28. Institutional Safety Climate 193Enrique Castro-Sánchez, Alison Holmes, and Didier Pittet 29. Personal Accountability for Hand Hygiene 201Robert M. Wachter and Peter Pronovost 30. Patient Participation and Empowerment 206Yves Longtin, Susan E. Sheridan, and Maryanne McGuckin 31. Religion and Hand Hygiene 216Jaffar A. Al-Tawfiq and Ziad A. Memish 32. Hand Hygiene Promotion from the US Perspective: PuttingWHO and CDC Guidelines into Practice 221Katherine Ellingson 33. WHO Multimodal Promotion Strategy 230Benedetta Allegranzi and Didier Pittet 34. Monitoring Your Institution (Hand Hygiene Self-Assessment Framework) 244Benedetta Allegranzi, Andrew J. Stewardson, and Didier Pittet 35. National Hand Hygiene Campaigns 249Claire Kilpatrick and Julie Storr 36. Hand Hygiene Campaigning: From One Hospital to the Entire Country 256Philip L. Russo and M. Lindsay Grayson 37. Improving Hand Hygiene through Joint Commission Accreditation and the Joint Commission Center for Transforming Healthcare 263Mark R. Chassin, Barbara I. Braun, and Anne Marie Benedicto 38. A Worldwide WHO Hand Hygiene in Healthcare Campaign 275Claire Kilpatrick, Julie Storr, and Benedetta Allegranzi 39. The Economic Impact of Improved Hand Hygiene 285Nicholas Graves 40. Hand Hygiene: Key Principles for the Manager 294Eleanor Murray, Alison Holmes, and Didier Pittet 41. Effect of Hand Hygiene on Infection Rates 299Benedetta Allegranzi, Stephan Harbarth, and Didier Pittet 42A.Hand Hygiene in Specific Patient Populations and Situations: Critically Ill Patients 317Caroline Landelle, Jean-Christophe Lucet, and Didier Pittet 42B. Hand Hygiene in Specific Patient Populations and Situations: Neonates and Pediatrics 324Walter Zingg and Hanan H. Balkhy 42C. Hand Hygiene in Long-Term Care Facilities and Home Care 329Maria Luisa Moro, Marie-Noëlle Chraïti, and Benedetta Allegranzi 42D.Hand Hygiene in Ambulatory Care 337Marie-Noëlle Chraïti, Sepideh Bagheri Nejad, and Benedetta Allegranzi 42E. Hand Hygiene in Hemodialysis 344Marie-Noëlle Chraïti, Sepideh Bagheri Nejad, and Benedetta Allegranzi 42F. Hand Hygiene in Specific Patient Populations and Situations: Anesthesiology 350François Stéphan 43. Hand Hygiene in Resource-Poor Settings 357Nizam Damani, Shaheen Mehtar, and Benedetta Allegranzi 44A. Role of Hand Hygiene in MRSA Control 367Stephan Harbarth 44B. Role of Hand Hygiene in Clostridium difficile Control 373John M. Boyce and Walter Zingg 44C. Role of Hand Hygiene in Respiratory Diseases Including Influenza 378Wing Hong Seto and Benjamin J. Cowling 44D. Handborne Spread of Noroviruses and its Interruption 385Syed A. Sattar and Yves Longtin 45. Conducting a Literature Review on Hand Hygiene 391Daniela Pires, Fernando Bellissimo-Rodrigues, and Didier Pittet Appendix 400 Index 409

Read more less

Book SynopsisManaging urologic cancer by preserving, as opposed to removing, affected tissue, is rapidly becoming the favoured choice for urologists and oncologists. Discover all available options and how to achieve the best possible patient management with this expert guide to the area. The editor, Mark Schoenberg, is an internationally-renown expert in this exciting new area and has recruited an outstanding team featuring some of the leading urologists/oncologists in North America and Europe to assist him.Table of ContentsList of Contributors xiii Preface xvii Cancer Genetics, Cancer Biology, and Tumor Growth and Metastasis: The Interaction of Cancer and Its Host Environment 1Mark C. Markowski and Kenneth J. Pienta Renal Cell Carcinoma 1 Bladder Cancer 3 Prostate Cancer 6 References 12 Pathological Basis of Tumor Characterization: Cytopathology, Surgical Pathology, and How Histo]Morphology Informs Treatment Decision Making 19Oleksandr N. Kryvenko and Fadi Brimo The Kidney 23 The Urothelium 27 The Testis 29 References 30 The Immunobiology of Tumor Ablation 33Rafi Kabarriti and Chandan Guha Manipulating the Immune System to Fight Cancer 33 Can We Take Advantage of Ablative Therapies to Activate the Immune System? 34 Immunomodulatory Properties of HIFU 35 Immunomodulatory Properties of Cryotherapy 36 Immunomodulatory Properties of Radiation Therapy 37 References 38 Computed Tomography of Urologic Malignancies: The Role of MDCT in Renal Cell Carcinoma and Transitional Cell Carcinoma 41Siva P. Raman and Elliot K. Fishman Introduction 41 MDCT Protocol Design 41 Three]Dimensional Reconstructions 44 Neoplasms of the Intrarenal Collecting Systems, Ureters, and Bladder 45 Solid Renal Parenchymal Lesions 49 Conclusion 55 References 55 MRI and Metabolic Imaging 59Louise Dickinson, Francesco Fraioli, Athar Haroon, and Clare Allen Magnetic Resonance Imaging 59 MRI Sequences 59 Clinical Applications of MRI for Prostate Cancer 61 Clinical Applications of MRI for Renal Cancer 63 Clinical Applications of MRI for Bladder Cancer 64 New Advances in MRI 65 Metabolic Imaging 66 Clinical Applications of PET–CT for Prostate Cancer 69 Active Surveillance for Low]Risk Prostate Cancer 113Laurence Klotz Introduction and Background 113 Rationale 113 Genetic Features of Low]Grade Prostate Cancer 114 Metastatic Potential 115 Limitations of PSA Kinetics 116 Role of MRI 116 Implications for Patient Management 117 Eligibility for Surveillance 118 Outcome of Surveillance 119 Modeling 119 AS in Practice 121 Conclusions 121 References 122 Tissue]Preserving Surgical Approaches in Urologic Oncology: The Therapeutic Mechanism for Tumor Ablation 127Ganesh Kartha and J. Stephen Jones Introduction 127 Cryoablation: Extreme Cold for Tumor Necrosis 128 Conclusion 130 References 130 Focal Therapy for Prostate Cancer: An Evidence]Based Approach to Tissue]Preserving Strategies 133Kara L. Watts, Yaalini Shanmugabavan, Victoria Chernyak, and Hashim Uddin Ahmed Introduction 133 Key Concepts in FT for PCa 134 Tissue]Preserving FTs 135 Cryotherapy 135 HIFU 137 Salvage Focal/Hemiablation HIFU 140 IRE 141 Radiation 142 Additional Therapies 143 Implications for Research 144 Conclusions 144 References 145 The Modern Basis for Nephron]Sparing Surgery in Patients with Renal Cancer: Biologic Heterogeneity, the Significance of Tumor Biopsy, and the Changing Roles of Partial Nephrectomy and Tumor Ablation 151Jeffrey J. Tomaszewski, Robert G. Uzzo, and David Y.T. Chen Introduction 151 Principal Treatment Options for SRMs and the Basis for Nephron Preservation 152 Comparative Effectiveness of Radical versus NSS 153 Rationale for Ablative Therapies 154 Treatment Trends for Stage I RCC 157 The Role of RMB 158 Challenges Posed by Intratumoral Heterogeneity 161 Conclusions 161 References 162 Bladder]Preserving Strategies in the Treatment of Urothelial Cancer: The Disease Spectrum and the Dawn of Molecular Surgical Guidance 169Stephan Kruck and Arnulf Stenzl Augmented Cystoscopy 170 Fiber]Optic Probe Technology 171 Conclusion 172 References 172 Image]Guided Thermal Ablation of Adrenal Malignancies 175Kyungmouk Steve Lee, Bradley B. Pua, and Stephen B. Solomon Introduction 175 Clinical Results 175 Preprocedural Evaluation 176 Technical Considerations 178 RFA 178 Microwave Ablation 179 Cryoablation 180 Complications 180 Follow]up 181 Conclusion 182 References 182 Managing Penile Cancer: Integrating Tissue Preservation, Energy]Based Therapeutics, and Surgical Reconstruction 185Arthur L. Burnett Introduction 185 Description 186 Diagnosis and Staging 186 Treatment 189 References 193 Testis Cancer: Testis]Sparing Cancer Surgery 199Nilay M. Gandhi and Pravin K. Rao Introduction 199 Imaging of Testicular Tumors 199 Bilateral Tumors 201 The Advent of Testis]Sparing Surgery 201 Concerns about TSS 201 Indications for TSS 204 Preoperative Considerations and Surgical Technique 204 Postoperative Care and Follow]Up 207 Considerations Regarding Surgical Technique 207 Outcomes of TSS 208 Summary 209 References 210 Nanotechnology: An Evolution in Tissue Preservation and Focal]Targeted Oncologic Therapy 213Kara L. Watts and Joshua M. Stern Introduction 213 Introduction to Nanotechnology 214 Types of Nanoparticles 214 Delivery and Use of Nanoparticles 217 Nanotechnology in Prostate Cancer 219 Imaging in Prostate Cancer 219 Therapeutics in Prostate Cancer 221 Nanotechnology in Renal Cancer 223 Nanotechnology in Other Urologic Cancers 224 Limitations of Nanoparticles 224 Future Directions and Conclusions 225 References 226 Trial Design Issues in the Study of Focal Therapy in Prostate and Kidney Cancer 233John B. Eifler and David F. Penson Issues around Endpoints in Studies of Focal Therapy 234 Issues around Defining the Study Population and the Control Arms of Comparative Studies in Focal Therapy 237 Issues around Selecting the Optimal Study Design in Focal Therapy 238 Conclusion 238 References 239 Index 000

Read more less

Book SynopsisAn authoritative resource that offers the statistical tools and software needed to design and plan valid clinical studies Now in its fourth and extended edition, Sample Sizes for Clinical, Laboratory and Epidemiology Studiesincludes the sample size software (SSS) and formulae and numerical tables needed to design valid clinical studies. The text covers clinical as well as laboratory and epidemiology studies and contains the information needed to ensure a study will form a valid contribution to medical research. The authors, noted experts in the field, explain step by step and explore the wide range of considerations necessary to assist investigational teams when deriving an appropriate sample size for their when planned study. The book contains sets of sample size tables with companion explanations and clear worked out examples based on real data. In addition, the text offers bibliography and references sections that are designed to be helpful with guidanTable of ContentsPreface vii 1 Basic Design Considerations 1 2 Further Design Considerations 29 3 Binary Outcomes 41 4 Ordered Categorical Outcomes 55 5 Continuous Outcomes 67 6 Rate Outcomes 83 7 Survival Time Outcomes 99 8 Paired Binary, Ordered Categorical and Continuous Outcomes 117 9 Confidence Intervals 137 10 Repeated Outcome Measures 157 11 Non‐Inferiority and Equivalence 169 12 Cluster Designs 195 13 Stepped Wedge Designs 215 14 More than Two Groups Designs 229 15 Genomic Targets and Dose‐Finding 239 16 Feasibility and Pilot Studies 251 17 Therapeutic Exploratory Trials: Single Arm with Binary Outcomes 269 18 Therapeutic Exploratory Trials: Survival, Dual Endpoints, Randomised and Genomic Targets 283 19 The Correlation Coefficient 305 20 Observer Agreement Studies 317 21 Reference Intervals and Receiver Operating Curves 339 22 Sample Size Software SSS 361 Cumulative References 363 Index 381

Read more less

Book SynopsisA concise, easy-to-read source of essential tips and skills for writing research papers and career management In order to be truly successful in the biomedical professions, one must have excellent communication skills and networking abilities. Of equal importance is the possession of sufficient clinical knowledge, as well as a proficiency in conducting research and writing scientific papers. This unique and important book provides medical students and residents with the most commonly encountered topics in the academic and professional lifestyle, teaching them all of the practical nuances that are often only learned through experience. Written by a team of experienced professionals to help guide younger researchers, A Guide to the Scientific Career: Virtues, Communication, Research and Academic Writing features ten sections composed of seventy-four chapters that cover: qualities of research scientists; career satisfaction and its determinants; publishing iTable of ContentsList of Contributors xxxiii Preface xliii Section I Successful Career 1 1 Defining and Re-Defining Success 3Mohammadali M. Shoja, R. Shane Tubbs and Dan O’Brien 2 Qualities of Research Scientists: Personality and Leadership Attributes of Research Team Members 15Fred Bertino and Mohammadali M. Shoja 3 Building a Personal Vision Statement 25Genevieve Pinto Zipp 4 Creativity and Novel Hypotheses 29Anthony V. D’Antoni 5 Confidence and Its Impact on Your Aspiring Career 33Toral R. Patel 6 Career Satisfaction and Its Determinants 45Nihal Apaydin 7 Spiritual Dimensions of Biomedical Research 55Mariana Cuceu, Beatrice Gabriela Ioan, Marcel Cuceu, Kyle E. Karches, 8 Publishing in Academic Medicine: Does It Translate into a Successful Career? 63Bradley K. Weiner, Paige Vargo and Joseph Fernandez 9 Assessing a Researcher’s Scientific Productivity and Scholarly Impact 69John Panaretos and Chrisovalantis Malesios Section II Communication 81 10 Manners in Academics 83R. Shane Tubbs 11 Emotional Intelligence: Its Place in Your Professional and Academic Careers 91Sandra Buerger and Gernot Buerger 12 Communication Skills 97Sandra Buerger 13 Learning Charisma 103R. Shane Tubbs 14 Essence of Collaborative Research: Leadership, Engaging Others, and Cooperativeness 109Rebecca Andall, Petru Matusz, Jerzy Gielecki and Marios Loukas 15 Personal Branding for Physicians and Researchers 113Tracy E. Bunting-Early 16 Dealing with Manipulative People 123George K. Simon Section III Research Ethics 139 17 Honesty and Truth in Academic Research and Writing 141Thomas F. Lüscher 18 Writing and Scientific Misconduct: Ethical and Legal Aspects 155Marcoen J.T.F. Cabbolet 19 Plagiarism and How to Avoid It 163Izet Masic 20 Conflicts of Interest: A Simple Explanation 179Bradley K. Weiner, Leslie A. Duncan and Paige E. Vargo 21.Gender Differences in Medical Research Productivity Peter F. Svider, Priyanka Shah, Adam J. Folbe, Jean Anderson Eloy Section IV Research Regulations 22 Institutional Review Boards: General Regulations, Institutional Obligations, and Personal Responsibility Anastasia A. Arynchyna, Sarah B. Putney, R. Peter Iafrate 23 International Research with Human SubjectsSarah B. Putney Section V Research Grants and Proposals 24 Grants and Funding Sources Jamie Dow, Chevis Shannon 25 Essentials of Grant Writing and Proposal Development Chevis N Shannon, Jamie Dow Section VI Research Practice 26 Clinical Research Methods and Designs Daxa M. Patel, Beverly C. Walters, James M. Markert 27 Retrospective Analysis from a Chart Review: a Step-by-Step Guide Philipp Hendrix, Christoph J. Griessenauer 28 Designing, Planning, and Conducting Clinical Trials Ramón Rodrigo, Juan Guillermo Gormaz, Matías Libuy, Daniel Hasson 29 Animal Models in Science and Research Ray Greek 30 How to Identify a Timely and Relevant Topic for a Literature Review Sanjay Patel, Jerzy Gielecki, Marios Loukas 31 The Structure and Conduct of a Narrative Literature Review Marco Pautasso 32 A Guideline for Conducting Systematic Reviews Paul Posadzki, Edzard Ernst 33 Clinical Management Guidelines Vijay Ravindra, Walavan Sivakumar, Kristin Kraus, Jay K. Riva-Cambrin, John Kestle 34 Why is the History of Medicine and Biology Important? Paul S. Agutter 35 Historical Articles: A Methodology Guide Anand N. Bosmia, Mohammadali M. Shoja Section VII Publication and Resources 36 An Introduction to Academic Publishing Mohammadali M. Shoja, R. Shane Tubbs 37 Various Types of Scientific Articles José Florencio F. Lapeña, Jr., Wilfred C.G. Peh 38 Authorship Stephen W. Carmichael 39 Recognition, Reward, and Responsibility: Why the Authorship of Scientific Papers Matters Elizabeth Wager 40 Biomedical Journals: Scientific Quality, Reputation, and Impact Factor Katherine G. Akers 41 Scholarly Open-Access Publishing Jeffrey Beall 42 How to find a suitable journal for your manuscript Mohammadali M. Shoja, Thomas P. Walker, Stephen W. Carmichael 43 Scientific Peer Review Christoph J. Griessenauer, Michelle K. Roach 44 How to Reply to Editors and Reviewers Paul Tremblay 45 Causes of manuscript rejection and how to handle a rejected manuscript Sung Deuk Kim, Matusz Petru, Jerzy Gielecki, Marios Loukas 46 Resources and Databases Koichi Watanabe 47 Research: A Construct Defined by Context Michael Dieter 48 Critical Evaluation of the Clinical Literature Jacopo Buti, Faizan Zaheer Section VIII Technical Writing 49 Writing for Your Audience Maria J. Grant 50 Principles of Writing a Good Scholarly Paper S. Jane Millward-Sadler 51 Tips for Scientific Writing Mark P. Henderson 52 Perspectives of a Medical Editor Marilyn Michael Yurk 53 The Art of Organizing Your Research Content Kristin N. Mount 54 Economy of Writing: How to Write Technical Content Arthur C. Croft 55 Writing an Effective Title and Abstract Sandra Buerger 56 Writing the Results Section Bulent Yalcin 57 Writing the Discussion Section for Original Research Articles Ayhan Cömert, Eyyub S.M. Al-Beyati 58 Reporting a Clinical Trial Dirk T. Ubbink 59 Publishing a Case Report S. Jane Millward-Sadler, Mohammadali M. Shoja 60 Writing Editorials Naomi Andall, Bharti Bhusnurmath, Shivayogi Bhusnurmath, Marios Loukas 61 Writing a Letter to the Editor Haley J. Moon, Joel A. Vilensky 62 Writing a Book Review James Hartley 63 Use of Illustrations and Figures to Enhance Scientific Presentations and Publications Marion Karl 64 How to Prepare Supplemental Materials for Scientific Publications Barbara J. Hoogenboom 65 Reference-Management Software Paul Tremblay, Thomas P. Walker Section IX Biostatistics 66 Basic Statistical Analysis for Original Studies Ganesh N. Dakhale, Sachin K. Hiware, Avinash V. Turankar, Mohini S. Mahatme, Sonali A. Pimpalkhute 67 An Overview of Systematic Review and Meta-Analysis Anthony V. D'Antoni, Loretta Cacace 68 An Introduction to Meta-Analysis Arindam Basu 69 Missing Values: How to Treat Them AppropriatelyDavid C. Howell Section X Academic Networking 70 Essentials of Interviewing for Prospective Medical Students and Residents Frederic J. Bertino, Talal A. Kaiser 71 Professional and Academic Societies and Meetings Philip R. Brauer 72 Getting the Most from Attending a Professional Meeting Peter J. Ward 73 Finding Research Opportunities as a Medical Student Frederic J. Bertino 74 A Guide to Writing a Curriculum Vitae Sanjay Patel, Petru Matusz, Marios Loukas Index

Read more less

Book SynopsisThe Biology and Therapeutic Application of Mesenchymal Cells comprehensively describes the cellular and molecular biology of mesenchymal stem cells and mesenchymal stromal cells, describing their therapeutic potential in a wide variety of preclinical models of human diseases and their mechanism of action in these preclinical models. Chapters also discuss the current status of the use of mesenchymal stem and stromal cells in clinical trials in a wide range of human diseases and disorders, for many of which there are limited, or no other, therapeutic avenues. Provides coverage on both the biology of mesenchymal stem cells and stromal cells, and their therapeutic applications Describes the therapeutic potential of mesenchymal stem and stromal cells in a wide variety of preclinical models of human diseases and their mechanism of action in these preclinical models Discusses the current status of mesenchymal stem and stromal cells in clinical trials iTable of ContentsContributors, xxvii Editor’s Preface, xxxv Section I: An overview of mesenchymal stem cells and mesenchymal stromal cells 1 The mesenchymal stem cell, the mesenchymal stromal cell, and the mesenchymal stromal cell exosome, 3Kerry Atkinson 2 The nomenclature of mesenchymal stem cells and mesenchymal stromal cells, 8Armand Keating Section II: The isolation and ex vivo expansion of mesenchymal stromal cells 3 The isolation and expansion of mesenchymal stromal cells from bone marrow, 13Celena F. Heazlewood 4 The biology and clinical applications of mesenchymal stromal cells derived from human gestational tissues, 24Celena F. Heazlewood 5 Human placenta-derived mesenchymal stem/stromal cells: fetal and maternal origins and critical parameters forex vivo expansion, 32Rebecca A. Pelekanos and Varda S. Sardesai Section III: The cellular and molecular biology of mesenchymal stromal cells 6 Epigenetic regulation of mesenchymal stem/stromal cell growth and multipotentiality, 41Sarah Elizabeth Hemming, Dimitrios Cakouros, and Stan Gronthos 7 Biological changes in human mesenchymal stromal cells during monolayer culture, 58Marietta Herrmann and Jennifer J. Bara 8 The effect of three-dimensional aggregates on the biology of mesenchymal stromal cells, 75Yijun Liu, Ang-Chen Tsai, Xuegang Yuan, and Teng Ma 9 Cell–cell signaling pathways that regulate mesenchymal stromal cell differentiation, 91Leah Etheridge, Rebecca A. Mason, Fatima Saleh, and Paul Genever 10 Regulation of mitochondrial transport in mesenchymal stromal cells, 104Shravani Mukherjee, Naveen K. Bhatraju, Tanveer Ahmad, and Anurag Agrawal 11 The regulation of adipogenesis from adipose-derived stem/stromal cells, 114Lin Chen and Lei Liu 12 Modulation of osteogenic differentiation in mesenchymal stromal cells, 131Sean Gaynard, Jessica Hayes, and Mary Murphy 13 The role of glycogen synthase kinase-3 inhibitors on bone remodeling, 148K. Jane Escott and Patrick J. O’Shea 14 Early molecular events during in vitro chondrogenesis, 167Tommy A. Karlsen, Rune B. Jakobsen, and Jan E. Brinchmann 15 The role of the extracellular matrix in the differentiation of mesenchymal stromal cells, 191Peishun Shou, Qing Chen, and Yufang Shi 16 Effects of hypoxic culture on bone marrow multipotent mesenchymal stromal cells: from bench to bedside, 196Shih-Chieh Hung 17 The role of cyclic tensile strain on osteogenesis and angiogenesis in human mesenchymal stem/stromal cells, 208Adisri Charoenpanich, Josephine Bodle, and Elizabeth Loboa 18 The evolving concept of mesenchymal stromal cells in regenerative medicine: from cell differentiation tosecretome, 222F.G. Teixeira, A. Pires, S.C. Serra, N. Sousa, and A.J. Salgado 19 The secretome of mesenchymal stem/stromal cells undergoing chondrogenic differentiation and those undergoing osteogenic or adipogenic differentiation, 236Beatriz Rocha, Francisco J. Blanco, and Cristina Ruiz-Romero 20 Mesenchymal stromal cell extracellular vesicles/exosomes, 250Ronne Wee Yeh Yeo, Ruenn Chai Lai, and Sai Kiang Lim 21 Role of tunneling nanotube crosstalk with distressed cardiomyocytes in controlling the heart repair potential of mesenchymal stromal cells, 264Anne-Marie Rodriguez and Meriem Mahrouf-Yorgov 22 The preferential homing of mesenchymal stromal cells to sites of inflammation, 286Catherine Sullivan 23 The role of chemokines in mesenchymal stromal cell homing to sites of inflammation, including infarctedmyocardium, 314Shan Wang and Yaojiong Wu 24 Live cell imaging and single cell tracking of’mesenchymal stromal cells in vitro, 323James A. Cornwell, Maria Z. Gutierrez, Richard P. Harvey and Robert E. Nordon 25 The role of mesenchymal stem/stromal cells in angiogenesis, 347Annelies Bronckaers and Ivo Lambrichts 26 The relationship between mesenchymal stromal cells and endothelial cells, 366Seyed Mahdi Nassiri and Reza Rahbarghazi 27 The radioresistance of mesenchymal stromal cells and their potential role in the management of radiation injury, 391Tara Sugrue, Irene Calvo-Asensio, and Rhodri Ceredig 28 The implications of multipotent mesenchymal stromal cells in tumor biology and therapy, 415Pratika Y. Hernanda, Maikel P. Peppelenbosch, and Qiuwei Pan 29 Mesenchymal stem/stromal cell therapy: mechanism of action and host response, 426Aideen Ryan, Mary Murphy, and Frank Barry 30 The differences between mesenchymal stromal cells and fibroblasts, 441Luigi Balducci, Sharon Natasha Cox, and Giulio Alessandri 31 Derivation of mesenchymal stem/stromal cells from induced pluripotent stem cells, 456Rebecca A. Pelekanos 32 The role of mesenchymal stem cells in hematopoiesis, 467Jean-Pierre Levesque, Rebecca N. Jacobsen, and Ingrid G. Winkler 33 The modulatory effects of mesenchymal stromal cells onthe innate immune system, 481Ko-Jiunn Liu, Men-Luh Yen, Li-Tzu Wang, and B. Linju Yen 34 The modulatory effects of mesenchymal stromal cells on the adaptive immune system, 490B. Linju Yen, Ko-Jiunn Liu, Men-Luh Yen, and Huey-Kang Sytwu 35 The role of mesenchymal stromal cells in the repair of acute organ injury, 496A.A. Temnov, A.V. Vagabov, A.N. Sklifas, V.I. Novoselov, and Y.A. Belyi 36 The use of mesenchymal stromal cells in the treatment of diseases of the cornea, 524Damien G. Harkin, Allison J. Sutherland, Laura J. Bray, Leanne Foyn, Fiona J. Li, and Brendan G. Cronin 37 The role of paracrine factors secreted by mesenchymal stromal cells in acute tissue injury, 544Ying Wang, Tania Velletri, Chunxing Zheng, and Yufang Shi 38 Treatment of lung disease by mesenchymal stromal cell extracellular vesicles, 553Antoine Monsel, Ying-gang Zhu, Varun Gudapati, and Jae-Woo Lee 39 Evaluating mesenchymal stem/stromal cells for treatment of asthma and allergic rhinitis, 573Tatyana Gavrilova, Saritha Kartan, Lauren S. Sherman, Oleta A. Sandiford, and Pranela Rameshwar 40 Stem cell therapies for Huntington’s disease, 581A.T. Crane, J. Rossignol, and G. L. Dunbar Section IV: The role of bioengineering in the therapeutic applications of mesenchymal stromal cells 41 Endometrial mesenchymal stromal cell and tissue engineering for pelvic organ prolapse repair, 601Shanti Gurung, Jerome A. Werkmeister, and Caroline E. Gargett 42 Closed automated large-scale bioreactors for manufacturing mesenchymal stromal cells for clinical use, 616Kerry Atkinson, Nicholas Timmins, G. Kiel, Celena Heazlewood, Michael Doran, and Gary Brooke Section V: GMP manufacturing of mesenchymal stromal cells for clinical use 43 Current good manufacturing practice for the isolation and ex vivo expansion of mesenchymal stromal cells derived from term human placenta for use in clinical trials, 621Kerry Atkinson, Dahlia Khalil, Celena Heazlewood, and Nina Ilic 44 A comparison of high-tier regulatory documents pertaining to biologic drugs including mesenchymal stromal cells in Australia, Europe, and the USA using a manual documentary analysis, 628Nina Ilic Section VI: The therapeutic application of mesenchymal stromal cells 45 The use of mesenchymal stromal cells in acute and chronic heart disease, 647Ariel Wolf, Wayne Balkan, and Joshua Hare 46 The role of mesenchymal stem/stromal cells in the management of critical limb ischemia, 661P.K. Gupta, Chullikana Anoop, Balasubramanian Sudha, R Mathiazhagan, Raj Swathi Sundar, and Majumdar Anish Sen 47 The role of mesenchymal stromal cells in the management of musculoskeletal disorders, 677Stefan Zwingenberger, Ishaq Ojodu, Maik Stiehler, and Stuart B. Goodman 48 The potential role of bone marrow mesenchymal stromal cells in the treatment of ischemic stroke, 690Yujun Pan and Ruohan Sun 49 The role of mesenchymal stromal cells in spinal cord injury, 714P. Jendelova, L. Machova-Urdzikova, and E. Sykova 50 The role of mesenchymal stromal cells in the treatment of ulcerative colitis and Crohn’s disease, 730Céline Gregoire, Chantal Lechanteur, Alexandra Briquet, Etienne Baudoux, Olivier Giet, Olivier Delloye, Frédéric Baron, Edouard Louis, and Yves Beguin 51 Mesenchymal stromal cells targeting kidney disease: benefits of a combined therapeutic approach, 754Brooke M. Huuskes and Sharon D. Ricardo 52 The biology and potential clinical applications of mesenchymal stromal cells in diseases of the lung, 770Yuben P. Moodley, Jesse D. Armitage, and Dino B.A. Tan 53 The role of mesenchymal stromal cells in diseases of the lung, 787Kerry Atkinson 54 Mesenchymal stromal cells for the treatment of’autoimmune diseases, 794Christopher N. Lewis and Jacques Galipeau 55 The role of mesenchymal stromal cells in bacterial infection, 814Sailaja Ghanta, Konstantin Tsoyi, and Mark A. Perrella 56 The use of mesenchymal stromal cells in solid organ transplantation, 825Céline Gregoire, Alexandra Briquet, François Jouret, Chantal Lechanteur, Etienne Baudoux, Olivier Giet, Olivier Delloye, Frédéric Baron, Olivier Detry, and Yves Beguin 57 The role of mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation, 836Kerry Atkinson 58 The role of mesenchymal stromal cells in the management of skin wounds, 841Sung-Whan Kim 59 The role of mesenchymal stromal cells in skin wound healing, 845Miao Teng and Hengshu Zhang Section VII: Mesenchymal stromal cells as delivery vehicles for therapeutic agents 60 The role of mesenchymal stromal cells in human brain tumors, 859Brittany C. Parker Kerrigan, Tal Shahar, Shinji Yamashita, and Frederick F. Lang 61 Mesenchymal stromal cells as gene delivery vehicles to treat nonmalignant diseases, 873Julie R. Beegle, Jan A. Nolta, and Fernando A. Fierro 62 Gene therapy for cancer using mesenchymal stromal cells, 892Ryosuke Uchibori and Keiya Ozawa Section VIII: The present and the future 63 Breaking news, 901Kerry Atkinson 64 Reconciling the stem cell and paracrine paradigms of mesenchymal stem cell function, 912Siddaraju V. Boregowda and Donald G. Phinney Glossary, 927 Index, 949

Read more less

Book SynopsisAll three An Aid to the MRCP PACES volumes, covering Stations 1, 2, 3, 4 and 5, together at a specially discouted price.

Read more less

Book SynopsisNtoumanis and Myers have done sport and exercise science researchers and students a tremendous service in producing An Introduction to Intermediate and Advanced Statistical Analyses for Sport and Exercise Scientists.Table of ContentsAbout the editors xiii List of contributors xv Foreword xix Preface xxi 1 Factorial ANOVA and MANOVA 1 General Introduction 1 Hypothesis Testing 2 Alpha Level 2 Assumptions 3 Further Considerations 4 Utility in Sport and Exercise Sciences 6 Treatment Conditions 6 Existing Conditions 6 Individual Characteristics 7 Recent Usage 7 The Substantive Example 7 Univariate: Factorial ANOVA 8 Univariate Assumptions 8 The Synergy 10 Factorial ANOVA Analysis Plan 10 Example of a Write]Up Compatible with the APA Publication Manual 11 Factorial MANOVA Analysis Plan 13 Example of a Write]Up Compatible with the APA Publication Manual 13 Summary 16 Acknowledgment 18 References 18 2 Repeated measures ANOVA and MANOVA 19 General Introduction 19 Between] versus Within]Subjects Variables 19 Hypothesis Testing 20 Assumptions 20 Further Considerations 21 Utility in Sport and Exercise Sciences 22 Multiple Treatment Conditions 23 Multiple Assessments 23 Longitudinal Studies 23 Recent Usage 24 The Substantive Example 24 Univariate: Repeated Measures ANOVA 24 Univariate Assumptions 25 Multivariate: Repeated Measures MANOVA 26 Multivariate Assumptions 26 The Synergy 27 Repeated Measures ANOVA Analysis Plan 27 Example of a Write]Up Compatible with the APA Publication Manual 29 Repeated Measures MANOVA Analysis Plan 29 Example of a Write]Up Compatible with the APA Publication Manual 31 Summary 32 Acknowledgment 34 References 34 3 Mediation and moderation via regression analysis 35 General Introduction 35 Utility of the Methods in Sport and Exercise Science 36 The Substantive Example 38 Mediation 38 The Synergy 38 Mediation 38 The Substantive Example 44 Moderation 44 The Synergy 45 Moderation 45 Summary 53 References 55 4 Item response theory and its applications in Kinesiology 57 General Introduction 57 What Is IRT? 59 Other Commonly Used IRT Models 60 Assumptions Related to IRT 62 Unidimensionality 62 Local Independence 62 Addressing Model]Data Fit 62 Inspecting Model Assumptions 63 Inspecting Expected Model Features 63 Inspecting Overall Model]Data Fit 64 Computer Simulation for Model]Data Fit Testing 64 Unique Features and Advantages of IRT 65 Estimation Invariance 65 Common Metric Scale 65 Item and Test Information 66 Test Relative Efficiency 68 Global “Reliability” Is no Longer a Concern 69 Item Bank and IRT]Based Test Construction 69 Parameter Estimation and Software 71 Utility of the Methodology in Kinesiology 71 IRT Limitations and Future Direction 72 Conclusion 73 References 74 5 Introduction to factor analysis and structural equation modeling 79 General Introduction 79 Utility of the Method in Sport and Exercise Science 80 Terminology and Methodology 83 Evaluating Model Fit 86 Interpreting Parameter Estimates 88 The Substantive Example 89 The Synergy 91 EFA: Establishing the Factor Structure 91 CFA: Testing the Measurement Models 93 Structural Equation Modeling: Adding the Regression Paths 96 Summary 98 References 99 6 Invariance testing across samples and time: Cohort]sequence analysis of perceived body composition 101 General Introduction to the Importance of Measurement Invariance 102 Cohort]Sequential Designs: Longitudinal Invariance across Samples and Time 106 Substantive Application: Physical Self]Concept 107 Methodology 111 The PSDQ Instrument 111 Statistical Analyses 111 Goodness of Fit 112 Results 113 Basic Cohort]Sequence Model: Four Cohort Groups and Four Waves 113 Cohort]Sequence Design of Multiple Indicators, Multiple Causes Models 115 Use of Model Constraint with Orthogonal Polynomial Contrasts to Evaluate Cohort Sequence and MIMIC Latent Means 116 Use of Latent Growth Curve Models to Evaluate Stability/Change over Time 119 LGC Results 123 Summary, Implications, and Further Directions 123 Methodological Implications, Limitations, and Further Directions 123 References 125 7 Cross]lagged structural equation modeling and latent growth modeling 131 General Introduction 131 A Theoretical Framework for the Study of Change 132 Utility of the Method in Sport and Exercise Science 132 Analysis of Change 132 The Substantive Example 134 Theoretical Background 134 The Data: Participants and Measurement 134 The Synergy 135 CLPM 135 CLPM Example 137 Latent Growth Modeling 140 LGM Example 141 Model 2a: Unconditional LGM 143 Model 2b: Conditional LGM 145 Model 2c: Unconditional LGM with TVCs 145 Model 3: Parallel Process LGM 146 Model 4: Second]Order LGM 148 Summary 150 References 151 8 Exploratory structural equation modeling and Bayesian estimation 155 General Introduction 155 Utility of the Methods in Sport and Exercise Science 156 The Substantive Example(s) 159 The Motivational Correlates of Mentally Tough Behavior 159 Developing Synergies through Statistical Modeling 161 ESEM 161 Bayesian Estimation 168 Summary 179 References 180 9 A gentle introduction to mixture modeling using physical fitness performance data 183 General Introduction 183 Utility of the Method in Sport and Exercise Science 186 The Substantive Example(s) 187 Class Enumeration in Mixture Models 188 The Estimation of Mixture Models 190 The Synergy 190 LPA of Grade 5 Students and Tests of Invariance across Gender Groups 190 Inclusion of Covariates in LPA Solutions 195 LTA 196 Mixture Regression Analyses of Grade 5 Students 198 Latent Basis Growth Mixture Analyses: Cardiovascular Fitness 202 Piecewise Growth Mixture Analyses: Physical Strength 203 Summary 204 Acknowledgments 205 References 206 10 Multilevel (structural equation) modeling 211 General Introduction 211 Multilevel Structural Equation Modeling 212 Utility of the Methodology in Sport and Exercise Science 214 The Substantive Examples 215 Coaching Competency–Collective Efficacy–Team Performance: 1–1–2 216 Action Planning Intervention–Physical Activity Action Plans–Physical Activity: 2–1–1 217 The Synergy 218 Coaching Competency–Collective Efficacy–Team Performance: 1–1–2 219 Action Planning Intervention–Physical Activity Action Plans–Physical Activity: 2–1–1 222 Summary 229 References 230 11 Application of meta]analysis in sport and exercise science 233 General Introduction 233 Stages of Meta]Analysis 233 Key Elements of Meta]Analysis 234 Goals of Meta]Analysis 236 Utility of the Methodology in Sport and Exercise Science 238 The Substantive Example 238 The Synergy 241 Univariate Meta]Analysis 241 Multivariate Meta]Analysis 245 Summary 249 Acknowledgment 251 References 251 12 Reliability and stability of variables/instruments used in sport science and sport medicine 255 Introduction 255 A. Assessment of Test–Retest Agreement Using Interval/Ratio Data 256 A Worked Example Using the Test–Retest Differences of the Biceps Skinfold Measurements 257 B. Utility of the Assessment of Test–Retest Stability Using Categorical/Likert]Type Data 260 The Substantive Example 261 Utility of the Test–Retest Stability Using Nonparametric Data 261 The Synergy 262 Utility of the Item by Item Approach to Test–Retest Stability 263 The Synergy 263 Summary 265 References 266 13 Sample size determination and power estimation in structural equation modeling 267 General Introduction 267 Power 268 Power Analysis in SEM 268 Utility of the Methodology in Sport and Exercise Science 269 Power Analysis Regarding Model]Data Fit: An Introduction 269 Power Analysis Regarding Focal Parameters: An Introduction 270 The Substantive Example 272 Bifactor Model in Sport and Exercise Science 272 Bifactor Model and the PETES 273 The Synergy 275 Power Analysis Regarding Model]Data Fit: A Demonstration 276 Power Analysis Regarding Focal Parameters: A Demonstration 278 Summary 281 References 282 Index 285

Read more less

Book SynopsisThe comprehensive and authoritative guide to clinical reproductive science The field of clinical reproductive science continues to evolve; this important resource offers the basics of reproductive biology as well as the most recent advance in clinical embryology. The author - a noted expert in the field - focuses on the discipline and covers all aspects of this field. The text explores causes of male and female infertility and includes information on patient consultation and assessment, gamete retrieval and preparation, embryo culture, embryo transfer and cryopreservation. Comprehensive in scope, the text contains an introduction to the field of clinical reproductive science and a review of assisted reproductive technology. The author includes information on a wide range of topics such as gonadal development, the regulation of meiotic cell cycle, the biology of sperm and spermatogenesis, in vitro culture, embryo transfer techniques, fundamentals of fertilisation, oocyte activation aTable of ContentsList of Contributors xi About the Editor xv Preface xvii Acknowledgements xix About the Companion Website xxi Section One Reproductive Science: Fundamentals of Human Reproductive Biology 1 1 Sexual Differentiation, Gonadal Development, and Development of the External Genitalia: A Review of The Regulation of Sexual Differentiation 3Rebecca M. Perrett 2 Male and Female Reproductive Anatomy 35Sara Sulaiman and James Coey 3 Fundamentals of Reproductive Endocrinology 45Derrick Ebot, Haider Hilal, Michael Carroll, and James Coey 4 The Ovaries, Oocytes, and Folliculogenesis 57Jacques Gilloteaux and James Coey 5 The Human Spermatozoa 65Allan Pacey and Katrina Williams 6 The Biology of Fertilization 75Michael Carroll 7 Human Embryo Development: From Zygote Stage to Peri‐Implantation Blastocyst 93Stéphane Berneau and Michael Carroll 8 The Female Reproductive Tract and Early Embryo Development: A Question of Supply and Demand 99Henry J. Leese and Daniel R. Brison Section Two Clinical Reproductive Science: Causes of Male and Female Infertility 109 9 Disorders of Male Reproductive Endocrinology 111Michael Carroll 10 Disorders of Female Reproductive Endocrinology 125Mahshid Nickkho‐Amiry and Cheryl T. Fitzgerald 11 Oocyte Aneuploidy and the Maternal Age Effect 133Mary Herbert 12 Female Reproductive Pathology: Peritoneal, Uterine, and Fallopian Tube Pathologies 147Kenneth Ma Kin Yue, Rosa Trigas, and Edmond Edi‐Osagie 13 Pathologies of the Male Reproductive Tract 159Aarush Sajjad, Muhammad A. Akhtar, and Yasmin Sajjad 14 The Impact of Infections on Reproduction and Fertility 177Val Edwards Jones 15 Nutrition, Fetal Health, and Pregnancy 189Emma Derbyshire 16 The Embryonic Environment and Developmental Origins of Health 195Tom P. Fleming and Congshan Sun 17 Lifestyle and Environmental Impacts on Fertility 205Ana‐Maria Tomova and Michael Carroll Section Three Clinical Reproductive Science In Practice: IVF and Assisted Reproductive Technologies 215 18 Assessing the Infertile Couple 217Narmada Katakam, Ruth Arnesen, Caroline Watkins, Bert Stewart, and Luciano G. Nardo 19 Ovarian Stimulation Protocols 231Nikolaos Tsampras and Cheryl T. Fitzgerald 20 Oocyte Retrieval Techniques and Culture of Oocytes 241Dawn Yell 21 Sperm Preparation: Strategy and Methodology 251Stephen Harbottle 22 Diagnostic Semen Analysis: Uncertainty, Clinical Value, and Recent Advances 265Mathew Tomlinson 23 Surgical Sperm Retrieval 279Muhammad A. Akhtar, Elizabeth Hester, Solmaz Gul Sajjad, and Yasmin Sajjad 24 In Vitro Fertilization and Intracytoplasmic Sperm Injection 291Bryan Woodward 25 Morphological Assessment of Embryos in Culture 303J. Diane Critchlow 26 In Vitro Culture of Gametes and Embryos – The Culture Medium 317Robbie Kerr 27 Incubators in the Assisted Reproductive Technology Laboratory 333Louise Hyslop 28 Embryo Transfer Techniques and Improving Embryo Implantation Rates 341Rachel Cutting 29 Cryopreservation of Gametes and Embryos 351Tope Adeniyi 30 Preimplantation Genetic Diagnosis and Screening 371Colleen Lynch and Brendan Ball 31 Long‐Term Follow‐Up of Children Conceived Through In Vitro Fertilization 385Omar Abdel‐Mannan and Alastair G. Sutcliffe Index 393

Read more less

Book SynopsisHelps those that use cell preservation to develop new protocols or improve existing protocols This book provides readers with the tools needed to develop or debug a preservation protocol for cells. The core structure and content of the text grew from a professional short course that has been offered at the Biopreservation Core Resource for the last 10 years. This comprehensive text describes, step by step, the individual elements of a protocol, including the relevant scientific principles for each phase of the protocol. It can be used by anyone who is involved in cell preservationeven by those who are not experts in freezing of cellsbecause it provides the scientific basis for those that want to understand the basis for the protocol. Preservation of Cells: A Practical Manual begins by first introducing readers to the subject of preserving cells. It then goes on to cover Pre-freeze Processing and Characterization; Formulation and Introduction of CryopreserTable of ContentsPreface xiii Acknowledgments xvii Nomenclature xix 1 Introduction 1 Mammalian Cells: Modern Workhorses 1 Products from Cells 1 Cells as Therapeutic Agents 2 Biomarkers for Health or Disease 2 In Vitro Models 3 Bridging the Gap 3 The Preservation Toolkit 5 Hypothermic Storage 5 Cryopreservation 6 Vitrification 7 Dry State Storage 8 Fit]for]Purpose 8 One Size Does Not Fit All 9 The Process is the Product 9 Reproducibility 12 Safety 12 Dispelling the Myth of the Cold Black Box 12 References 13 2 Pre]freeze Processing and Characterization 15 Pre]freeze Processing 15 Digestion of Cells from Intact Tissue 15 Hypothermic Storage 16 Selection of Subpopulations 17 Activation or Stimulation 18 Genetic Modification 18 Culture 19 Pre]freeze Process Monitoring 19 Pre]freeze Characterization 20 Identity 20 Genetic Stability 21 Enumeration 21 Purity 22 Adventitious Agents 22 Microbial Testing of Cell Therapy Products 23 Special Considerations for the Characterization of Cell Therapies 24 Annotation of Pre]freeze Processing 24 Scientific Principles 25 Putting Principles into Action 25 References 26 3 Formulation and Introduction of Cryopreservation Solutions 29 Importance of Cryoprotective Agents 29 Mechanisms of Cryoprotection 31 Formulating a Cryopreservation Solution 31 Formulation of a Vitrification Solution 33 Characterization and Quality Control for Cryoprotective Solutions 34 Toxicity of CPAs 35 Osmotic Toxicity 35 Biochemical Toxicity 36 Developing a Protocol for Introducing CPA Solutions 37 The Basic Experiment 37 Introduction of Vitrification Solutions 38 Cell Concentration 39 Removal of CPA Solution 40 Safety Considerations for Cryopreservation Solutions 40 Cryopreservation Containers 41 Overwraps 42 Labeling 43 Sample Annotation 44 Scientific Principles 44 Putting Principles into Practice 44 References 44 4 Freezing Protocols 47 Importance of Cooling Rate 47 Controlled]rate Freezing 48 Controlled Cooling]rate Protocols 49 Segment 1: Initial Hold Period 49 Segment 2: Cooling 50 Uncontrolled Nucleation 53 Manual Nucleation 54 Automatic Nucleation 54 Verifying Segment 2 (Including S2a) 55 “Delayed” Latent Heat 55 Segment 3 56 Verifying Segment 3 56 Other Types of Controlled]rate Protocols 57 Passive Freezing 57 Transfer to Storage 59 Vitrification 60 Independent Temperature Measurement 60 Scientific Principles 61 Putting Principles into Practice 62 References 62 5 Storage and Shipping of Frozen Cells 65 Scientific Basis for Selection of a Storage Temperature 65 Additional Considerations for Vitrified Samples 67 Standards, Guidelines, and Best Practices 67 Facilities 68 Storage Equipment and Environment 69 Mapping Storage Devices and Setting Alarm Limits 70 Monitoring Systems 71 Safety 71 Inventory Management System 72 Stability in Storage 72 Temperature Fluctuations 73 Influence of Background Ionizing Radiation on Stability in Storage 74 Shelf]Life of Samples in Storage 75 Fit]for]Purpose Storage Practices 75 Risk Mitigation in Long]Term Storage 76 Shipping or Transport of Cells 76 General Shipping Considerations 77 Liquid Nitrogen Dry Shippers 78 Temperature Mapping of a Shipper 79 Packaging of Samples Being Shipped 79 Monitoring of Shipments 79 Responsibilities 79 Sample Annotation 80 Scientific Principles 80 Putting Principles into Practice 81 References 81 6 Thawing and Post]Thaw Processing 85 Thawing Equipment 86 Transporting Samples Prior to Thawing 87 Estimating Your Thawing Rate 87 Thawing and Infusion of Cell Therapy Products 89 Safety Considerations for Thawing 90 Post]Thaw Processing 90 Post]Thaw Washing 90 Dilution 91 Infusion of Cells Immediately Post]Thaw 91 Removal of Vitrification Solutions 92 Wash Solutions 92 Scientific Principles 94 Putting Principles into Practice 94 References 94 7 Post]Thaw Assessment 97 Common Measures Used in Post]Thaw Assessment 98 Physical Integrity 98 Metabolic Activity 99 Mechanical Activity 100 Mitotic Activity 101 Differentiation Potential 102 Transplantation Potential 103 Strategies to Improve the Accuracy and Reproducibility of Post]Thaw Assessment 103 Eliminate Measurement Bias 103 Compensating for Post]Thaw Apoptosis 105 Post]Thaw Assessment Using a Single Measure 106 Optical Methods of Post]Thaw Assessment 106 Release Criteria 107 Scientific Principles 107 Putting Principles into Practice 107 References 108 8 Algorithm]Driven Protocol Optimization 111 Small Cell Number/High Throughput Approach 113 Validating Operation of the Algorithm 114 Flexibility 115 Practical Notes 115 Modeling in Cryobiology 115 References 116 Protocols Introduction 117 Protocol Contributors 118 Cryopreservation of Endothelial Cells in Suspension 119 Principle 119 Equipment and Supplies 119 Equipment 119 Supplies 120 Safety 120 Procedure 121 Cell Preparation 121 Preparation of Cryoprotectant Solution 121 Using Powdered HES 122 Using Pentastarch Solution 122 Cryoprotectant Addition 122 Freezing 122 Controlled]rate Freezing with a Methanol Bath 122 Alternative Freezing Procedure 123 Thawing 123 Expected Results 123 References 123 Cryopreservation of Peripheral Blood Mononuclear Cells from Whole Blood 125 Principle 125 Protocol 1: Isolation of PBMCS Directly over Ficoll]Hypaque 125 Equipment 125 Materials 126 Reagents 126 Procedure 126 Protocol 2: Isolation of PBMCS Using SepMates 127 Equipment 127 Materials 128 Reagents 128 Procedure 128 Appendix A Human Serum AB Freezing Media 129 Materials 129 Equipment 130 Reagents 130 Procedure 130 Cryopreservation of Human Adipose Stem Cells 131 Principle 131 Equipment and Supplies 131 Reagents and Media 132 Procedure 133 Isolation of Human ASCs from Lipoaspirate 133 Magnetic Cell Sorting (Optional) 135 Cryopreservation 135 Controlled]rate Freezing of Human ASCs 135 Thawing Human ASCs 137 Notes 138 Reference 139 Cryopreservation of Red Blood Cells 141 Method I: High Glycerol/Slow Cooling Technique (Meryman and Hornblower 1972) 141 Preparation of the RBC Concentrate 141 Addition of the Cryoprotective Solution 141 Cooling 142 Rewarming 142 Removal of the Cryoprotectant and Debris 142 Method II: A Low Glycerol/Rapid Cooling Technique (Rowe, Eyster, and Kellner 1968) 143 Method III: Hydroxyethylstarch/Rapid Cooling Technique (Sputtek 2007) 144 References 146 Cryopreservation of Oocytes by Slow Freezing 147 Principle 147 Specimen Requirements 147 Equipment and Supplies Needed 147 Equipment 147 Supplies 148 Procedure 148 Safety 152 Calculations 152 Reporting Results 152 Procedure Notes 153 Limitations of Procedure 153 Oocyte Vitrification and Warming 155 Principle 155 Equipment and Supplies 155 Equipment 155 Supplies 155 Procedure 156 Quality Control 160 Safety 161 Transportation of Hematopoietic Progenitor Cells and Other Cellular Products 163 Principle/Rationale 163 Specimen 163 Equipment/Reagents 163 Quality Control 164 Procedure 164 Additional Information 165 Further Reading 165 Cryopreservation of Hematopoietic Progenitor Cells 167 Principle/Rationale 167 Protocol/Processing Schema 168 Specimen 168 Equipment/Reagents 168 QualityControl 169 Procedure169 Appendix A Alternate Cryopreservation Harness Set]2 or 4 Bags 173 Further Reading 173 Thawing of Hematopoietic Progenitor Cells 175 Principle/Rationale 175 Equipment/Reagents 175 QualityControl 176 Procedure176 Further Reading 177 Processing and Cryopreservation of T]Cells 179 Principle/Rationale 179 Protocol/Processing Schema: N/A 179 Specimens179 Equipment/Reagents 179 Quality Control 180 Procedure 180 Further Reading 182 Thawing and Reinfusion of Cryopreserved T]Cells 183 Principle/Rationale 183 Protocol/Processing Schema 183 Specimen 184 Equipment/Reagents 184 Quality Control 184 Procedure 184 Further Reading 187 Index 189

Read more less

Book SynopsisGeneral Practice Cases at a Glance is a workbook of clinical scenarios, ideal for those working in general practice, on their GP rotations, or looking to improve their history-taking, diagnostic and management planning skills.Trade Review"The more clinical cases one studies, the better the critical skills one develops in learning how to approach the numerous complaints one may encounter, along with developing the understanding that there can be many presentations of a common diagnosis. This books adds a number of cases to help this development." (Doody Enterprises 2016)Table of ContentsPreface vii Part 1 Introduction 1 1 The consultation 2 2 Clinical reasoning to reach a diagnosis 4 Part 2 Cases 7 1 My baby is burning up 8 2 I need something for hay fever 10 3 I can’t seem to shift this cough 12 4 My knee is very bad 14 5 I have migraine 16 6 I’ve come for my flu jab 18 7 He’s a little terror 20 8 I’ve got a problem with my shoulder 22 9 I can’t believe how much weight I’ve put on 24 10 It’s my back passage 26 11 I am pregnant again 28 12 My baby has an upset tummy 30 13 My ear really hurts 32 14 I’m worried about my drinking 33 15 She cries all the time 34 16 I need something to help me sleep 36 17 My eye hurts 38 18 I think I should get this prostate test, doctor 40 19 I can’t live with this pain much longer 41 20 I’ve got a red eye 44 21 I’m fed up with my spots 46 22 I’ve come for the results of my blood tests 48 23 I’d like to talk to you about HRT 50 24 I’ve got a bit of a discharge 52 25 I’m feeling tired and woozy 54 26 I think I need to get my blood pressure checked 56 27 Well, I’m pregnant 58 28 I’ve been feeling short of breath 60 29 She’s coughing non-stop 62 30 I’m worried about my memory 64 31 I’ve got this pain in my chest, doctor 66 32 I’ve been having terrible stomach cramps 68 33 I’m concerned this mole has been growing 70 34 I seem to have lost weight 72 35 I’m worried about my erection 74 36 I think the cancer has got me 76 37 I’m all over the place these days 78 38 She’s had tummy ache for two days 80 39 I don’t want to have my period when I am on holiday 82 40 It’s my leg 84 41 I’m having terrible diarrhoea 86 42 The nurse did my diabetes check last week. I’m here for the results 88 43 My skin is really itchy 90 44 Doctor, I’m just feeling really down 92 45 I’ve got a really bad burning in my stomach 93 46 I want to talk about my risk of breast cancer 94 47 I’ve got a terrible back ache 96 48 I’d like antibiotics please 98 49 I’m tired all the time 100 50 I’m worried about this lump, doctor 102 List of abbreviations 105 Index of cases by speciality 106 Index 107

Read more less

Book SynopsisIn the era of cost cutting and lack of adequate health insurance for many patients, clinical skills and time spent with patients are not adequately compensated.Table of ContentsTable of Normal Laboratory Values, ix About the Author, xi Dedication, xiii Acknowledgments, xv Preface, xvii Introduction, xix How the book should be used and understood, xxi 1 Skin and Soft Tissue Infections, 1 Case 1.1 Soft tissue infection following traumatic aquatic exposure, 1 Case 1.2 Soft tissue infection of the hand and wrist in an 81-year-old man, 6 Case 1.3 A 41-year-old Caucasian female with right arm swelling, 12 Case 1.4 A 24-year-old female with fever and arm swelling, 15 Case 1.5 A 72-year-old male with necrotic soft tissue elbow infection, 16 Case 1.6 A 37-year-old man with severe body aches and fever, 18 2 Fever of Unknown Origin and Drug-Induced Fever, 25 Case 2.1 Hypersensitivity masquerading as sepsis, 25 Case 2.2 A psychiatric patient with HIV infection and fever, 32 Case 2.3 A hypertensive patient with 2 months of fever and chills, 36 Brief review and discussion of drug-induced fever, 38 Lessons learned from these two cases, 40 3 Dermatologic Manifestations of Infectious and Non-infectious Diseases, 41 Case 3.1 A 45-year-old patient referred for "persistent shingles", 41 Case 3.2 A 39-year-old female with fever and acute rash illness, 46 Case 3.3 A 45-year-old female with subacute rash illness for 2 weeks, 50 Case 3.4 An 82-year-old man with a chronic non-healing elbow wound, 55 4 Diseases Acquired Through Close Contact with Animals, 61 Case 4.1 A 10-month-old child with "worms", 61 Case 4.2 Infectious complication of cat scratch, 67 Case 4.3 A young man with acute left arm lymphadenopathy, 72 5 Travel-associated Blood-borne Parasitic Infection, 77 Case 5.1 A 15-year-old adolescent male with fever and thrombocytopenia, 77 Case 5.2 A 23-year-old Caucasian male with fever and chills, 81 Case 5.3 A 57-year-old male with acute-onset fever and chills, 83 Comparison of the characteristics of five patients with malaria seen between 1998 and 2015, 86 6 Gulf Coast Tick Rash Illness, 93 Case 6.1 Woman with rash and prolonged eschar following a tick bite, 93 Case 6.2 A 58-year-old male with generalized body aches and fever, 97 7 Infectious Diseases Associated with Trauma and Outdoor Activities, 103 Introduction, 103 Case 7.1 A 30-year-old man with thumb infection and forearm nodules, 103 Case 7.2 Severe infection and sepsis following recreational fishing, 108 Classification and characteristics of infectious diseases associated with trauma and outdoor activities, 114 8 Acute and Chronic Subcutaneous Fungal Infections, 121 Case 8.1 Exophytic skin lesion masquerading as cancer, 121 Case 8.2 Chronic persistent subcutaneous fungal infection of the leg, 124 Case 8.3 A young man with a laceration injury contaminated with soil, 130 9 Endocarditis with Unusual Organisms or Characteristics, 137 Case 9.1 Man with dyspnea, cough, fever, and weight loss, 137 Case 9.2 Confusing staining characteristics and false identification of a pathogen by automated system in a seriously ill patient, 143 10 Severe Systemic Fungal and Other Infections in AIDS Patients, 153 Case 10.1 HIV patient with progressive shortness of breath, 153 Case 10.2 Recurrent multiorgan infection in an immunocompromised patient, 161 11 Toxic Manifestations of Infectious and Non-infectious Diseases, 171 Case 11.1 An odd presentation for toxic shock syndrome, 171 Case 11.2 A peculiar and dramatic presentation of septic shock, 176 Case 11.3 A 45-year-old woman with rash, hepatitis, and lymphadenopathy, 185 12 Skin and Soft Tissue Infections Seen Post Hurricane Katrina in 2005, 195 Introduction, 195 Case 12.1 A 76-year-old Caucasian female with leg laceration, 195 Case 12.2 A 76-year-old man with rapid-onset cellulitis, 198 Case 12.3 A 61-year-old man with diabetic neuropathy, 200 Case 12.4 A 45-year-old man from a refugee camp with calf laceration, 201 General comments on soft tissue infections in relation to Hurricane Katrina, 202 13 Other Miscellaneous Infections, 211 Case 13.1 A 17-month-old child with facial swelling and adenopathy, 211 Case 13.2 Persistent headache in a 50 year old with known migraine, 217 Case 13.3 A 54-year-old man with skin lesions with central numbness, 223 Case 13.4 Delayed diagnosis in a young woman with migratory joint pain, 231 Index, 241

Read more less

Book SynopsisHealthcare Professionalism: Improving Practice through Reflections on Workplace Dilemmas provides the tools and resources to help raise professional standards within the healthcare system. Taking an evidence and case-based approach to understanding professional dilemmas in healthcare, this book examines principles such as applying professional and ethical guidance in practice, as well as raising concerns and making decisions when faced with complex issues that often have no absolute right answer. Key features include: Real-life dilemmas as narrated by hundreds of healthcare students globally A wide range of professionalism and inter-professionalism related topics Information based on the latest international evidence Using personal incident narratives to illustrate these dilemmas, as well as regulatory body professionalism standards, Healthcare Professionalism is an invaluable resource for students, healthcare professTrade Review'...excellent layout and presentation, especially the way the text is broken up into boxes to highlight common themes throughout each chapter, such as learning outcomes for reflective sessions and case study narratives. Each chapter is also rounded off with a summary, discussion points, learning activities and recommended reading, which helps the reader to draw conclusions at each stage to consolidate learning...there is much learning to be gained from the insightful reflections of a wider, multidisciplinary body of students' – Nursing Standard 'This book explores important professionalism dilemmas, including patient safety errors, consent and confidentiality ... The chapters include thought-provoking narratives on personal incidents and case studies that clearly link theory with practice. Detailed referencing provides an evidence-based, robust approach to tackling professionalism dilemmas.' – Surgeons’ News, The Royal College of Surgeons of Edinburgh“This book presents a valuable and realistic structure for teaching and learning how to become and develop as professional in any healthcare discipline. The usefulness of this book lies in the approach to guiding and developing the student's professional identify and the educator's teaching strategies to promote corrective actions based on reflections shaped by professional dilemmas founded on failures of professionals in various healthcare disciplines” Linda S. Hansen, MSN, RN, Michigan State University College of Nursing on behalf of Doody’s Aug 17 'The key strength of this book is that it continually links the theory of professionalism to the reality of day-to-day practice ... the authors do an excellent job of exposing the commonalities and differences in the perspectives of the various health care professions.' Anesthesia and Analgesia Table of ContentsForeword xi About the Authors xiii Acknowledgements xv Author Contributions xvii 1 Introduction 1 References 4 2 What is Healthcare Professionalism? 7 Introduction 8 Who is Responsible for Setting Professionalism Codes of Conduct? 8 What is the Ethical Basis of Healthcare Professionalism? 10 How is Professionalism Understood Across Regulatory Bodies’ Codes of Conduct? 12 How is Professionalism Linguistically Framed Across Healthcare Professionalism Codes of Conduct? 15 What are Stakeholders’ Understandings of Professionalism Across Different Country Cultures? 16 What are Students’ Understandings of Professionalism Across Country Cultures? 19 Professionalism: Embodied Identities? 23 Chapter Summary 25 References 26 3 Teaching and Learning Healthcare Professionalism 31 Introduction 32 Why Teach and Learn Professionalism? 32 What is a Curriculum? 33 How is Professionalism Taught and Learnt? 35 What Curricula‐related Professionalism Dilemmas do Healthcare Students Experience? 42 Chapter Summary 45 References 46 4 Assessing Healthcare Professionalism 51 Introduction 52 Why Assess Professionalism? 52 How is Professionalism Assessed? 53 What are the Key Challenges Facing Professionalism Assessment? 56 What Assessment‐related Professionalism Dilemmas are Learners Experiencing? 58 Chapter Summary 65 References 67 5 Identity‐related Professionalism Dilemmas 71 Introduction 71 How do Professional Identities Relate to Learning? 72 Are Professional Identities Easily Developed? 73 What are the Consequences of Professional Identities? 74 What are Identity‐related Professionalism Dilemmas? 75 What Identity‐related Professionalism Dilemmas Occur Across the Pre‐university to Year 1 Transition? 76 Identity Dilemmas Across Undergraduate Healthcare Education 78 Identity Dilemmas Across Transitions into Practice 81 Emotional impact and resistance 82 Chapter Summary 83 References 85 6 Consent‐related Professionalism Dilemmas 89 Introduction 90 What is Consent and why does it Matter? 90 What are the Common Myths about Patient consent for student involvement in their care? 93 What are Common Consent‐related Professionalism Dilemmas? 97 What is the Impact of Consent‐related Professionalism Dilemmas? 100 How do Students Act in the Face of Consent‐related Professionalism Dilemmas? 102 Chapter summary 103 References 105 7 Patient Safety‐related Professionalism Dilemmas 109 Introduction 110 How Have Patient Safety and Associated Terms been Defined? 110 What are the Factors that can Influence Patient Safety in the Workplace? 111 What Types of Patient Safety‐related Dilemmas Occur Across Different Healthcare Professions? 113 How can Healthcare Learners’ Actions and Roles Develop a Positive Workplace Culture of Patient Safety? 119 Chapter Summary 122 References 123 8 Patient Dignity‐related Professionalism Dilemmas 127 Introduction 128 What is Patient Dignity? 128 Why Does Patient Dignity Matter? 129 What are Dignity Violations and How do they Arise? 130 What Patient Dignity‐related Professionalism Dilemmas do Healthcare Learners Witness or Participate in? 133 What is the Impact of Patient Dignity‐related Professionalism Dilemmas? 139 How do Learners Act in the Face of Patient Dignity‐related Professionalism Dilemmas? 140 Chapter Summary 142 References 143 9 Abuse‐related Professionalism Dilemmas 145 Introduction 146 What are Equality, Diversity and Dignity at Work and Why Do They Matter? 146 What is Workplace Abuse and its Relationship with Power? 149 What are the Causes of Workplace Abuse? 151 What are the Consequences of Workplace Abuse? 152 What Abuse‐related Professionalism Dilemmas do Healthcare Learners Experience? 152 How can Workplace Abuse be Prevented and Managed? 158 Chapter Summary 160 References 161 10 E‐professionalism‐related Dilemmas 167 Introduction 168 What are the Benefits of OSNs for Professionalism? 168 What are the Challenges of OSNs for Professionalism? 169 What is E‐professionalism and Why is it Important? 170 What E‐professionalism Lapses do Healthcare Learners Commit? 172 What are the Repercussions for E‐professionalism‐related Lapses? 176 What are the Psychological, Social and Technological Factors Associated with Social Media Use? 177 What are the Regulatory Recommendations for the Prevention and Management of E‐professionalism Lapses? 180 Chapter Summary 181 References 182 11 Professionalism Dilemmas Across National Cultures 187 Introduction 188 What is Culture? 188 What Different Cultural Dimensions are there? 189 What are Eastern and Western Cultural Spaces? 191 How can we Develop Cultural and Intercultural Capability? 195 What are the Professionalism Dilemmas Across Different Cultural Spaces? 198 How are Situations Culturally Interpreted? Intercultural Dilemmas on Medical Electives by Western Students 202 Chapter Summary 204 References 205 12 Professionalism Dilemmas Across Professional Cultures 207 Introduction 208 What are the Roles of Different Healthcare Professionals? 209 How do Professionalism Dilemmas Compare Across Healthcare Students? 211 Interprofessional Dilemmas: Hierarchies, Roles and Conflict 214 How do Dilemmas Around Role Boundaries Come About? 218 What are Students’ Reactions and Actions in the Face of Interprofessional Dilemmas? 219 How can Interprofessional Conflict be Managed? 220 Chapter Summary 222 References 224 13 Conclusions 227 Power, Hierarchy, Conformity and Resistance 227 Negative Emotions, Empathy and Moral Distress 228 Looking Forward: Education, Training and Practice 229 Looking Forward: Research 231 Looking Back: Researcher Reflexivity 232 Coda 233 References 234 Afterword: Healthcare Professionalism: Improving Practice through Reflections on Workplace Dilemmas 237 Index 241

Read more less

Book SynopsisApplied Anatomy for Clinical Procedures at a Glance is a concise resource combining high-quality images and step-by-step instructions to provide expert guidance on the major core training pathways in medicine, surgery and anaesthesia. Written by an experienced team of Foundation Training programme directors and clinical skills examiners, this unique revision and learning guide aligns with training pathways rather than anatomical area to support Foundation doctors and core trainees master these vital clinical procedures. Succinct yet thorough descriptions of each procedure include photographs of surface anatomy, line diagrams of the anatomy, instructions on the procedural techniques, and practical tips for performing the procedures safely whilst minimising risks of complications. All major aspects of Foundation procedures and Core training in applied anatomy are covered, including catheterisation, ECGs, central venous cannulation, basic suturing and anastomotic techniques, endotracheTable of ContentsContributors vii 1 Scrubbing up 1Sherif Kirollos and Ramez Kirollos 2 Setting up a sterile field and draping the patient 4Sherif Kirollos and Ramez Kirollos 3 Three-way tap 6Jane Sturgess 4 Common equipment for core clinical procedures 8Jane Sturgess 5 Local anaesthetic infiltration 12Sherif Kirollos and Ramez Kirollos 6 Obtaining consent 14Francesca Crawley 7 Manometer for central venous pressure and lumbar puncture 16Jane Sturgess 8 Bladder irrigation sets 18Jane Sturgess 9 Underwater seal for chest drains 20Jane Sturgess 10 Male catheterisation 22Francesca Crawley 11 Female catheterisation 24Francesca Crawley 12 Arterial blood gases 26Francesca Crawley 13 Performing an electrocardiogram 30Francesca Crawley 14 Oropharyngeal airway 32Jane Sturgess 15 Nasopharyngeal airway 34Jane Sturgess 16 Laryngeal mask airway 36Jane Sturgess 17 Central venous cannulation (high approach internal jugular) 38Jane Sturgess 18 Central venous cannulation (low approach internal jugular) 42Jane Sturgess 19 Central venous cannulation (subclavian) 46Jane Sturgess 20 Direct current cardioversion 50Francesca Crawley 21 Intercostal drains 52Francesca Crawley 22 Pleural tap 54Francesca Crawley 23 Inserting a nasogastric tube 56Francesca Crawley 24 Lumbar puncture 58Jane Sturgess 25 Bone marrow aspirate 62Francesca Crawley and Charles Crawley 26 Ascitic tap 64Francesca Crawley 27 Paracentesis 66Francesca Crawley 28 Knee aspiration 68Sherif Kirollos and Ramez Kirollos 29 Skin biopsy 70Sherif Kirollos and Ramez Kirollos 30 Basic suturing 72Sherif Kirollos and Ramez Kirollos 31 Basic anastomotic techniques 76Sherif Kirollos and Ramez Kirollos 32 Abscess drainage and debridement 78Sherif Kirollos and Ramez Kirollos 33 Bag mask ventilation (adults) 82Jane Sturgess 34 Endotracheal intubation (adults) 86Jane Sturgess 35 Needle cricothryoidotomy (adults) 90Jane Sturgess 36 Surgical cricothyroidotomy 94Sherif Kirollos and Ramez Kirollos 37 Defibrillation 96Francesca Crawley 38 Spinal injection 100Jane Sturgess 39 Epidural injection 104Jane Sturgess 40 Procedure-related safety 108Kirsty Cattle Index 110

Read more less

Book SynopsisAlthough there are many texts that provide quality information for the identification of fungi, researchers and technologists rarely have time to read the text. Most are rushed for time and seek morphological information that helps guide them to the identification of fungi.Table of ContentsPreface xi Acknowledgments xiii Abbreviations xv Part I Divisions of the Fungi 1 1 Morphological Growth Index 3 1.1 Filamentous Bacteria 3 1.2 Yeasts and Yeast‐like Organisms 3 1.3 Yeast/Yeast‐like Organisms That Produce Hyphae 4 1.4 Thermally Dimorphic Fungi 4 1.5 Thermally Monomorphic Molds 4 1.6 Dematiaceous (Brown or Black Colored Fungi) 6 1.7 Other Fungi for Which No Photographs are Available 8 2 Division of Fungi by Type of Sporulation 9 2.1 Annelloconidia 9 2.2 Arthroconidia 9 2.3 Arthroconidia and Blastoconidia 9 2.4 Arthroconidia; Spherule in Tissue 9 2.5 Basidiospores 9 2.6 Phialoconidia 9 2.7 Produce Only Macroconidia 10 2.8 Macroconidia and Microconidia 10 2.9 Perithecium and Ascospores 10 2.10 Sporangia or Sporangiospores 10 2.11 Sporangia with Rhizoids 11 2.12 Produce Only Microconidia 11 2.13 Microconidia and Chlamydoconidia 11 2.14 Microconidia and Arthroconidia 11 2.15 Microconidia and Cleistothecium 11 2.16 Yeast Only 12 2.17 Yeast and Hyphae and Phialides 12 2.18 Yeast and Pseudohyphae 12 2.19 Yeast and Conidia 12 3 Division of Fungi, Yeast, and Bacteria by Morphological Group 13 3.1 Actinomycetes, Yeast, and Yeast‐like Organisms 13 3.2 Dimorphic Organisms 13 3.3 Dermatophytes 13 3.4 Zygomycetes (Aseptate) 14 3.5 Hyaline Molds (Septate) 14 3.6 Dematiaceous Fungi (Septate) 14 Part II Descriptions and Photographs of Microorganisms 17 4 Actinomycetes, Yeast (Thermally Monomorphic), and Yeast‐like Organisms 19 4.1 Microorganisms with Fungal‐like Morphology Occurring in Fungal Cultures 19 4.2 Yeast and Yeast‐like Fungi 19 4.3 Candida spp 34 4.4 Prototheca spp 36 4.5 Arthrographis kalrae 39 4.6 Cryptococcus neoformans 44 4.7 Geotrichum candidum 47 4.8 Malassezia spp 56 4.9 Trichosporon spp 58 5 Yeast (Thermally Dimorphic) 63 5.1 Blastomyces dermatitidis 63 5.2 Coccidioides immitis 69 5.3 Histoplasma capsulatum 73 5.4 Sporothrix schenckii 83 6 Zygomycetes (Aseptate) 89 6.1 Lictheimia (Absidia) corymbifera 89 6.2 Conidiobolus lamprauges, coronatus, incongruus 95 6.3 Cunninghamella bertholletiae 102 6.4 Mucor spp 106 6.5 Rhizomucor spp 116 6.6 Rhizopus spp 121 6.7 Syncephalastrum racemosum 130 7 Dermatophytes 135 7.1 Microsporum spp 135 7.2 Trichophyton spp 145 7.3 Epidermophyton floccosum 161 8 Hyaline Molds (Septate) 167 8.1 Aspergillus spp 167 8.2 Beauveria bassiana 182 8.3 Emmonsia spp 187 8.4 Fusarium spp 193 8.5 Gliocladium 215 8.6 Malbranchea spp 220 8.7 Paecilomyces spp 223 8.8 Penicillium spp 228 8.9 Ramichloridium spp 232 8.10 Schizophyllum commune 238 8.11 Scopulariopsis brevicaulis 244 8.12 Scopulariopsis brumptii 250 8.13 Sepedonium spp 254 8.14 Sporotrichum pruinosum 258 8.15 Trichoderma spp 264 8.16 Trichothecium roseum 271 8.17 Chrysosporium tropicum 274 9 Dematiaceous Fungi (Septate) 281 9.1 Acremonium spp 281 9.2 Alternaria spp 289 9.3 Aureobasidium pullulans 292 9.4 Bipolaris spicifera, Curvularia hawaiiensis (B. hawaiensis), and C. australiensis (B. australiensis) 297 9.5 Chaetomium spp 305 9.6 Cladophialophora (Xylohypha) bantiana 308 9.7 Cladophialophora boppi 311 9.8 Cladophialophora carrionii 314 9.9 Cladosporium sphaerospermum 317 9.10 Cladosporium spp 320 9.11 Curvularia spp 327 9.12 Epicoccum spp 332 9.13 Exserohilum spp 337 9.14 Fonsecaea 343 9.15 Hormonema dematioides 351 9.16 Hortaea (Phaeoannellomyces, Exophiala) werneckii 355 9.17 Madurella spp 361 9.18 Neoscytalidium spp 369 9.19 Nigrospora spp 376 9.20 Ochroconis (Dactylaria) spp 380 9.21 Phaeoacremonium parasiticum 385 9.22 Phialemonium spp 390 9.23 Phialophora spp 395 9.24 Pithomyces sp 401 9.25 Pseudallescheria boydii 407 9.26 Scedosporium 412 9.27 Stachybotrys chartarum 417 9.28 Stemphylium sp 422 9.29 Ulocladium sp 425 9.30 Phoma sp 429 9.31 Rhinocladiella basitona 435 9.32 Exophiala dermatitidis (Wangella dermatitidis) 441 9.33 Exophiala jeanselmei 447 Additional Reading 453 Index 000

Read more less